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ABSTRACT	  
The	  chromosome	  passenger	  complex	  (CPC)	  is	  an	  essential	  mitotic	  
regulator	  with	  key	  roles	  in	  mitotic	  processes	  such	  as	  chromosome	  
condensation,	  spindle	  dynamics,	  chromosome	  bi-­‐orientation,	  the	  spindle	  
checkpoint	  and	  cytokinesis.	  The	  Aurora	  B	  kinase	  is	  the	  CPC’s	  catalytic	  subunit.	  
Its	  targeting	  and	  activation	  are	  dependent	  on	  interactions	  with	  the	  other	  
components	  of	  the	  complex:	  inner	  centromere	  protein	  (INCENP),	  survivin	  and	  
borealin/Dasra	  B.	  INCENP	  serves	  both	  as	  a	  scaffolding	  subunit	  for	  the	  CPC	  as	  
a	  whole	  and	  as	  an	  activator	  of	  Aurora	  B	  via	  its	  highly	  conserved	  INbox	  
domain.	  	  
Aurora	  B	  is	  a	  putative	  anti-­‐cancer	  target;	  several	  inhibitors	  of	  the	  
kinase	  are	  currently	  in	  clinical	  trials.	  All	  these	  are	  ATP-­‐analogues	  targeting	  the	  
kinase	  active	  site.	  The	  protein-­‐protein	  interaction	  between	  Aurora	  B	  and	  the	  
INCENP	  INbox	  is	  also	  essential	  for	  CPC	  function.	  Earlier	  studies	  have	  
demonstrated	  that	  INCENP	  INbox	  mutants	  unable	  to	  bind	  and/or	  activate	  
Aurora	  B	  cannot	  rescue	  lethality	  in	  the	  absence	  of	  endogenous	  INCENP.	  	  
The	  first	  goal	  of	  this	  study	  was	  to	  test	  the	  in	  vivo	  effects	  of	  disrupting	  
the	  interaction	  between	  endogenous	  wild	  type	  INCENP	  and	  Aurora	  B.	  For	  
this,	  a	  cell-­‐based	  CPC	  function	  assay	  was	  developed	  in	  HeLa	  cells.	  Using	  this	  
assay,	  I	  show	  that	  expression	  of	  soluble	  INbox	  in	  HeLa	  cells	  produces	  a	  
significant	  increase	  in	  multinucleated	  and	  micronucleated	  cells:	  both	  effects	  
consistent	  with	  Aurora	  B	  loss	  of	  function.	  Expression	  of	  soluble	  INbox	  bearing	  
the	  mutations	  W845G	  and/or	  F881A	  does	  not	  elicit	  this	  effect	  suggesting	  that	  
those	  mutants	  cannot	  bind	  to	  Aurora	  B	  and	  occlude	  INCENP	  binding.	  The	  
result	  concerning	  the	  F881A	  mutant	  contrasts	  with	  earlier	  reports	  that	  
equivalent	  mutants	  could	  bind,	  but	  not	  activate,	  Aurora	  B.	  Expression	  of	  an	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INbox	  mutant	  lacking	  the	  C-­‐terminal	  TSS	  motif	  reported	  to	  be	  involved	  in	  
Aurora	  B	  activation	  but	  not	  binding	  has	  effects	  similar	  to	  those	  of	  the	  wild	  
type	  INbox.	  
Using	  the	  INbox/Aurora	  B	  interaction	  as	  a	  model,	  a	  secondary	  goal	  of	  
this	  study	  was	  to	  develop	  and	  evaluate	  a	  novel	  approach	  to	  identify	  small	  
peptides	  capable	  of	  dissociating	  intracellular	  protein-­‐protein	  interactions.	  For	  
this,	  a	  library	  of	  small	  (5-­‐9	  residues	  long)	  circular	  peptides	  (CPs)	  mimicking	  
the	  INbox	  was	  generated	  using	  the	  split	  intein	  circular	  ligation	  of	  proteins	  and	  
peptides	  (SICLOPPS)	  methodology	  and	  assayed	  using	  the	  cell-­‐based	  CPC	  
function	  assay.	  Over	  two	  successive	  rounds	  of	  screening,	  a	  small	  number	  of	  
CPs	  were	  identified	  that	  caused	  a	  significant	  increase	  in	  rates	  of	  
multinucleated	  and	  micronucleated	  cells.	  Although	  statistically	  significant,	  
these	  increases	  were	  very	  modest.	  Furthermore,	  due	  to	  high	  heterogeneity	  in	  
SICLOPPS	  processing	  efficiencies,	  it	  was	  not	  practicable	  to	  compare	  the	  
effects	  of	  different	  peptides	  side-­‐by-­‐side	  by	  transfection.	  The	  level	  of	  
variation	  in	  processing	  efficiency	  –	  thus,	  CP	  production	  –	  was	  unexpectedly	  
high	  and	  puts	  into	  question	  the	  functional	  complexity	  of	  more	  commonly	  
used	  combinatorial	  cyclic	  peptide	  libraries	  derived	  using	  current	  SICLOPPS	  
methodology.	  	  
The	  results	  of	  this	  study	  are	  divided	  into	  three	  sections.	  The	  first	  is	  a	  
methods	  section	  concerning	  the	  testing	  of	  SICLOPPS	  in	  HeLa	  cells	  and	  the	  
development	  of	  a	  cell-­‐based	  CPC	  function	  assay.	  In	  the	  second,	  the	  effects	  of	  
expressing	  soluble	  INbox	  and	  mutants	  thereof	  in	  HeLa	  cells	  are	  presented.	  
The	  final	  results	  section	  presents	  the	  results	  of	  the	  feasibility	  study	  of	  the	  
rationally-­‐designed	  genetically	  encoded	  library	  approach.	   	  
	   3	  
LAY	  SUMMARY	  
	   In	  order	  for	  our	  bodies	  to	  grow	  and	  to	  replace	  lost	  cells,	  our	  cells	  must	  
divide	  in	  a	  tightly	  controlled	  and	  orchestrated	  manner.	  To	  achieve	  this,	  the	  
chromosomes	  that	  contain	  the	  cell’s	  genetic	  information	  are	  first	  duplicated	  
then	  segregated	  into	  two	  identical	  cells,	  termed	  daughter	  cells,	  which	  are	  
then	  separated.	  It	  is	  imperative	  that	  each	  daughter	  cell	  receives	  one,	  and	  
only	  one,	  copy	  of	  each	  of	  the	  duplicated	  chromosomes.	  Failure	  to	  maintain	  
this	  fidelity	  can	  lead	  to	  cell	  death,	  birth	  defects	  and	  cancer.	  
The	  chromosomal	  passenger	  complex	  performs	  several	  essential	  
functions	  during	  the	  process	  of	  cell	  division.	  In	  particular,	  the	  complex	  helps	  
ensure	  that	  each	  of	  the	  two	  daughter	  cells	  contains	  an	  exact	  replica	  of	  the	  
genetic	  information	  present	  in	  the	  original	  cell.	  The	  complex	  also	  serves	  key	  
functions	  in	  cytokinesis	  –	  the	  process	  by	  which	  the	  two	  daughter	  cells	  
become	  irreversibly	  separated.	  The	  chromosomal	  passenger	  complex	  exerts	  
its	  functions	  by	  modifying	  other	  proteins	  via	  its	  Aurora	  B	  subunit.	  The	  other	  
parts	  of	  the	  complex	  serve	  to	  activate	  Aurora	  B	  and	  direct	  its	  activity	  to	  
where	  it	  is	  required.	  
Inhibiting	  Aurora	  B	  through	  different	  approaches	  is	  a	  useful	  strategy	  
for	  understanding	  its	  function.	  This	  is	  also	  being	  pursued	  as	  an	  anti-­‐cancer	  
strategy	  as	  loss	  of	  Aurora	  B	  function	  preferentially	  kills	  cancerous	  cells,	  which	  
are	  more	  sensitive	  than	  healthy	  cells	  to	  errors	  in	  cell	  division.	  Drugs	  designed	  
to	  inhibit	  Aurora	  B	  all	  target	  its	  active	  site	  –	  the	  region	  through	  which	  it	  
modifies	  other	  proteins.	  However,	  blocking	  key	  interactions	  between	  Aurora	  
B	  and	  other	  chromosomal	  passenger	  complex	  members	  had	  been	  proposed	  
as	  an	  alternative	  means	  of	  abrogating	  chromosomal	  passenger	  complex	  
function	  by	  interfering	  with	  Aurora	  B	  activity	  and/or	  localisation.	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To	  study	  the	  effects	  of	  blocking	  interactions	  within	  the	  chromosomal	  
passenger	  complex,	  I	  devised	  an	  assay	  monitoring	  cell	  division	  in	  cancer	  cells.	  
Using	  this	  assay,	  I	  demonstrate	  that	  disturbing	  the	  binding	  between	  Aurora	  B	  
and	  inner	  centromere	  protein	  (INCENP)	  in	  cancer	  cells	  has	  a	  significant	  
negative	  impact	  on	  cell	  division.	  Furthermore,	  I	  confirm	  the	  importance	  
mimicking	  key	  features	  within	  the	  interaction	  for	  blocking	  it.	  	  
Further	  to	  validating	  the	  effects	  of	  blocking	  the	  interaction	  between	  
Aurora	  B	  and	  INCENP,	  I	  wanted	  to	  determine	  whether	  it	  could	  be	  teased	  
apart	  with	  small	  compounds,	  as	  this	  would	  suggest	  that	  it	  might	  be	  amenable	  
to	  being	  inhibited	  with	  drugs.	  To	  test	  this,	  I	  created	  a	  library	  of	  small	  
fragments	  resembling	  key	  features	  within	  the	  Aurora	  B	  and	  INCENP	  
interaction.	  Although	  some	  fragments	  modestly	  affected	  cell	  division,	  the	  
evidence	  gathered	  is	  too	  preliminary	  to	  reach	  conclusions	  about	  the	  potential	  
of	  the	  interaction	  as	  a	  drug	  target.	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CHAPTER	  1:	  INTRODUCTION	  
1.1	   PROTEIN-­‐PROTEIN	  INTERACTIONS	  &	  PEPTIDES	  	  
Protein-­‐protein	  interactions	  (PPIs)	  are	  viewed	  as	  promising,	  if	  
technically	  challenging,	  drug	  targets	  (reviewed	  by	  (Sillerud	  and	  Larson,	  2005;	  
Wells	  and	  McClendon,	  2007;	  Zutshi	  et	  al.,	  1998)).	  Such	  surfaces	  are	  typically	  
more	  divergent	  than	  the	  enzyme	  active	  sites	  that	  have	  long	  been	  favoured	  in	  
drug	  development	  campaigns.	  Inhibitors	  of	  active	  sites	  such	  as	  substrate	  
analogues	  are	  often	  plagued	  by	  off-­‐target	  effects	  due	  to	  the	  modular	  nature	  
of,	  and	  high	  degree	  of	  conservation	  amongst,	  such	  surfaces.	  However,	  the	  
large	  size	  of	  PPI	  surfaces	  relative	  to	  compounds	  with	  drug-­‐like	  properties	  has	  
discouraged	  efforts	  to	  develop	  inhibitors	  targeting	  these.	  The	  flat	  
conformation	  of	  such	  contact	  surfaces	  also	  presents	  fewer	  binding	  pockets	  
for	  small	  molecules.	  Another	  limiting	  factor	  has	  been	  the	  relative	  scarcity	  of	  
suitable	  templates	  on	  which	  to	  base	  analogues	  with	  drug-­‐like	  properties.	  A	  
notable	  success	  in	  this	  area	  was	  the	  development	  human	  double	  minute	  2	  
(HDM2,	  a.k.a.	  MDM2)	  binders	  based	  on	  information	  gained	  from	  structural	  
and	  mutagenesis	  studies	  of	  a	  p53-­‐derived	  peptide	  (reviewed	  by	  (Wells	  and	  
McClendon,	  2007).	  The	  use	  of	  peptide	  or	  miniprotein	  mimics	  to	  disrupt	  
oligomerization	  interfaces	  has	  also	  yielded	  promising	  leads	  for	  antagonists	  of	  
receptors	  and	  viral	  enzymes	  (reviewed	  by	  (Zutshi	  et	  al.,	  1998)	  and	  (Cochran,	  
2000).	  	  
TARGETING	  PROTEIN-­‐PROTEIN	  INTERACTIONS	  WITH	  PEPTIDES	  
Peptide	  mimics	  with	  primary	  amino	  acid	  sequence	  homology	  to	  either	  
interacting	  partner	  have	  an	  extensive	  track	  record	  as	  competitive	  inhibitors	  
of	  protein-­‐protein	  and	  protein-­‐substrate	  interactions	  in	  in	  vitro	  assays.	  Short	  
peptides	  that	  mimic	  binding	  motifs,	  dimerization	  interfaces	  and	  substrates	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are	  routinely	  used	  in	  in	  vitro	  assays.	  Attempts	  to	  use	  such	  peptides	  against	  
intracellular	  PPIs	  in	  vivo	  have	  been	  hampered	  by	  difficulties	  in	  delivering	  
these	  into	  cells,	  and	  their	  poor	  stability	  therein.	  	  
DELIVERING	  PEPTIDES	  INTO	  CELLS	  	  
Attempts	  to	  assess	  the	  activities	  of	  short	  peptides	  in	  live	  cells	  have	  
thus	  far	  been	  limited	  to	  extra-­‐cellular	  applications	  or	  relied	  on	  bulky,	  and	  
potentially	  interfering,	  tags	  or	  scaffolds	  –	  these	  are	  exemplified	  by	  cell	  
penetrating	  peptides	  (CPPs)	  and	  peptide	  aptamers,	  respectively.	  Table	  1.1	  
summarizes	  this	  and	  other	  notable	  applications	  of	  short	  peptide	  mimics	  as	  
inhibitors	  and,	  when	  applicable,	  their	  method	  of	  delivery.	  For	  example,	  Yuan	  
and	  colleagues	  fused	  a	  19	  residue	  long	  fragment	  of	  the	  polo	  kinase	  1	  (Plk1)	  
polo	  box	  to	  a	  16-­‐mer	  antennapedia	  homeodomain,	  a	  cell	  penetrating	  peptide	  
that	  acted	  as	  a	  carrier	  to	  translocate	  the	  polo	  box	  peptide	  into	  cells	  (Yuan	  et	  
al.,	  2002).	  Soluble	  polo	  box	  was	  hypothesized	  to	  compete	  against	  
endogenous	  Plk1	  for	  substrate	  binding.	  Treatment	  with	  the	  polo	  box-­‐
antennapedia	  fusion	  peptide	  caused	  a	  G2/M	  arrest	  and	  induced	  apoptosis	  in	  
multiple	  cell	  types	  compared	  to	  treatment	  with	  the	  16-­‐mer	  antennapedia	  
domain	  alone.	  Point	  mutations	  to	  the	  polo	  box	  portion	  of	  the	  fusion	  peptide	  
quelled	  its	  dominant	  negative	  effects.	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Mimic	   Target	   Delivery	   Notes	   Ref	  
NFAT	   Calcineurin	   N/A	   EA	   (Aramburu	  et	  al.,	  1999;	  Roehrl	  et	  al.,	  2004)	  
HIV-­‐1	  Tat	   TAR	  (RNA)	   CPP*	   ChemCP	   (Lalonde	  et	  al.,	  2011)	  
P21WAF	   PCNA	   N/A	   IV	   (Warbrick	  et	  al.,	  1995)	  
Survivin	   Hsp90	   CPP	   	   (Plescia	  et	  al.,	  2005)	  
HIV-­‐1	  gp160	   (self)	   N/A	   IV;	  EA	   (Wild	  et	  al.,	  1992)	  
ASFV	  54	   dynein	  light	  chain	   CPP	   	   (Hernáez	  et	  al.,	  2010)	  
MEK-­‐1	   ERK	   CPP	   	  	   (Kelemen	  et	  al.,	  2002)	  
Plk1	  polo-­‐
box	   Multiple	   CPP	   	   (Yuan	  et	  al.,	  2002)	  
Pbs2p	   Sho1p	  SH3	  domain	   aptamer	   Y2H	   (Woodman	  et	  al.,	  2005)	  
Table	  1.1	  –	  Selected	  examples	  of	  peptide	  inhibitors	  with	  primary	  amino	  acid	  
sequence	  homology	  (CPP:	  cell	  penetrating	  peptide;	  ChemCP:	  chemically	  
synthesized	  cyclic	  peptide;	  EA:	  extracellular	  application;	  IV:	  in	  vitro	  
application;	  N/A:	  non	  applicable	  because	  of	  non-­‐intracellular	  application,	  see	  
‘notes’	  for	  further	  explanation;	  Y2H:	  yeast	  2	  hybrid).	  *	  HIV-­‐1	  Tat	  contains	  a	  
well-­‐characterized	  cell	  penetrating	  peptide	  sequence,	  its	  mimic	  retains	  
properties	  known	  to	  aid	  cell	  permeability	  –	  namely:	  it	  is	  arginine-­‐rich	  
PEPTIDE	  APTAMERS	  
Aptamers	  are	  a	  means	  of	  presenting	  either	  short	  peptide	  or	  nucleic	  
acid	  epitopes	  in	  vivo.	  These	  genetically-­‐encoded	  constructs	  rely	  on	  a	  constant	  
nucleic	  acid	  or	  protein	  scaffold	  to	  stabilize	  and	  constrain	  a	  variable	  loop	  
containing	  the	  epitope	  (reviewed	  by	  Hoppe-­‐Seyler	  et	  al.,	  2004),	  a	  commonly	  
used	  scaffold	  for	  peptide	  aptamers	  is	  that	  of	  E.	  coli	  thioredoxin	  –	  a	  109	  
residue	  protein	  (Colas	  et	  al.,	  1996).	  As	  they	  are	  genetically	  encoded,	  
aptamers	  lend	  themselves	  to	  the	  generation	  of	  large	  combinatorial	  libraries,	  
which	  are	  typically	  screened	  against	  yeast	  two-­‐hybrid	  reporters.	  This	  
approach	  is	  usually	  the	  favoured	  application	  of	  peptide	  aptamers;	  they	  are	  
seldom	  used	  to	  generate	  discrete	  rationally	  designed	  peptide	  mimics.	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CELL-­‐PENETRATING	  PEPTIDES	  
As	  non-­‐covalently	  bound	  carriers	  or	  as	  fusion	  proteins,	  CPPs	  can	  
translocate	  cargo	  such	  as	  proteins	  and	  nucleic	  acids	  across	  the	  plasma	  
membrane	  independently	  of	  the	  endocytic	  pathway	  (reviewed	  by	  Järver	  and	  
Langel,	  2004;	  Lindgren	  et	  al.,	  2000).	  Two	  major	  CPP	  subtypes	  have	  been	  
identified	  thus	  far,	  consisting	  of	  either	  ampiphatic	  or	  positively	  charged	  
stretches	  of	  residues.	  An	  example	  of	  the	  latter	  category	  is	  the	  transactivation	  
domain	  of	  the	  HIV-­‐1	  protein	  Tat	  (Frankel	  and	  Pabo,	  1988)	  –	  the	  most	  
predominantly	  used	  CPP	  for	  peptide	  delivery.	  First	  identified	  in	  1988,	  the	  
minimal	  region	  required	  for	  translocation	  was	  eventually	  narrowed	  down	  to	  
an	  arginine-­‐rich	  stretch	  of	  approximately	  a	  dozen	  residues	  (Vivès	  et	  al.,	  
1997).	  The	  use	  CPP	  fusions	  in	  complex	  systems	  has	  been	  hampered	  by	  poor	  
cell-­‐type	  specificity	  in	  uptake	  (Järver	  and	  Langel,	  2004).	  Toxicity	  is	  another	  
drawback:	  some	  CPP	  types	  have	  been	  shown	  to	  be	  cytotoxic	  and	  it	  has	  also	  
been	  reported	  that,	  even	  though	  the	  minimal	  Tat	  CPP	  is	  non-­‐toxic,	  larger	  Tat	  
fusion	  peptides	  exhibit	  a	  general	  length-­‐dependent	  cytotoxicity	  (Cardozo	  et	  
al.,	  2007).	  	  
SPLIT	  INTEIN	  CIRCULAR	  LIGATION	  OF	  PROTEINS	  AND	  PEPTIDES	  
In	  contrast	  to	  the	  approaches	  discussed	  above,	  the	  split	  intein	  circular	  
ligation	  of	  proteins	  and	  peptides	  (SICLOPPS)	  system	  allows	  for	  the	  
intracellular	  production	  of	  genetically	  encoded	  cyclic	  peptides	  (CPs)	  without	  
recourse	  to	  tags.	  Developed	  by	  Stephen	  Benkovic	  and	  colleagues	  in	  the	  late	  
nineties,	  the	  technique	  relies	  on	  the	  naturally	  split	  intein	  from	  the	  
Synechocystis	  sp.	  PCC6803	  (Ssp)	  DNA	  polymerase	  III	  subunit	  DnaE	  (Scott	  et	  
al.,	  1999).	  As	  illustrated	  in	  panel	  A	  of	  Figure	  1.1.1,	  the	  two	  halves	  of	  the	  Ssp	  
DnaE	  helicase	  are	  encoded	  by	  two	  separate	  reading	  frames,	  in	  different	  






















Figure 1.1.1 - Principle of the SICLOPPS method. (A) The N- and C- terminal 
parts of the Ssp DnaE split intein originate from two separate open reading 
frames. These interact in trans to catalise the post-translational splicing of the 
DnaE N- and C- terminal peptides to form the mature protein (after Wu et al., 
1998).  (B) Spit inteins can also ligate proteins and peptides in cis. If the native 
intein order is maintained, sequences which are proximal and distal to the 
respective halves of the split intein are joined upon intein processing. (C) In 
contrast to this, reversing the order of the intein halves leads to the 
head-to-tail circularisation of the intervening sequence (after Abel-Santos et 
al., 2003). Legend: ext: extein; Int: intein; N: amino; C: carboxy. 
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RATIONALE	  
In	  their	  endogenous	  context,	  a	  split	  intein	  catalyzes	  the	  post-­‐
translational	  protein	  splicing	  of	  N-­‐	  and	  C-­‐terminal	  exteins	  in	  trans	  whilst	  
simultaneously	  excising	  itself	  from	  the	  protein	  product.	  In	  the	  instance	  of	  the	  
Ssp	  DnaE	  split	  intein,	  processing	  results	  in	  seamless	  ligation	  of	  the	  two	  gene	  
translation	  products	  thereby	  reconstituting	  the	  active	  DnaE	  helicase.	  Split	  
inteins	  can	  also	  act	  in	  cis	  and	  catalyse	  the	  head-­‐to-­‐tail	  circularization	  of	  the	  
intervening	  protein	  sequence	  when	  their	  order	  is	  reversed	  (Figure	  1.1.1,	  
panel	  B	  and	  C,	  respectively)	  –	  therein	  lies	  the	  crux	  of	  the	  SICLOPPS	  technique.	  	  
One	  can	  generate	  a	  desired	  CP	  by	  encoding	  its	  sequence	  in	  an	  
intervening	  stretch	  of	  residues	  between	  the	  C-­‐	  and	  N-­‐terminal	  inteins.	  
Polypeptides	  reported	  to	  have	  been	  circularized	  using	  this	  approach	  range	  in	  
length	  from	  whole	  proteins	  to	  peptides	  as	  small	  as	  4	  residues	  (Scott	  et	  al.,	  
2001;	  Scott	  et	  al.,	  1999).	  By	  generating	  the	  extein	  region	  of	  the	  SICLOPPS	  
construct	  (i.e.	  that	  encoding	  the	  fragment	  which	  will	  be	  excised	  and	  
circularized)	  using	  randomized	  oligos,	  one	  can	  generate	  very	  large	  
combinatorial	  libraries	  encoding	  highly	  diverse	  CPs	  (Scott	  et	  al.,	  2001).	  Typical	  
applications	  of	  the	  SICLOPPS	  methodology	  have	  involved	  screening	  such	  
combinatorial	  libraries.	  
ADVANTAGES	  
CPs	  possess	  numerous	  advantages	  over	  their	  linear	  counterparts	  
(reviewed	  in	  Craik,	  2006;	  Trabi	  and	  Craik,	  2002).	  Due	  to	  the	  lack	  of	  termini	  
accessible	  to	  exopeptidases,	  head-­‐to-­‐tail	  circularization	  of	  peptides	  confers	  
greater	  stability	  (for	  example,	  see	  Szewczuk	  et	  al.,	  1992).	  Peptide	  
circularization	  is	  a	  popular	  approach	  for	  enhancing	  a	  peptide’s	  affinity.	  This	  is	  
thought	  to	  be	  achieved	  by	  limiting	  a	  ligand’s	  conformational	  flexibility	  
thereby	  reducing	  changes	  in	  entropy	  upon	  binding	  (Khan	  et	  al.,	  1998).	  In	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practice	  however,	  it	  is	  possible	  for	  binding	  entropy	  to	  be	  enhanced,	  reduced	  
or	  unaltered	  between	  cyclic	  peptides	  and	  linear	  analogues	  (Udugamasooriya	  
et	  al.,	  2008).	  
Further	  advantages	  of	  the	  SICLOPPS	  technique	  lie	  in	  its	  ease	  of	  
delivery	  and	  minimal	  requirements	  for	  extraneous	  sequence.	  Firstly,	  in	  
common	  with	  aptamers,	  these	  constructs	  are	  genetically	  encoded.	  This	  
circumvents	  the	  issues	  surrounding	  peptide	  cell-­‐permeability.	  Furthermore,	  
the	  protein	  splicing	  is	  autocatalytic,	  requiring	  no	  accessory	  factors.	  The	  
technique	  is,	  therefore,	  amenable	  to	  any	  cell	  types	  that	  can	  be	  readily	  
transfected.	  Lastly,	  the	  only	  absolute	  extein	  sequence	  requirement	  is	  a	  
nucleophillic	  residue	  in	  position	  +1	  of	  the	  circularized	  fragment	  (Wu	  et	  al.,	  
1998).	  This	  represents	  a	  vast	  improvement	  on	  the	  length	  of	  accessory	  
residues	  required	  for	  either	  aptamer-­‐	  or	  CPP-­‐mediated	  peptide	  delivery.	  	  
APPLICATIONS	  	  
The	  sheer	  size	  and	  complexity	  of	  combinatorial	  libraries	  raises	  both	  
tantalizing	  prospects	  and	  logistical	  headaches.	  Of	  particular	  concern	  are	  the	  
limitations	  imposed	  on	  screen	  strategy	  by	  the	  nature	  of	  such	  libraries,	  and	  
difficulties	  in	  target	  identification.	  Combinatorial	  genetically-­‐encoded	  CP	  
libraries	  must	  be	  produced	  in	  pooled	  formats	  (Abel-­‐Santos	  et	  al.,	  2003).	  
Screening	  them	  therefore	  requires	  either	  strong	  positive	  selection	  or	  
resolution	  by	  deep	  sequencing.	  Screens	  published	  to	  date	  have	  relied	  on	  the	  
former	  –	  either	  by	  lethality	  suppression	  or	  reverse	  two-­‐hybrid	  approaches	  
(Horswill	  et	  al.,	  2004;	  Kritzer	  et	  al.,	  2009).	  This	  strategy	  serves	  two	  purposes:	  
to	  enrich	  for	  positive	  clones;	  and	  to	  permit	  the	  identification	  of	  the	  CP	  giving	  
rise	  to	  the	  desired	  phenotypic	  outcome.	  The	  latter	  is	  achieved	  by	  sequencing	  
the	  library	  construct	  present	  in	  positive	  clones.	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However,	  cell	  survival	  is	  not	  theoretically	  essential	  for	  recovering	  
genetically	  encoded	  hits	  screen	  in	  vivo.	  The	  potential	  of	  dropout	  screens	  
comparing	  population-­‐wide	  CP	  distribution	  before	  and	  after	  selection	  has	  
been	  investigated	  in	  S.	  cerevisiae	  (R.	  Almeida	  &	  C.	  Arndt,	  personal	  
communication).	  In	  that	  instance,	  the	  variable	  sequence	  of	  the	  CP	  serves	  a	  
purpose	  analogous	  to	  a	  yeast	  barcode	  and	  screen	  hits	  are	  the	  sequences	  
present	  in	  the	  population	  prior	  to,	  but	  not	  after,	  phenotypic	  selection.	  
Despite	  the	  suitability	  of	  intein-­‐mediated	  peptide	  circularisation	  to	  a	  
wide	  variety	  of	  cell	  types,	  screens	  of	  combinatorial	  CP	  libraries	  have	  almost	  
exclusively	  been	  carried	  out	  in	  prokaryotes	  or	  lower	  eukaryotes.	  To	  date,	  a	  
single	  attempt	  to	  screen	  such	  a	  CP	  library	  in	  human	  cells	  –	  generated	  using	  an	  
artificially-­‐split	  Ssp	  DnaB	  intein	  –	  has	  been	  published:	  in	  2002,	  Kinsella	  and	  
colleagues	  tested	  a	  relatively	  low	  complexity	  (1.6x105	  members)	  cyclic	  
pentapeptide	  library	  in	  human	  B	  cells	  to	  find	  inhibitors	  of	  interleukin-­‐4	  (IL-­‐4)	  
signalling	  (Kinsella	  et	  al.,	  2002).	  In	  this	  study,	  researchers	  engineered	  a	  
reporter	  containing	  the	  promoter	  of	  the	  germ	  line	  epsilon	  gene	  that,	  if	  
expressed,	  would	  sensitize	  cells	  to	  subsequent	  exposure	  to	  diphtheria	  toxin.	  
In	  B	  cells,	  the	  epsilon	  gene	  promoter	  is	  induced	  by	  IL-­‐4	  signaling.	  This	  screen	  
relied	  on	  lethality	  suppression	  read	  out:	  hits	  were	  isolated	  by	  finding	  
diphtheria	  toxin-­‐resistant	  cells	  under	  conditions	  where	  IL-­‐4	  signaling	  should	  
be	  active.	  The	  success	  of	  this	  study	  was	  deemed	  limited	  as	  the	  13	  hits	  
identified	  through	  screening	  did	  not	  show	  higher	  activity	  than	  existing	  
inhibitors	  and	  their	  mechanism	  of	  action	  could	  not	  be	  ascertained.	  
Compared	  to	  cell	  based	  screens	  employing	  reporters	  such	  as	  reverse	  
two	  hybrid	  systems,	  phenotypic	  screens	  do	  not	  necessarily	  require	  prior	  
target	  identification	  (reviewed	  in	  Butcher,	  2005).	  In	  theory,	  this	  permits	  the	  
identification	  of	  novel	  players	  and	  pathways	  giving	  rise	  to	  the	  outcome	  of	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interest.	  However,	  whilst	  phenotype-­‐based	  screens	  of	  combinatorial	  CP	  
libraries	  have	  yielded	  hits,	  it	  is	  disappointing	  that	  no	  interacting	  partners	  for	  
these	  have	  thus	  far	  been	  identified	  despite	  attempts	  to	  do	  so	  (Kinsella	  et	  al.,	  
2002;	  Kritzer	  et	  al.,	  2009).	  For	  example,	  Kritzer	  and	  colleagues	  prepared	  
affinity	  reagents	  based	  on	  their	  most	  potent	  CP	  hits	  but	  were	  unable	  to	  pull	  
down	  binding	  partners.	  Whilst	  preliminary	  structure-­‐activity	  relationship	  
studies	  can	  still	  be	  carried	  out	  using	  a	  phenotypic	  assay,	  failure	  to	  identify	  
interacting	  partners,	  and	  by	  extension	  probable	  targets,	  can	  hamper	  further	  
lead	  optimization	  and	  constitutes	  a	  translation	  roadblock.	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1.2	   CELL	  DIVISION	  AND	  CANCER	  
In	  multi-­‐cellular	  organisms,	  controlled	  cell	  division	  is	  required	  to	  meet	  
the	  demands	  of	  development,	  growth	  and	  tissue	  turnover.	  As	  the	  cell	  cycle	  
progresses,	  the	  genome	  is	  first	  replicated	  then	  partitioned	  into	  two	  daughter	  
cells.	  Further	  to	  the	  genome,	  other	  cellular	  structures	  such	  as	  mitochondria,	  
the	  endoplasmic	  reticulum	  and	  Golgi	  bodies	  must	  also	  be	  replicated	  and	  
partitioned.	  Due	  to	  their	  relevance	  to	  this	  project,	  I	  will	  principally	  focus	  here	  
on	  the	  dynamics	  of	  genomic	  material	  throughout	  the	  vertebrate	  cell	  cycle.	  
An	  overview	  of	  the	  cell	  cycle	  is	  presented	  in	  Figure	  1.2.1.	  Cells	  first	  
undergo	  a	  growth	  phase	  (gap	  1	  or	  G1),	  followed	  by	  a	  synthesis	  phase	  (S;	  in	  
which	  DNA	  synthesis	  takes	  place)	  then	  a	  second	  growth	  phase	  (gap	  2	  or	  G2).	  
Together,	  this	  series	  of	  steps	  are	  known	  as	  interphase.	  The	  newly	  replicated	  
genome	  is	  subsequently	  partitioned	  in	  mitosis	  (M)	  –	  a	  dynamic	  and	  tightly	  
orchestrated	  process	  (see	  below).	  Many	  cells	  do	  not	  actively	  divide	  and	  are	  in	  
a	  quiescent	  state	  (known	  as	  gap	  0	  or	  G0);	  some	  of	  them	  can	  re-­‐enter	  the	  cell	  
cycle	  given	  appropriate	  external	  stimulus	  whereas	  others	  cannot.	  Progress	  
through	  the	  cell	  cycle	  is	  tightly	  controlled	  and	  subject	  to	  a	  number	  of	  
checkpoints.	  	  
MITOSIS	  &	  CYTOKINESIS	  –	  AN	  OVERVIEW.	  
Mitosis	  is	  the	  process	  by	  which	  the	  replicated	  genome	  is	  faithfully	  segregated	  
into	  two	  daughter	  nuclei	  and	  cytokinesis	  is	  that	  by	  which	  two	  daughter	  cells	  
are	  formed.	  These	  are	  highly	  dynamic	  processes	  involving	  drastic	  changes	  in	  
chromosome,	  microtubules	  and	  membranes	  (Robbins	  and	  Gonatas,	  1964).	  As	  
cells	  enter	  mitosis,	  the	  diffuse	  and	  accessible	  genomic	  material	  present	  in	  the	  
interphase	  nucleus	  undergoes	  drastic	  morphological	  and	  spatial	  







Figure 1.2.1 - The cell cycle. Following mitotic exit, newly created daughter 
cells enter interphase (green). Interphase constitutes the majority of the cell 
cycle and is interupted by S phase, during which the genome is replicated. 
The duplicated genome is subsequently partitioned into two daughter nuclei 
through mitosis (blue) before a cytoplasmic division creates two daughter 
cells - this latter process is known as cytokinesis. Following division, cells can 
also exit the cell cycle and become quiescent (G0: quiescence; G1: gap1; G2: 
Gap 2; M: mitosis; S: synthesis).
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described	  by	  early	  cytologists	  based	  on	  microscopy	  observations.	  The	  
hallmarks	  of	  each	  phase	  are	  highlighted	  below;	  for	  an	  illustrative	  overview	  of	  
these,	  please	  consult	  Figure	  1.2.2.	  	  
1. Prophase	  	  
Centrosome	  separation	  occurs	  and	  individual	  centrioles	  migrate	  to	  
opposite	  poles	  of	  the	  cell	  –	  these	  will	  form	  the	  focused	  poles	  from	  
which	  spindle	  microtubules	  emanate.	  Within	  a	  still	  intact	  nuclear	  
envelope,	  chromosomes	  condense	  and	  individual	  sister	  chromatid	  
pairs	  become	  visible.	  
2. Prometaphase	  
Nuclear	  envelope	  breakdown	  occurs	  allowing	  for	  spindle	  microtubules	  
to	  enter	  the	  chromosome-­‐containing	  compartment.	  Chromosomes	  
associate	  with	  said	  microtubules	  through	  both	  lateral	  and	  end-­‐on	  
attachments	  and	  start	  to	  congress	  towards	  the	  center	  of	  the	  mitotic	  
spindle.	  
3. Metaphase	  
Metaphase	  is	  a	  transient	  but	  key	  mitotic	  phase:	  the	  point	  at	  which	  all	  
chromosomes	  have	  congressed	  to	  the	  metaphase	  plate	  (i.e.	  the	  
spindle	  midzone)	  and	  become	  bi-­‐oriented.	  Bipolar	  attachment	  of	  sister	  
chromatids	  generates	  tension	  across	  their	  kinetochores	  and	  leads	  to	  
the	  cessation	  of	  local	  production	  of	  a	  ‘wait	  anaphase’	  signal.	  Once	  all	  
sister	  chromatid	  pairs	  are	  bi-­‐oriented,	  the	  lack	  of	  unattached	  
kinetochores	  represses	  the	  inhibition	  of	  the	  anaphase	  promoting	  
complex,	  leading	  to	  the	  proteolytic	  degradation	  of	  cyclin	  B	  and	  other	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4. Anaphase	  
The	  link	  between	  sister	  chromatids	  is	  broken	  as	  centromeric	  cohesion	  
is	  cleaved.	  Spindle	  forces	  pull	  apart	  the	  sister	  chromatids	  causing	  
these	  to	  segregate	  towards	  opposite	  poles.	  	  
5. Telophase	  	  
The	  spindle	  begins	  to	  disassemble,	  the	  nuclear	  envelope	  reforms	  
around	  each	  daughter	  nucleus	  and	  chromosomes	  begin	  to	  decondense	  
within	  these.	  This	  is	  the	  final	  phase	  of	  nuclear	  division.	  
6. Cytokinesis	  
The	  separation	  of	  the	  two	  daughter	  cells	  begins	  during	  telophase.	  
Driven	  by	  an	  actomyosin	  contractile	  ring,	  the	  equatorial	  cortex	  (i.e.	  the	  
cell	  membrane	  situated	  over	  the	  spindle	  midzone)	  begins	  to	  ingress,	  
forming	  the	  cleavage	  furrow.	  This	  cleavage	  furrow	  then	  continues	  to	  
ingress	  until	  it	  reaches	  the	  midbody	  (i.e.	  the	  transient	  structure	  
derived	  from	  the	  spindle	  midzone,	  which	  is	  necessary	  for	  cellular	  
division).	  The	  thin	  intracellular	  bridge	  between	  the	  two	  daughter	  cells	  
is	  then	  resolved	  through	  abscission.	  It	  should	  be	  noted	  that	  although	  
cytokinesis	  typically	  follows	  mitosis,	  the	  two	  processes	  are	  distinct	  and	  







Figure 1.2.2 - The stages of mitosis illustrated with respects to chromosome 
(blue), spindle (red) and membrane (green) dynamics (after Ruchaud et al., 
2007).
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THE	  MITOTIC	  CHECKPOINT	  
	   Failure	  to	  maintain	  genetic	  fidelity	  in	  mitosis	  has	  deleterious	  
circumstances	  and	  can	  result	  in	  cell	  death	  or	  genetic	  aberrations	  that	  have	  
the	  potential	  to	  drive	  neoplastic	  transformations	  (e.g.	  by	  loss	  of	  tumour	  
suppressor	  genes).	  Like	  S	  phase,	  progression	  through	  mitosis	  is	  controlled	  by	  
checkpoints	  to	  ensure	  genomic	  integrity.	  	  
Anaphase	  onset	  and	  the	  separation	  of	  sister	  chromatids	  must	  be	  
prevented	  until	  all	  sisters	  are	  bi-­‐oriented.	  This	  is	  achieved	  by	  the	  inhibition	  of	  
the	  anaphase	  promoting	  complex/cyclosome	  (APC/C)	  by	  a	  mitotic	  checkpoint	  
complex	  (MCC)	  that	  is	  generated	  at	  unattached	  kinetochores	  (Kulukian	  et	  al.,	  
2009;	  Sudakin	  et	  al.,	  2001)	  –	  the	  specific	  role	  of	  Aurora	  B	  and	  the	  CPC	  in	  this	  
process	  will	  be	  elaborated	  upon	  in	  section	  1.3.	  As	  chromomes	  achieve	  
biorientation,	  MCC	  production	  ceases	  and	  the	  APC/C	  becomes	  activated.	  The	  
APC/C	  is	  an	  E3	  ubiquitin	  ligase;	  its	  activation	  triggers	  the	  ubiquitination	  and	  
destruction	  of	  substrates	  containing	  an	  epitope	  known	  as	  the	  destruction	  box	  
(D	  box)	  (King	  et	  al.,	  1995).	  Substrates	  include	  cyclin	  B	  and	  securin,	  an	  inhibitor	  
of	  the	  protease	  separase	  whose	  substrates	  include	  cohesin	  (Hagting	  et	  al.,	  
2002;	  King	  et	  al.,	  1995).	  Cohesin	  cleavage	  resolves	  pericentromeric	  cohesion	  
and	  the	  linkage	  between	  sister	  chromatids,	  which	  can	  then	  segregate	  to	  
opposite	  poles	  (Uhlmann	  et	  al.,	  1999).	  
CANCER	  THERAPY	  –	  A	  PRIMER	  
Cancer	  is	  usually	  a	  disease	  characterized	  by	  unfettered	  cell	  division	  
driven	  by	  genomic	  lesions.	  Cancerous	  tissues	  typically	  proliferate	  rapidly	  and	  
thus	  possess	  elevated	  mitotic	  indexes	  relative	  to	  most	  healthy	  tissues.	  
Furthermore,	  the	  compromised	  checkpoints	  that	  permit	  deregulated	  
proliferation	  can	  lead	  to	  cells	  proceeding	  through	  the	  cell	  cycle	  despite	  the	  
presence	  of	  faults,	  which	  can	  lead	  to	  cell	  death.	  These	  features	  have	  been	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exploited	  to	  preferentially	  target	  cancerous	  cells	  with	  cytotoxic	  therapies.	  
With	  few	  relatively	  recent	  exceptions,	  cancer	  therapies	  have	  either	  targeted	  
DNA	  metabolism	  or	  mitosis	  (the	  latter	  is	  discussed	  in	  greater	  detail	  in	  the	  
next	  section.)	  	  
Although	  the	  consequences	  of	  treatment	  with	  DNA	  damaging	  agents	  
are	  suffered	  most	  acutely	  by	  actively	  cycling	  cells,	  the	  genomic	  integrity	  of	  all	  
cells	  –	  including	  quiescent	  cells	  –	  can	  be	  affected.	  Further	  to	  deleterious	  side	  
effects	  due	  to	  the	  death	  of	  healthy	  but	  rapidly	  proliferating	  cells	  (e.g.	  
neutropenia),	  treatment	  with	  DNA	  damaging	  agents	  such	  as	  radiation	  risks	  
giving	  rise	  to	  an	  increased	  frequency	  of	  subsequent	  neoplasms	  in	  the	  future	  
(Boice	  et	  al.,	  1985;	  Brenner	  et	  al.,	  2000).	  	  
Further	  challenges	  in	  treating	  cancer	  stem	  from	  genomic	  instability	  –	  a	  
hallmark	  of	  cancer	  that	  generates	  diversity	  within	  the	  cancerous	  cell	  
population.	  This	  diversity	  creates	  significant	  therapeutic	  challenges	  as	  
treatment	  drives	  resistance	  by	  positively	  selecting	  for	  drug-­‐resistant	  sub	  
populations.	  Mechanisms	  of	  resistance	  include	  the	  overexpression	  of	  drug	  
efflux	  pumps	  and	  the	  acquisition	  of	  mutations	  to	  the	  drug	  target	  site	  
(Gottesman,	  2002).	  As	  it	  is	  unspecific,	  the	  former	  confers	  multi-­‐drug	  
resistance.	  A	  well-­‐characterized	  instance	  of	  the	  latter	  mode	  of	  resistance	  is	  
the	  acquisition	  of	  so-­‐called	  ‘gate-­‐keeper’	  mutations	  conferring	  resistance	  to	  
imanitib	  –	  a	  small	  molecule	  inhibitor	  of	  the	  Bcr-­‐Abl	  oncogenic	  gene	  fusion	  
product	  (Shah	  et	  al.,	  2002).	  Therapeutically	  speaking,	  like	  human	  
immunodeficiency	  virus	  (HIV)	  infection,	  cancer	  is	  considered	  a	  ‘moving	  
target’.	  	  
As	  in	  the	  HIV	  field,	  combination	  therapy	  is	  used	  in	  the	  treatment	  of	  
cancer.	  Furthermore,	  our	  growing	  understanding	  of	  the	  genetic	  lesions	  
capable	  of	  driving	  the	  proliferation	  of	  transformed	  cells	  is	  creating	  new	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avenues	  for	  the	  development	  of	  novel	  therapeutic	  agents.	  Additionally	  to	  
generic	  approaches	  targeting	  key	  phases	  of	  the	  cell	  cycle,	  substantial	  
investments	  are	  being	  made	  into	  agents	  exploiting	  tumour-­‐specific	  drivers	  
and	  weaknesses	  along	  with	  companion	  diagnostics	  for	  use	  in	  personalized	  
medicine	  treatment	  approaches.	  
ANTI-­‐MITOTICS	  AS	  CANCER	  THERAPEUTICS	  
As	  previously	  highlighted,	  the	  potential	  for	  collateral	  damage	  from	  
DNA	  damaging	  agents	  extends	  to	  quiescent	  cells.	  The	  rationale	  for	  interfering	  
with	  mitotic	  progression	  as	  anticancer	  therapeutic	  strategy,	  in	  contrast	  to	  
DNA	  damaging	  agents,	  was	  to	  limit	  such	  potential	  damage	  to	  actively	  cycling	  
cells.	  As	  their	  name	  implies,	  anti-­‐mitotics	  are	  agents	  disrupting	  progression	  or	  
completion	  of	  mitosis.	  The	  first	  such	  agent	  introduced	  into	  the	  clinic	  were	  
vinca	  alkaloids	  –	  small	  molecule	  microtubule	  destablising	  agents.	  
Microtubule-­‐targeting	  agents	  have	  proven	  effective	  in	  the	  clinic.	  Early	  
anti-­‐mitotic	  agents	  now	  in	  clinical	  use	  include	  microtubule	  poisons	  such	  as	  
vinca	  alkaloids	  and	  taxanes,	  which	  respectively	  promote	  microtubule	  
destabilization	  and	  stabilization	  at	  high	  concentrations	  and	  a	  concomitant	  
block	  in	  mitosis	  (Jordan	  and	  Wilson,	  2004).	  Exposure	  of	  cultured	  cells	  and	  
tumour	  xenografts	  to	  microtubule	  poisons	  results	  in	  mitotic	  arrest,	  slippage	  
and	  eventual	  cell	  death.	  Although	  increases	  in	  tumour	  mitotic	  indexes	  can	  be	  
observed	  in	  most	  patients	  treated	  with	  paclitaxel,	  these	  does	  not	  necessarily	  
correlate	  with	  apoptotic	  indexes	  or	  overall	  tumour	  treatment	  response	  
(Symmans	  et	  al.,	  2000).	  However,	  as	  microtubules	  are	  also	  essential	  
components	  of	  non-­‐cycling	  cells,	  microtubule-­‐targeted	  agents	  have	  
unintended	  and	  potentially	  limiting	  side	  effects.	  Peripheral	  neuropathy	  is	  a	  
particular	  concern	  and	  may	  be	  linked	  to	  disrupted	  axonal	  transport,	  which	  
requires	  dynamic	  microtubules	  (Lee	  and	  Swain,	  2006).	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The	  therapeutic	  success	  and	  unintended	  side	  effects	  of	  microtubule	  
poisons	  have	  motivated	  the	  search	  for	  drug	  targets	  whose	  activity	  is	  wholly	  
restricted	  to	  mitosis.	  Mitotic	  kinesin	  inhibitors,	  which	  disrupt	  spindle	  
formation,	  have	  entered	  clinical	  trials	  (Huszar	  et	  al.,	  2009).	  Inhibitors	  of	  
mitotic	  kinases	  including	  cyclin-­‐dependent	  kinases,	  polo	  and	  Aurora	  kinases	  
have	  also	  been	  developed	  and	  significant	  efforts	  have	  been	  invested	  into	  
their	  clinical	  development	  (Keen	  and	  Taylor,	  2004;	  Lens	  et	  al.,	  2010).	  	  
It	  is	  important	  to	  caution	  that,	  although	  efficacious	  in	  pre-­‐clinical	  
models	  such	  as	  culture	  cancer	  cells	  and	  rodent	  xenographs,	  the	  performance	  
of	  these	  newer	  anti-­‐mitotic	  compounds	  in	  clinical	  trials	  has	  been	  
disappointing	  thus	  far.	  These	  compounds	  are	  no	  better	  tolerated	  than	  other	  
chemotherapeutic	  agents	  and	  disease	  response	  has	  been	  modest	  at	  best.	  
Poor	  clinical	  efficacy	  relative	  to	  microtubule	  targeting	  agents	  has	  recently	  
lead	  some	  to	  suggest	  that	  the	  mode	  of	  action	  of	  microtubule	  poisons	  may	  
transcend	  their	  effects	  in	  mitotic	  cells	  and	  encompass	  other	  essential	  
processes	  such	  as	  vesicle	  trafficking	  and	  angiogenesis	  (Komlodi-­‐Pasztor	  et	  al.,	  
2011;	  Mitchison,	  2012).	  Furthermore,	  as	  summarized	  within	  those	  opinion	  
pieces,	  the	  doubling	  times	  –	  thus	  the	  portion	  of	  cells	  in	  mitosis	  –	  within	  
tumours	  can	  be	  much	  lower	  than	  those	  in	  cell	  lines	  and	  animal	  xenograft	  
models.	  These	  results	  put	  into	  question	  the	  rationale	  for	  the	  specific	  
targeting	  of	  mitotic	  activities	  and	  suggest	  that	  the	  action	  of	  effective	  anti-­‐
tumour	  therapeutic	  strategies,	  including	  those	  affecting	  DNA	  replication,	  may	  
extend	  beyond	  specific	  cell	  cycle	  phases.	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1.3	   AURORA	  B	  AND	  THE	  CHROMOSOMAL	  PASSENGER	  
COMPLEX	  
The	  CPC	  orchestrates	  a	  number	  of	  key	  events	  during	  mitosis	  and	  
shows	  dynamic,	  and	  highly	  characteristic,	  spatio-­‐temporal	  localization	  
throughout	  this	  process	  (reviewed	  in	  Ruchaud	  et	  al.,	  2007)	  –	  its	  composition	  
and	  localization	  are	  outlined	  in	  figures	  1.3.1	  and	  1.3.2,	  respectively.	  The	  
localization	  of	  the	  CPC	  was	  first	  described	  by	  Cooke	  and	  colleagues	  using	  anti-­‐
INCENP	  antibodies	  (Cooke	  et	  al.,	  1987).	  At	  the	  onset	  of	  mitosis,	  the	  CPC	  is	  
present	  both	  on	  chromosome	  arms	  and	  at	  centromeres,	  promoting	  mitotic	  
chromosome	  structure	  via	  the	  phosphorylation	  of	  substrates	  including	  
histones	  and	  chromosomal	  scaffold	  proteins.	  CPC	  localisation	  gradually	  
becomes	  increasingly	  centromeric	  as	  mitosis	  progresses	  towards	  metaphase,	  
wherein	  it	  promotes	  chromosome	  bi-­‐orientation	  and	  ensures	  integrity	  of	  the	  
spindle	  checkpoint	  until	  bi-­‐orientation	  is	  achieved.	  The	  complex	  then	  
translocates	  to	  the	  equatorial	  cortex	  and	  spindle	  midzone	  at	  anaphase	  and	  
helps	  stabilize	  the	  central	  spindle.	  The	  complex	  eventually	  accumulates	  in	  the	  
midbody	  in	  cytokinesis	  wherein	  it	  regulates	  contractile	  ring	  formation	  and	  
abscission.	  The	  roles	  of	  the	  CPC	  are	  explored	  in	  greater	  detail	  later	  in	  this	  
chapter.	  	  
Further	  to	  Aurora	  B,	  the	  CPC	  contains	  a	  further	  three	  non-­‐enzymatic	  
subunits:	  the	  inner	  centromere	  protein	  (INCENP)	  (Cooke	  et	  al.,	  1987),	  survivin	  
(Bolton	  et	  al.,	  2002)	  and	  borealin/Dasra-­‐B	  (hereafter	  referred	  to	  as	  borealin;	  
(Gassmann	  et	  al.,	  2004;	  Sampath	  et	  al.,	  2004).	  Whilst	  the	  latter	  two	  members	  
function	  as	  targeting	  subunits,	  INCENP	  serves	  dual	  roles	  within	  the	  complex:	  
both	  as	  a	  scaffolding	  subunit,	  and	  as	  an	  activator	  of	  Aurora	  B.	  CPC	  
composition	  and	  function	  are	  highly	  conserved	  throughout	  eukaryotes	  but	  







Figure 1.3.1 - The composition of the chromosomal passenger complex. The 
kinase Aurora B is responsible for the complexe’s catalytic activity, and 
borealin, survivin and INCENP form a localisation module required to direct 
the CPC’s activity. The three members of the localisation module interact via a 






Figure 1.3.2 - Localisation of the chromosomal passenger complex during 
mitosis. The CPC (green) is first localised to chromosomes arms (blue), then to 
the centromeres until metaphase. Upon anaphase onset, the CPC relocalises 
to the spindle (red) and eventually becomes concentrated into the midbody 
(after Ruchaud et al., 2007).
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AURORA	  B	  AND	  THE	  AURORA	  KINASE	  FAMILY	  
Aurora	  B	  is	  a	  member	  of	  a	  conserved	  family	  of	  serine/threonine	  
kinases.	  A	  further	  two	  paralogues	  are	  present	  in	  vertebrates:	  Aurora	  A	  and	  C.	  
Aurora	  A	  is	  widely	  expressed	  and	  plays	  a	  role	  in	  centrosome	  maturation	  and	  
spindle	  organization	  (Glover	  et	  al.,	  1995)	  whereas	  Aurora	  C,	  whose	  
expression	  is	  restricted	  to	  the	  germ	  line	  and	  early	  embryos,	  is	  essential	  for	  
male	  meiosis	  and	  early	  embryogenesis	  (Avo	  Santos	  et	  al.,	  2011;	  Balboula	  and	  
Schindler,	  2014;	  Fernández-­‐Miranda	  et	  al.,	  2011;	  Kimmins	  et	  al.,	  2007).	  First	  
identified	  in	  Drosophila	  by	  Glover	  and	  colleagues,	  Aurora	  A	  was	  the	  first	  
member	  of	  the	  Aurora	  kinase	  family	  to	  be	  discovered.	  
Despite	  their	  divergent	  functions,	  there	  is	  a	  high	  degree	  of	  
conservation	  amongst	  the	  Aurora	  kinases.	  The	  respective	  localizations	  and	  
substrate	  specificities	  of	  the	  Auroras	  are	  directed	  via	  their	  cognate	  binding	  
partners	  (reviewed	  in	  Carmena	  et	  al.,	  2009).	  The	  CPC	  serves	  this	  adaptor	  
function	  for	  both	  Aurora	  B	  and	  C,	  which	  both	  bind	  to	  INCENP	  via	  its	  INbox	  
domain	  (Adams	  et	  al.,	  2001;	  Li	  et	  al.,	  2004).	  Aurora	  A	  is	  known	  to	  interact	  
with	  a	  number	  of	  adaptors,	  the	  best	  characterized	  of	  which	  is	  the	  
microtubule-­‐binding	  protein	  TPX2	  (Kufer	  et	  al.,	  2002).	  	  
That	  substrate	  specificity	  of	  Aurora	  kinases	  is	  achieved	  through	  
localisation	  has	  been	  highlighted	  in	  a	  number	  of	  studies.	  Most	  notably,	  a	  
single-­‐residue	  mutation	  in	  the	  TPX2-­‐binding	  domain	  of	  Aurora	  A	  to	  the	  
analogous	  residue	  in	  Aurora	  B	  leads	  to	  INCENP	  binding,	  Aurora	  B-­‐like	  
localization,	  and	  can	  rescue	  the	  loss	  of	  Aurora	  B	  (Hans	  et	  al.,	  2009).	  Ectopic	  
expression	  of	  Aurora	  C	  can	  also	  rescue	  Aurora	  B	  loss	  of	  function	  (Sasai	  et	  al.,	  
2004).	  Conversely,	  expression	  of	  a	  kinase-­‐dead	  Aurora	  C	  mutant	  interferes	  
with	  CPC	  function	  reiterating	  effects	  of	  kinase-­‐dead	  Aurora	  B	  expression	  
(Chen	  et	  al.,	  2005;	  Girdler	  et	  al.,	  2006;	  Sasai	  et	  al.,	  2004).	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ACCESSORY	  CPC	  SUBUNITS:	  INCENP,	  SURVIVIN	  &	  BOREALIN	  
As	  outlined	  earlier,	  the	  CPC	  consists	  of	  Aurora	  B,	  INCENP,	  survivin	  and	  
borealin.	  The	  stoichiometry	  of	  the	  full	  complex	  is	  still	  to	  be	  elucidated	  but	  
survivin	  and	  N-­‐terminal	  fragments	  of	  INCENP	  (1-­‐58)	  and	  borealin	  (10-­‐109)	  
form	  a	  1:1:1	  complex	  (Jeyaprakash	  et	  al.,	  2007)	  and	  Aurora	  B	  and	  INCENP	  
form	  either	  a	  1:1	  or	  a	  2:2	  complex,	  the	  latter	  of	  which	  through	  an	  activation	  
loop	  exchange	  between	  two	  Aurora	  B	  subunits	  (Sessa	  et	  al.,	  2005;	  Elkins,	  
2012).	  Purified	  Borealin	  forms	  a	  homodimer	  (Bourhis	  et	  al.,	  2009),	  as	  does	  
purified	  survivin	  (Chantalat	  et	  al.,	  2000;	  Verdecia	  et	  al.,	  2000).	  Together	  
however,	  purified	  borealin	  and	  survivin	  form	  a	  1:1	  complex	  (Bourhis	  et	  al.,	  
2007).	  	  A	  further	  protein,	  telophase	  disk	  60	  protein	  (TD60),	  shows	  passenger-­‐
like	  localization	  but	  is	  not	  stably	  associated	  with	  the	  complex	  itself	  and	  will	  
not	  be	  considered	  here	  (Martineau-­‐Thuillier	  et	  al.,	  1998).	  
	   As	  illustrated	  in	  Figure	  1.3.2,	  the	  CPC	  possesses	  activity	  (Aurora	  B)	  and	  
localization	  (survivin	  and	  borealin)	  modules	  with	  INCENP	  providing	  an	  
elongated	  flexible	  linker	  between	  the	  two.	  One	  current	  model	  proposes	  that	  
INCENP	  acts	  as	  ‘leash’	  through	  which	  Aurora	  B	  is	  flexibly	  tethered	  to	  specific	  
sites	  recognized	  via	  the	  tripartite	  localization	  domain	  (Santaguida	  and	  
Musacchio,	  2009).	  This	  would	  permit	  the	  kinase	  limited	  but	  flexible	  reach	  to	  
phosphorylate	  substrates.	  The	  localization	  module	  is	  formed	  via	  a	  tripartite	  
interaction	  between	  the	  INCENP	  N-­‐terminus,	  borealin	  and	  the	  C-­‐terminus	  or	  
survivin.	  All	  three	  domains	  adopt	  a	  helical	  conformation	  and	  interact	  with	  
each	  other	  to	  form	  a	  triple	  helix	  bundle	  (Jeyaprakash	  et	  al.,	  2007).	  The	  C-­‐
terminus	  of	  INCENP	  crowns	  the	  N-­‐terminal	  lobe	  of	  Aurora	  B	  (Sessa	  et	  al.,	  
2005).	  This	  interaction	  not	  only	  links	  Aurora	  B	  to	  the	  localization	  domain	  but,	  
most	  importantly,	  activates	  the	  kinase	  (see	  ‘Aurora	  B	  activation’	  section).	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INCENP	  
First	  described	  in	  by	  Cooke	  and	  colleagues	  1987,	  INCENP	  was	  the	  first	  
CPC	  component	  to	  be	  identified	  (Cooke	  et	  al.,	  1987).	  INCENP	  was	  discovered	  
via	  a	  chromosome	  scaffold	  monoclonal	  antibody	  screen	  by	  virtue	  of	  its	  highly	  
dynamic	  and	  stereotypical	  mitotic	  localization.	  The	  epitope	  was	  found	  to	  
associate	  with	  the	  inner	  centromere	  up	  until	  metaphase	  (giving	  the	  protein	  
its	  name),	  and	  then	  transfer	  to	  the	  spindle	  midzone	  and	  equatorial	  cortex	  
upon	  anaphase	  onset	  –	  the	  hallmarks	  of	  what	  is	  now	  known	  as	  ‘passenger-­‐
like’	  localization.	  	  
INCENP	  serves	  two	  primary	  functions:	  it	  acts	  as	  a	  scaffold	  for	  the	  CPC	  
by	  linking	  its	  localization	  and	  activity	  modules	  via	  its	  highly	  conserved	  
termini,	  and	  it	  activates	  Aurora	  B	  kinase.	  The	  latter	  function	  will	  be	  discussed	  
in	  detail	  in	  the	  ‘Aurora	  B	  activation’	  section.	  The	  INCENP	  N-­‐terminus	  is	  bound	  
by	  the	  two	  localization	  subunits	  of	  the	  CPC:	  survivin	  and	  borealin;	  its	  C-­‐
terminus	  contains	  the	  INbox,	  via	  which	  it	  binds	  and	  activates	  Aurora	  B.	  Distal	  
to	  INCENP’s	  N-­‐terminal	  alpha	  helical	  survivin	  and	  borealin	  interaction	  domain	  
is	  a	  heterochromatin	  protein	  1	  (HP1)	  interacting	  domain	  through	  which	  
INCENP	  interacts	  with	  chromatin	  (Ainsztein	  et	  al.,	  1998).	  The	  intervening	  
extended	  stretch	  of	  residues	  linking	  the	  two	  INCENP	  termini	  is	  less	  highly	  
conserved	  and	  structured.	  This	  domain	  is	  also	  known	  to	  associate	  with	  
microtubules	  (Wheatley	  et	  al.,	  2001)	  and	  is	  posited	  to	  offer	  flexibility	  and	  
‘reach’	  for	  Aurora	  B.	  	  
BOREALIN	  
Also	  known	  as	  Dasra,	  borealin	  was	  identified	  simultaneously	  through	  
two	  independent	  studies	  investigating	  proteins	  associated	  with	  mitotic	  
chromosomes	  or	  the	  mitotic	  scaffold	  (Gassmann	  et	  al.,	  2004;	  Sampath	  et	  al.,	  
2004).	  As	  indicated	  earlier,	  borealin	  participates	  in	  the	  formation	  of	  a	  triple	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helix	  bundle,	  which	  it	  does	  via	  its	  N-­‐terminus.	  The	  central	  region	  of	  borealin	  
interacts	  with	  the	  endosomal	  sorting	  complexes	  required	  for	  transport	  III	  
(ESCRT-­‐III)	  complex	  –	  a	  cytosolic	  membrane	  remodeling	  complex	  required	  for	  
abscission	  (see	  ‘Roles	  of	  the	  chromosomal	  passenger	  complex	  –	  in	  
cytokinesis’	  below.)	  As	  mentioned	  earlier,	  purified	  borealin	  forms	  a	  
homodimer,	  which	  it	  does	  via	  its	  C-­‐terminus.	  A	  Mps1	  phosphorylation	  site	  
within	  this	  dimerization	  domain	  is	  required	  for	  Aurora	  B	  activity	  in	  mitosis	  
(Bourhis	  et	  al.,	  2009).	  	  
SURVIVIN	  
	   Survivin	  is	  an	  essential	  protein	  first	  identified	  as	  a	  member	  of	  the	  
inhibitor	  of	  apoptosis	  (IAP)	  family	  by	  virtue	  of	  its	  zinc-­‐coordinated	  N-­‐terminal	  
BIR	  (baculovirus	  IAP	  repeat)	  domain	  (Ambrosini	  et	  al.,	  1997).	  Although	  first	  
presumed	  to	  possess	  an	  anti-­‐apoptotic	  role	  by	  virtue	  of	  its	  conserved	  BIR	  
domain,	  this	  domain	  binds	  to	  mitotic	  substrates	  with	  much	  greater	  affinity	  
than	  to	  the	  pro-­‐apoptotic	  Smac/DIABLO	  peptide	  (Du	  et	  al.,	  2012).	  Moreover,	  
survivin	  does	  not	  bind	  to	  apoptotic	  protease	  caspase	  3	  (Banks	  et	  al.,	  2000;	  Li	  
et	  al.,	  2008).	  Cells	  lacking	  survivin	  show	  increased	  chromosome	  alignment	  
and	  cytokinesis	  defects,	  which	  are	  consistent	  with	  it	  possessing	  mitotic	  
functions	  (Carvalho	  et	  al.,	  2003;	  Lens	  et	  al.,	  2003).	  
The	  C-­‐terminus	  of	  survivin	  consists	  of	  a	  helical	  domain	  that	  interacts	  
with	  itself	  to	  form	  a	  homodimer,	  or	  with	  borealin	  and	  the	  INCENP	  N-­‐terminus	  
to	  form	  the	  triplex	  helix	  bundle	  described	  earlier.	  The	  survivin	  N-­‐terminal	  BIR	  
domain	  is	  necessary	  for	  CPC	  localization	  to	  the	  centromere,	  but	  not	  the	  
spindle,	  in	  vertebrates	  (see	  ‘Chromosomal	  passenger	  complex	  localisation’	  
section	  below).	  In	  human	  and	  chicken	  DT40	  cells,	  survivin	  BIR	  mutants	  fail	  to	  
recruit	  Aurora	  B	  in	  early	  mitosis	  but	  do	  not	  affect	  the	  kinase’s	  post-­‐anaphase	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relocation	  to	  the	  spindle	  midzone	  and	  midbody	  (Lens	  et	  al.,	  2006;	  Yue	  et	  al.,	  
2008).	  	  
AURORA	  B	  ACTIVATION	  
Activation	  of	  Aurora	  B	  is	  mediated	  by	  interactions	  between	  the	  N-­‐
terminal	  lobe	  of	  the	  kinase	  and	  the	  highly-­‐conserved	  the	  INCENP	  C-­‐terminus:	  
the	  INbox (Adams	  et	  al.,	  2001;	  Adams	  et	  al.,	  2000;	  Kaitna	  et	  al.,	  2000).	  Full	  
activation	  of	  Aurora	  B	  by	  the	  INCENP	  INbox	  occurs	  via	  a	  sequence	  of	  
phosphorylation	  events	  (Bishop	  and	  Schumacher,	  2002).	  A	  crystal	  structures	  
of	  the	  two	  proteins	  has	  revealed	  that	  the	  INbox	  does	  not	  make	  contact	  with	  
either	  the	  Aurora	  B	  catalytic	  cleft	  or	  its	  activation	  loop	  (Figure	  1.3.3).	  Rather,	  
it	  allosterically	  promotes	  the	  opening	  of	  the	  catalytic	  cleft	  and	  trans	  
activation	  (Elkins	  et	  al.,	  2012;	  Sessa	  et	  al.,	  2005).	  Local	  enrichment	  of	  Aurora	  
B	  and	  INCENP	  is	  also	  required	  for	  the	  kinase’s	  activation,	  as	  demonstrated	  by	  
the	  artificial	  clustering	  of	  INCENP-­‐bound	  Aurora	  B	  using	  anti-­‐INCENP	  
antibodies	  (Kelly	  et	  al.,	  2007).	  
INbox	  binding	  to	  Aurora	  B	  generates	  the	  fully	  active	  CPC	  complex	  
through	  a	  sequence	  of	  phosphorylation	  events.	  Upon	  INCENP	  binding,	  Aurora	  
B	  phosphorylates	  a	  conserved	  threonine-­‐serine-­‐serine	  (TSS)	  motif	  located	  in	  
the	  C-­‐terminus	  of	  the	  INbox	  (Bishop	  and	  Schumacher,	  2002;	  Honda	  et	  al.,	  
2003).	  Phosphorylation	  of	  the	  TSS	  motif	  promotes	  phosphorylation	  of	  
threonine	  232	  on	  the	  Aurora	  B	  activation	  loop	  by	  Aurora	  B	  in	  trans	  (Yasui	  et	  
al.,	  2004).	  A	  recent	  xray	  crystallography	  study	  of	  the	  human	  Aurora	  B-­‐INbox	  
interaction	  detected	  a	  diametrically	  arranged	  structure	  in	  which	  Aurora	  B	  
activation	  loops	  are	  exchanged	  between	  adjacent	  Aurora	  B-­‐INbox	  dimers	  
(Elkins	  et	  al.,	  2012).	  Although	  the	  biological	  significance	  of	  this	  arrangement	  











Aurora B activity - H3S10 phoshorylation 
Figure 1.3.3 - Activation of Aurora B by the INCENP INbox. (A) The INCENP 
INbox (green) wraps around the N-terminal lobe of Aurora B (gray) and does 
not make contact with either the activation or catalytic loop (blue and red, 
respectively). Residues highlighted in orange are the two absolutely 
conserved residues that, when mutated, result in loss of Aurora B activation 
by the INbox (after Sessa et al., 2005; PDB:2BFY). (B) INCENP INbox mutants 
can only partially rescue Aurora B activity levels in chicken DT40 INCENP 
knockout cells (INCENPOFF). Basal Aurora B activity present in the knockout is 
further diminished by treatment with the Aurora B inhibitor ZM447439 (after 
Xu et al., 2009). For consistency, residues are numbered according to their 
homologous coordinates in human INCENP.
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Mutagenesis	  of	  both	  the	  TSS	  motif	  and	  other	  highly	  conserved	  residues	  
within	  the	  INbox	  has	  yielded	  a	  series	  of	  CPC	  hypomorphs	  (Figure	  1.3.3;	  Sessa	  
et	  al.,	  2005;	  Xu	  et	  al.,	  2009;	  Xu	  et	  al.,	  2010).	  Previous	  work	  from	  members	  of	  
our	  group	  has	  demonstrated	  that	  the	  chicken	  mutant	  of	  INCENP	  equivalent	  
to	  human	  INCENPW845G	  is	  incapable	  of	  binding	  and	  activating	  Aurora	  B,	  
whereas	  the	  one	  equivalent	  to	  INCENPF881A	  binds	  the	  kinase,	  but	  is	  activation-­‐
deficient	  (Xu	  et	  al.,	  2009).	  Neither	  of	  these	  mutants	  can	  rescue	  viability	  in	  the	  
absence	  of	  endogenous	  INCENP.	  As	  indicated	  in	  Figure	  1.3.3,	  in	  the	  absence	  
of	  INCENP	  Aurora	  B	  possesses	  a	  detectable	  basal	  activity	  that	  is	  sensitive	  to	  
treatment	  with	  active	  site	  inhibitors.	  	  
CHROMOSOMAL	  PASSENGER	  COMPLEX	  LOCALISATION	  
CPC	  localisation	  throughout	  mitosis	  is	  dynamic	  and	  tightly	  
orchestrated.	  As	  outlined	  earlier,	  the	  CPC	  is	  first	  present	  both	  on	  
chromosome	  arms	  and	  at	  centromeres	  in	  early	  mitosis.	  Its	  localisation	  
gradually	  becomes	  restricted	  to	  the	  centromere	  as	  mitosis	  progresses	  
towards	  metaphase.	  Upon	  anaphase	  onset,	  the	  complex	  translocates	  to	  the	  
equatorial	  cortex	  and	  spindle	  midzone,	  eventually	  accumulating	  in	  the	  
midbody	  during	  cytokinesis.	  Given	  the	  relevance	  to	  this	  project,	  I	  will	  outline	  
here	  the	  known	  mechanisms	  governing	  Aurora	  B	  localisation	  to	  the	  
centromere	  and	  to	  the	  spindle	  midzone	  and	  midbody.	  
TO	  THE	  CENTROMERE	  
The	  CPC	  first	  localises	  to	  chromatin	  in	  late	  S	  phase	  through	  INCENP	  
binding	  to	  HP1	  (Ainsztein	  et	  al.,	  1998).	  As	  mitosis	  progresses	  towards	  
metaphase,	  the	  complex	  is	  released	  from	  arms	  by	  Aurora	  B’s	  phosphorylation	  
of	  H3S10,	  which	  opposes	  HP1	  binding	  to	  the	  adjacent	  H3K9	  methylation	  mark	  
(Nozawa	  et	  al.,	  2010).	  The	  gradual	  focusing	  of	  the	  CPC	  to	  centromeres	  over	  
prometaphase	  and	  metaphase	  is	  achieved	  via	  the	  recognition	  of	  two	  histone	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marks:	  H2A	  phosphorylated	  at	  threonine	  120	  (H2AT120p)	  and	  H3	  at	  
threonine	  3	  (H3T3p).	  Respectively,	  these	  marks	  are	  laid	  down	  at	  centromeres	  
in	  early	  mitosis	  by	  the	  kinetochore-­‐associated	  kinase	  budding	  uninhibited	  by	  
benzimidazoles	  (Bub1)	  (Kawashima	  et	  al.,	  2010)	  and	  haspin	  kinase	  (Dai	  et	  al.,	  
2005).	  Phosphorylation	  of	  H3T3	  creates	  a	  binding	  site	  recognised	  by	  the	  BIR	  
domain	  of	  survivin	  (Kelly	  et	  al.,	  2010;	  Wang	  et	  al.,	  2010;	  Yamagishi	  et	  al.,	  
2010).	  Structural	  studies	  have	  determined	  that	  the	  recognition	  of	  H3T3p	  by	  
survivin	  is	  mediated	  by	  BIR	  domain	  recognition	  of	  an	  N-­‐terminal	  tetrapeptide	  
(Du	  et	  al.,	  2012;	  Jeyaprakash	  et	  al.,	  2011;	  Niedzialkowska	  et	  al.,	  2012).	  
Bioinformatics	  searches	  using	  the	  tetrapeptide	  consensus	  identified	  
shugoshin	  as	  a	  potential	  survivin	  interactor.	  The	  aforementioned	  H2AT120p	  
mark	  is	  recognized	  by	  shugoshin	  that,	  in	  turn,	  interacts	  with	  borealin	  to	  
recruit	  the	  CPC	  (Kawashima	  et	  al.,	  2007;	  Kawashima	  et	  al.,	  2010;	  Yamagishi	  et	  
al.,	  2010).	  Localisation	  of	  the	  CPC	  to	  the	  centromere	  is	  particularly	  crucial	  for	  
mitotic	  fidelity;	  the	  complex’s	  role	  in	  this	  process	  is	  discussed	  later	  in	  this	  
chapter.	  
TO	  THE	  MIDZONE	  AND	  MIDBODY	  
Upon	  anaphase	  onset,	  the	  CPC	  is	  first	  lost	  from	  the	  centromeres.	  CPC	  
centromeric	  recruitment	  ceases	  as	  the	  histone	  H3	  threonine	  3	  
phosphorylation	  mark	  is	  removed	  from	  chromatin	  (Qian,	  2011;	  Vagnarelli,	  
2011).	  Additionally,	  the	  CPC	  is	  actively	  removed	  from	  chromosomes	  as	  
Aurora	  B	  is	  first	  ubiquitylated	  then	  removed	  by	  the	  CDC48	  –	  an	  AAA+	  ATPase	  
(Ramadan,	  2007).	  The	  subsequent	  targeting	  of	  the	  CPC	  to	  the	  central	  spindle	  
during	  the	  transition	  into	  anaphase	  requires	  INCENP.	  Firstly,	  removal	  of	  a	  
CDK1	  mark	  on	  INCENP	  is	  required	  for	  re-­‐location	  of	  the	  CPC	  to	  the	  spindle	  
midzone	  (Hümmer	  and	  Mayer,	  2009).	  The	  contribution	  of	  other	  CPC	  subunits	  
to	  this	  localization	  is	  less	  clear.	  A	  survivin	  BIR-­‐domain	  mutant	  that	  fails	  to	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recruit	  the	  CPC	  to	  centromeres	  does	  not	  impede	  its	  relocalisation	  to	  the	  
spindle	  midzone	  upon	  anaphase	  onset	  (Lens,	  2006).	  Full	  Aurora	  B	  activity	  is	  
required	  for	  CPC	  transfer	  to	  the	  spindle	  midzone	  at	  anaphase;	  cytokinesis	  
remains	  defective	  in	  the	  presence	  of	  CPC	  hypomorphs,	  even	  those	  capable	  of	  
rescuing	  chromosomal	  alignment	  and	  other	  defects	  associated	  with	  CPC	  loss	  
of	  function	  (Xu	  et	  al.,	  2009).	  	  
ROLES	  OF	  THE	  CHROMOSOMAL	  PASSENGER	  COMPLEX	  
The	  CPC	  helps	  orchestrate	  numerous	  mitotic	  processes	  and	  the	  
abrogation	  of	  its	  activity	  has	  pleiotropic	  consequences.	  In	  early	  mitosis,	  the	  
CPC	  phosphorylates	  several	  chromatin	  substrates	  and	  is	  solely	  responsible	  for	  
phoshorylating	  histone	  H3	  on	  serine	  10	  and	  28	  (Giet	  and	  Glover,	  2001;	  
Sugiyama	  et	  al.,	  2002).	  The	  CPC	  also	  acts	  to	  increase	  recruitment	  of	  
condensin	  I	  to	  mitotic	  chromosomes,	  correct	  erroneous	  kinetochore-­‐
microtubule	  attachments,	  activate	  the	  spindle	  assembly	  checkpoint	  and	  
support	  spindle	  midzone	  formation.	  In	  cytokinesis,	  the	  CPC	  helps	  regulate	  
contractile	  ring	  formation	  and	  abscission.	  The	  roles	  of	  the	  CPC	  in	  mitosis	  and	  
cytokinesis	  are	  extensively	  reviewed	  in	  Carmena,	  2012	  and	  van	  der	  Waal	  et	  
al.,	  2012.	  Due	  to	  their	  relevance	  to	  this	  project,	  I	  will	  elaborate	  here	  on	  
Aurora	  B’s	  role	  in	  chromosome	  bi-­‐orientation	  and	  cytokinesis.	  It	  should	  also	  
be	  noted	  that,	  further	  to	  the	  above	  mitotic	  and	  cytokinetic	  functions,	  a	  
recent	  report	  suggests	  that	  Aurora	  B	  activity	  during	  interphase	  is	  required	  for	  
proper	  mitotic	  progression	  (Hayashi-­‐Takanaka	  et	  al.,	  2009).	  	  
Although	  not	  considered	  in	  great	  detail	  here,	  it	  is	  important	  to	  note	  
that	  spatiotemporal	  direction	  and	  restriction	  of	  CPC	  activity	  is	  reinforced	  
through	  a	  series	  of	  synergistic	  and	  antagonistic	  interactions	  with	  other	  
mitotic	  regulators.	  These	  functional	  interactions	  include	  kinase-­‐crosstalk	  with	  
polo	  kinase	  (Lens	  et	  al.,	  2010),	  and	  the	  removal	  of	  phosphorylation	  marks	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from	  Aurora	  B	  substrates	  by	  protein	  phosphatases	  (Emanuele	  et	  al.,	  2008;	  Liu	  
et	  al.,	  2010).	  	  
IN	  SISTER	  CHROMATID	  BI-­‐ORIENTATION	  
In	  order	  to	  maintain	  mitotic	  fidelity	  and	  ensure	  that	  each	  daughter	  cell	  
receives	  one	  –	  and	  only	  one	  –	  copy	  of	  each	  chromosome,	  sister	  chromatids	  
must	  be	  oriented	  to	  opposite	  poles	  prior	  to	  their	  separation.	  Failure	  to	  
achieve	  bi-­‐orientation	  can	  lead	  to	  aneuploidy,	  which	  can	  have	  serious	  
consequences	  and	  potentially	  lead	  to	  cancer	  initiation	  (Holland	  and	  
Cleveland,	  2009).	  Thus,	  prior	  to	  their	  separation	  at	  anaphase,	  the	  attachment	  
of	  sister	  chromatids	  to	  microtubules	  emanating	  from	  opposite	  poles	  must	  
first	  be	  achieved	  and	  recognized	  by	  the	  appropriate	  sensors.	  Converging	  
fields	  of	  Aurora	  B	  and	  protein	  phosphatase	  1	  (PP1)	  activity,	  respectively,	  
emanating	  from	  the	  inner	  centromere	  and	  outer	  kinetochore,	  create	  a	  
phosphorylation	  gradient	  across	  the	  kinetochore	  in	  metaphase.	  The	  PP1	  
gamma	  isoform	  is	  recruited	  to	  the	  outer	  kinetochore	  by	  its	  interaction	  with	  
the	  N-­‐terminus	  of	  KNL1,	  this	  interaction	  is	  itself	  opposed	  by	  Aurora	  B	  
phosphorylation	  of	  the	  PP1	  docking	  motif	  on	  KNL1	  (Liu	  et	  al.,	  2010).	  This	  
gradient	  promotes	  chromosome	  bi-­‐orientation	  by	  destabilizing	  kinetochore-­‐
microtubule	  attachments	  that	  do	  not	  generate	  tension	  (Liu	  et	  al.,	  2009;	  Liu	  et	  
al.,	  2010;	  Tanaka	  et	  al.,	  2002).	  Sister	  chromatid	  bi-­‐orientation	  results	  in	  
tension,	  which	  draws	  kinetochores	  outwards	  from	  the	  gradient	  of	  Aurora	  B	  
activity.	  The	  importance	  of	  tension	  and	  the	  spatial	  segregation	  of	  Aurora	  B	  
substrates	  in	  error	  correction	  has	  been	  illustrated	  in	  a	  study	  KMN	  network	  
components,	  which	  are	  part	  of	  the	  outer	  kinetochore	  (Welburn	  et	  al.,	  2010). 
Further	  to	  destabilizing	  incorrectly	  attached	  kinetochores	  to	  promote	  
bi-­‐orientation,	  Aurora	  B	  phosphorylation	  of	  several	  kinetochore	  components	  
generates	  transiently	  unattached	  kinetochores	  that,	  in	  turn,	  activate	  the	  
	   36	  
spindle	  assembly	  checkpoint	  (Ditchfield	  et	  al.	  2003,	  Hauf	  et	  al.	  2003,	  
Khodjakov	  and	  Pines	  2010).	  As	  the	  presence	  of	  even	  a	  single	  unattached	  
kinetochore	  is	  sufficient	  to	  produce	  a	  ‘wait	  anaphase	  signal’	  (Rieder	  et	  al.,	  
1995),	  the	  generation	  of	  transiently	  unattached	  kinetochores	  prevents	  
premature	  anaphase	  onset.	  Incorrect	  (syntelic	  and	  merotelic)	  attachments	  
that	  can	  be	  maintained	  in	  the	  absence	  of	  Aurora	  B	  function,	  satisfy	  the	  
spindle	  checkpoint,	  leading	  to	  chromosome	  segregation	  errors	  (Hauf	  et	  al.,	  
2003).	  Recent	  evidence	  also	  hints	  to	  a	  more	  direct	  role	  for	  Aurora	  B	  in	  
checkpoint	  activation	  via	  the	  recruitment	  of	  the	  mitotic	  checkpoint	  kinase	  
Mps1	  (Saurin	  et	  al.,	  2011).	  	  
Rather	  than	  block	  mitotic	  progression,	  Aurora	  B	  inactivation	  can	  allow	  
cells	  to	  proceed	  to	  anaphase	  without	  first	  achieving	  chromosome	  bi-­‐
orientation,	  resulting	  in	  widespread	  chromosome	  misalignment.	  It	  is	  for	  this	  
reason	  that	  some	  choose	  to	  refer	  to	  Aurora	  B	  inhibitors	  as	  mitotic	  drivers	  
rather	  than	  anti-­‐mitotics	  (Keen	  and	  Taylor,	  2009).	  Interestingly,	  a	  survivin	  BIR	  
domain	  mutant	  that	  cannot	  localise	  the	  CPC	  to	  centromeres,	  but	  which	  does	  
not	  affect	  CPC	  localization	  from	  anaphase	  onwards,	  can	  rescue	  lethality	  in	  the	  
absence	  of	  wild	  type	  survivin	  in	  chicken	  DT40	  cells	  (Yue	  et	  al.,	  2008).	  This	  
mutant	  grew	  with	  comparable	  kinetics	  to	  cells	  containing	  wild	  type	  survivin	  
but	  presented	  a	  small	  yet	  significant	  decrease	  in	  mitotic	  arrest	  when	  treated	  
with	  taxol.	  Although	  functionally	  important,	  the	  biological	  importance	  of	  
centromeric	  CPC-­‐mediated	  error	  correction	  in	  vertebrates	  is	  uncertain.	  	  
IN	  CYTOKINESIS	  
Upon	  anaphase	  onset,	  the	  equatorial	  cleavage	  furrow	  ingresses,	  
eventually	  leading	  to	  the	  formation	  of	  a	  midbody	  that	  will	  undergo	  
abscission,	  resulting	  in	  the	  separation	  of	  the	  two	  daughter	  cells.	  Aurora	  B	  
relocalizes	  from	  the	  centromeres	  to	  the	  spindle	  midzone	  and	  to	  the	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equatorial	  cortex	  upon	  anaphase	  onset,	  where	  it	  persists	  as	  the	  midbody	  
forms.	  Cytokinesis	  failure	  is	  a	  striking	  hallmark	  of	  CPC	  loss	  of	  function	  (Terada	  
et	  al.,	  1998)	  but	  its	  role	  in	  this	  process	  is	  less	  well	  understood	  than	  that	  in	  
chromosome	  bi-­‐orientation.	  	  
The	  CPC	  interacts	  with	  a	  number	  of	  central	  spindle	  components	  and	  its	  
activity	  is	  required	  for	  localisation	  of	  centralspindlin	  to	  the	  midzone	  (Douglas	  
et	  al.,	  2010).	  Centralspindlin,	  in	  turns,	  regulates	  the	  recruitment	  of	  Ect2	  –	  the	  
guanosine	  exchange	  factor	  for	  RhoA	  (Nishimura	  and	  Yonemura,	  2006).	  RhoA	  
is	  a	  GTPase	  involved	  in	  contractile	  ring	  formation	  and	  maturation	  (Drechsel	  et	  
al.,	  1997).	  Aurora	  B	  and	  INCENP	  also	  interact	  with	  a	  number	  of	  cytoskeleton	  
components	  in	  several	  organisms,	  such	  as	  actin	  in	  Dictyostelium	  (Chen	  et	  al.,	  
2007)	  and	  the	  formin	  FHOD-­‐1	  in	  humans	  (Ozlü	  et	  al.	  ,	  2010).	  	  
In	  S.	  cerevisiae,	  the	  CPC	  participates	  in	  the	  no-­‐cut	  pathway,	  which	  acts	  
to	  prevent	  DNA	  damage	  by	  delaying	  the	  completion	  of	  abscission	  should	  DNA	  
be	  present	  in	  the	  cytokinetic	  furrow	  (Norden	  et	  al.,	  2006). Although	  
experimental	  evidence	  is	  more	  limited,	  the	  CPC	  has	  been	  implicated	  in	  a	  
similar	  pathway	  –	  known	  as	  the	  abscission	  checkpoint	  –	  in	  humans	  
(Steigemann	  et	  al.,	  2009).	  The	  CPC	  interacts	  directly	  with	  components	  of	  the	  
ESCRT-­‐III	  complex	  via	  borealin,	  and	  Aurora	  B	  phosphorylates	  the	  CHMP4C	  
component	  of	  the	  complex	  (Capalbo	  et	  al.,	  2012;	  Carlton	  et	  al.,	  2012).	  
Phosphorylation	  of	  ESCRT-­‐III	  components	  by	  Aurora	  B	  is	  thought	  to	  prevent	  
the	  completion	  abscission	  thus	  regulate	  the	  timing	  of	  cytokinesis. 
Cytokinesis	  failure	  leading	  to	  eventual	  mitotic	  catastrophe	  in	  
subsequent	  mitoses	  is	  proposed	  to	  be	  the	  principal	  sequence	  of	  events	  by	  
which	  Aurora	  B	  inactivation	  leads	  to	  cell	  death	  (Kaestner	  et	  al.,	  2009).	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AURORA	  B	  IN	  CANCER	  
Aurora	  B	  overexpression	  has	  been	  reported	  in	  various	  cancer	  types	  
and	  is	  associated	  with	  poor	  prognosis	  (Pannone	  et	  al.;	  Smith	  et	  al.,	  2005).	  
However,	  Aurora	  B	  overexpression	  fails	  to	  transform	  cells	  in	  in	  vitro	  
transformation	  assays	  (in	  contrast,	  Aurora	  A	  expression	  does	  transform	  cells,	  
see (Wang	  et	  al.,	  2006)	  –	  it	  is,	  therefore,	  not	  an	  oncogene	  per	  se	  (Kanda	  et	  
al.,	  2005).	  Furthermore,	  protein	  levels	  of	  Aurora	  B	  and	  CPC	  components	  peak	  
in	  G2/M.	  As	  increased	  proliferation	  –	  thus	  elevated	  mitotic	  rates	  –	  are	  a	  
hallmark	  of	  many	  neoplasms,	  higher	  levels	  of	  Aurora	  B	  may	  merely	  be	  
coincidental	  in	  cancerous	  tissues.	  This	  would	  mean	  that	  an	  increased	  mitotic	  
index,	  rather	  than	  increased	  levels	  of	  Aurora	  B,	  would	  correlate	  with	  poor	  
prognosis.	  	  
AURORA	  B	  INHIBITORS	  AS	  ANTI-­‐CANCER	  THERAPEUTICS	  
Despite	  the	  debate	  surrounding	  Aurora	  B’s	  role	  in	  tumourigenesis,	  
treatment	  with	  Aurora	  B	  inhibitors	  preferentially	  kills	  actively	  proliferating	  
cells	  irrespective	  of	  p53	  status	  (Ditchfield	  et	  al.,	  2003).	  Furthermore,	  the	  ATP	  
analogues	  AZD1152	  and	  GSK1070916,	  which	  preferentially	  inhibit	  Aurora	  B,	  
have	  been	  shown	  to	  inhibit	  tumour	  growth	  in	  xenograft	  models	  (Hardwicke	  
et	  al.,	  2009;	  Wilkinson	  et	  al.,	  2007).	  Taken	  together,	  these	  results	  have	  
promoted	  Aurora	  B	  as	  an	  anticancer	  target	  (Girdler	  et	  al.,	  2006).	  	  
Further	  to	  cytokinesis	  failure,	  Aurora	  B	  inactivation	  permits	  mitotic	  
progression	  in	  the	  presence	  of	  taxol-­‐stabilized	  microtubules.	  Therefore,	  
Aurora	  B	  inhibitors	  might	  potentiate	  the	  effects	  of	  taxane	  treatment	  by	  
promoting	  premature	  mitotic	  exit	  and	  catastrophe,	  rather	  than	  mitotic	  arrest	  
(Yang	  et	  al.,	  2009).	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AN	  OVERVIEW	  OF	  EXISTING	  AURORA	  B	  &	  PAN-­‐AURORA	  INHIBITORS	  
Several	  pan-­‐Aurora	  and	  Aurora	  B-­‐preferential	  inhibitors	  have	  
undergone	  pre-­‐clinical	  development	  and,	  in	  some	  instances,	  progressed	  to	  
phase	  I	  and	  II	  clinical	  trials.	  Furthermore,	  a	  number	  of	  these	  compounds	  are	  
now	  commonly	  used	  research	  tools	  –	  Aurora	  B-­‐specific	  inhibitors	  are	  
summarized	  in	  Table	  1.3.	  	  
The	  current	  panel	  of	  Aurora	  B	  inhibitors	  consists	  solely	  of	  ATP-­‐
analogues.	  This	  raises	  two	  potential	  issues:	  lack	  of	  specificity	  and	  
susceptibility	  to	  resistant	  mutants.	  Firstly,	  although	  these	  compounds	  show	  a	  
marked	  affinity	  for	  Aurora	  B,	  these	  are	  promiscuous	  to	  a	  degree	  –	  inhibiting	  
Aurora	  B	  paralogues	  at	  higher	  concentrations	  and,	  in	  some	  instances,	  
unrelated	  kinases	  (see	  Bain	  et	  al.,	  2007)	  and	  the	  remark	  column	  in	  Table	  1.3).	  
Secondly,	  the	  common	  mechanism	  of	  action	  of	  Aurora	  B	  inhibitors	  is	  
anticipated	  to	  limit	  its	  clinical	  targeting.	  A	  study	  carried	  out	  by	  the	  group	  of	  
Stephen	  Taylor	  sought	  to	  identify	  Aurora	  B	  mutants	  resistant	  to	  ZM447439	  
(Girdler	  et	  al.,	  2008).	  These	  mutants	  readily	  arose	  in	  a	  hypermutable	  cancer	  
cell	  line	  and,	  critically,	  proved	  to	  be	  resistant	  to	  all	  other	  Aurora	  B	  inhibitors	  
tested.	  This	  result	  predicts	  the	  occurrence	  of	  pan-­‐resistance	  to	  Aurora	  B	  
inhibitors	  in	  the	  clinic	  and	  has	  been	  independently	  replicated	  in	  leukemia	  
cells	  (Failes	  et	  al.,	  2012).	  	  
As	  alluded	  to	  whilst	  discussing	  antimitotics	  more	  generally,	  the	  
performance	  of	  Aurora	  inhibitors	  in	  clinical	  trials	  has	  limited.	  In	  some	  
instances,	  promising	  patient	  outcomes	  were	  observed	  but	  these	  are	  thought	  
to	  have	  occurred	  due	  to	  the	  fortuitous	  binding	  of	  compounds	  to	  imatinib-­‐
resistant	  Bcr-­‐Abl	  kinase	  (Fei	  et	  al.,	  2010;	  Modugno	  et	  al.,	  2007).	  The	  lack	  of	  
biomarker(s)	  capable	  of	  identifying	  potential	  responder	  populations	  also	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impedes	  the	  chances	  of	  success	  of	  Aurora	  B	  or	  pan	  Aurora	  inhibitors	  in	  the	  
clinic.	  	  
Compound	   Company	   Phase	   Indication	   Remark	  
AZD1152	   AstraZeneca	   II	  
AML,	  advanced	  
solid	  tumours	  
Aurora	  C	  inhibition	  
GSK1070916A	   GSK	   I	  
Advanced	  solid	  
tumours	  
Aurora	  C	  inhibition	  
ZM447439	   AstraZeneca	   RT	   N/A	   Aurora	  A	  inhibition	  
Hesperadin	   Boehringer	  Ingelheim	   RT	   N/A	  
LCK,	  CHK1,	  MAPKAP-­‐
K1,	  MKK1,	  PHK	  and	  
AMPK	  inhibition	  
Table	  1.3	  –	  Currently	  available	  Aurora	  B	  preferential	  inhibitors,	  their	  clinical	  
status	  (RT:	  research	  tool),	  indication	  (N/A:	  non	  applicable	  due	  to	  research	  use	  
only),	  and	  remarks	  indicating	  any	  known	  off	  target	  effects	  (after	  Lens	  et	  al.,	  
2010	  and	  Carmena	  and	  Earnshaw	  2003)	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1.4	   AIMS	  OF	  THE	  PROJECT	  
Evidence	  suggests	  that	  targeting	  Aurora	  B	  interactors	  might	  prove	  to	  
be	  an	  effective	  alternative	  strategy	  for	  abrogating	  CPC	  function.	  A	  
downregulator	  of	  survivin	  expression	  –	  YM155	  –	  showed	  promise	  in	  
inhibiting	  tumor	  growth	  in	  xenograft	  models	  but	  had	  very	  limited	  success	  in	  
phase	  II	  clinical	  trials	  (Lewis	  et	  al.,	  2011;	  Nakahara	  et	  al.,	  2007).	  The	  potential	  
of	  targeting	  protein-­‐protein	  interactions	  within	  the	  CPC	  has	  been	  
acknowledged	  but	  thus	  far	  dismissed	  due	  to	  perceived	  challenges	  in	  
developing	  drugs	  capable	  of	  binding	  such	  surfaces	  (Keen	  and	  Taylor,	  2004).	  
In	  light	  of	  the	  inability	  of	  certain	  INbox	  mutants	  to	  fully	  rescue	  Aurora	  
B	  activity	  in	  the	  absence	  of	  endogenous	  INCENP	  (Xu	  et	  al.,	  2009),	  we	  propose	  
the	  following	  hypothesis:	  competitive	  inhibition	  of	  the	  interaction	  between	  
Aurora	  B	  and	  the	  INCENP	  INbox	  ought	  to	  result	  in	  loss	  of	  Aurora	  B	  activity	  
and	  localization.	  Thus,	  this	  may	  constitute	  a	  novel	  strategy	  for	  the	  inhibition	  
of	  CPC	  function.	  Because	  these	  would	  be	  distinct	  from	  the	  current	  crop	  of	  
ATP-­‐competitive	  inhibitors,	  PPI	  inhibitors	  of	  CPC	  function	  could	  be	  valuable	  
for	  both	  research	  and	  clinical	  use.	  In	  theory,	  these	  would	  not	  be	  susceptible	  
to	  Aurora	  B	  mutations	  conferring	  resistance	  to	  multiple	  ATP	  analogue	  
inhibitors	  (Failes	  et	  al.,	  2012;	  Girdler	  et	  al.,	  2008).	  	  
Furthermore,	  INbox-­‐mediated	  protein-­‐protein	  interactions	  represent	  
an	  attractive	  target	  as	  their	  disruption	  might	  curtail	  the	  activation	  not	  only	  of	  
Aurora	  B,	  but	  also	  Aurora	  C	  –	  the	  latter	  is	  overexpressed	  in	  some	  cancers,	  
which	  is	  associated	  with	  poor	  prognosis	  (Takahashi	  et	  al.,	  2000).	  
Furthermore,	  ectopic	  Aurora	  C	  expression	  has	  the	  potential	  to	  compensate	  
for	  loss	  of	  Aurora	  B	  function.	  Aurora	  C	  has	  been	  reported	  to	  rescue	  both	  
Aurora	  B	  knockdown,	  and	  overexpression	  of	  catalytically	  dead	  Aurora	  B	  (Sasai	  
et	  al.,	  2004;	  Yan	  et	  al.,	  2005).	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The	  first	  aim	  of	  this	  project	  was	  to	  ascertain	  the	  effects	  of	  competitive	  
inhibition	  of	  Aurora	  B-­‐INbox	  binding.	  In	  contrast	  to	  previously	  published	  
results,	  we	  wished	  to	  investigate	  conditions	  in	  which	  all	  endogenous	  CPC	  
components	  are	  present.	  Should	  these	  results	  support	  the	  targeting	  of	  this	  
interaction,	  a	  secondary	  aim	  of	  the	  project	  was	  to	  test	  whether	  this	  
interaction	  can	  be	  modulated	  by	  drug-­‐like	  compounds.	  That	  is,	  whether	  small	  
compounds	  with	  drug-­‐like	  properties	  can	  elicit	  the	  desired	  effect.	  For	  this,	  a	  
library	  of	  small	  INbox	  mimetic	  peptides	  was	  designed,	  built	  and	  screened.	  
Current	  methods	  used	  to	  find	  short	  peptides	  and	  other	  small	  
molecules	  disrupting	  PPIs	  rely	  on	  exogenous	  proteins,	  in	  either	  in	  vitro	  or	  in	  
heterologous	  assay	  environments.	  In	  that	  setting,	  off-­‐target	  effects	  are	  
difficult	  to	  assess	  and	  the	  readout	  cannot	  include	  a	  measure	  of	  activity	  on	  
endogenous	  substrates.	  SICLOPPS	  methodology	  was	  deployed	  to	  overcome	  
the	  dual	  hurdles	  of	  peptide	  delivery	  and	  stability	  which	  currently	  hamper	  the	  
assessment	  and	  optimization	  of	  short	  peptide	  mimics	  as	  antagonists	  of	  
intracellular	  PPIs	  in	  cell-­‐based	  assays.	  	  
As	  the	  intention	  was	  to	  assess	  peptide	  activity	  against	  endogenous	  
proteins,	  new	  screening	  and	  library	  design	  approaches	  had	  to	  be	  considered.	  
In	  contrast	  to	  their	  combinatorial	  counterparts,	  mimetic	  libraries	  would	  
consist	  of	  a	  relatively	  small	  number	  of	  discrete	  members.	  Although	  less	  
chemically	  diverse,	  discrete	  mimetic	  libraries	  are	  more	  amenable	  to	  cell-­‐
based	  screens	  using	  human	  cell	  lines	  and	  allow	  for	  complex	  screen	  readouts.	  	  
Assessing	  the	  potential	  of	  genetically	  encoded	  CP	  mimics	  to	  disrupt	  
protein-­‐protein	  interactions	  in	  vivo	  was	  a	  tertiary	  goal	  of	  this	  project.	  Given	  
the	  wealth	  of	  structural	  and	  molecular	  biological	  data	  concerning	  the	  CPC	  
upon	  which	  one	  can	  draw	  upon	  to	  intuitively	  design	  mimetic	  peptide	  
inhibitors,	  Aurora	  B	  was	  deemed	  a	  strong	  candidate	  for	  trialing	  this	  approach.	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CHAPTER	  2:	  MATERIALS	  AND	  METHODS	  
2.1	   TISSUE	  CULTURE	  TECHNIQUES	  
CELL	  CULTURE	  
HeLa	  Kyoto	  cells,	  a	  widely	  used	  adherent	  isolate	  of	  the	  HeLa	  cell	  line,	  
were	  grown	  in	  Dulbecco’s	  modified	  Eagle	  medium	  (DMEM;	  GIBCO,	  Life	  
Technologies)	  supplemented	  with	  1%	  fetal	  bovine	  serum	  (FBS,	  SIGMA)	  and	  
1X	  penicillin/streptomycin	  (GIBCO,	  Life	  Technologies).	  Cells	  were	  passaged	  as	  
required	  by	  first	  washing	  in	  1X	  phosphate	  buffered	  saline	  (PBS;	  GIBCO,	  Life	  
Technologies),	  trypsinizing	  by	  the	  addition	  of	  TrypLE™	  Express	  (GIBCO,	  Life	  
Technologies)	  followed	  by	  a	  short	  incubation	  at	  37oC,	  and	  diluting	  in	  fresh	  
warm	  medium.	  Typically,	  cells	  would	  be	  passaged	  at	  a	  1/10	  dilution	  every	  
two	  days	  or	  upon	  reaching	  approximately	  70%	  confluence.	  
For	  storage,	  cells	  were	  harvested	  from	  near	  confluent	  flasks	  by	  first	  
washing	  in	  1XPBS,	  trypsinizing	  and	  quenching	  with	  medium	  to	  a	  final	  volume	  
of	  10ml.	  Cells	  were	  transferred	  to	  a	  15ml	  falcon	  tube,	  spun	  down	  gently	  (5	  
minutes	  at	  1000	  RCF),	  resuspended	  in	  1.5ml	  freezing	  medium	  (10%	  dimethyl	  
sulfoxide	  (DMSO),	  90%	  FBS)	  and	  transferred	  to	  a	  cryogenic	  vial.	  Vials	  were	  
stored	  at	  -­‐80oC	  for	  initial	  freezing	  and	  maintained	  at	  that	  temperature	  for	  
short-­‐term	  storage	  (1-­‐3	  months);	  for	  long	  term	  storage,	  vials	  were	  
transferred	  to	  liquid	  nitrogen	  roughly	  one	  week	  after	  initial	  freezing.	  
TRANSFECTION-­‐GRADE	  DNA	  PREPARATION	  
Unless	  otherwise	  stated,	  DNA	  samples	  used	  for	  transfection	  were	  
prepared	  from	  50ml	  overnight	  cultures	  using	  a	  (QIAGEN)	  as	  directed	  by	  the	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manufacturer	  with	  the	  following	  modification:	  following	  initial	  filtration,	  1ml	  
endotoxin	  removal	  (ER)	  buffer	  (QIAGEN,	  available	  from	  the	  EndoFree	  kit	  
range)	  was	  added	  to	  the	  cell	  lysates	  and	  incubated	  on	  ice	  for	  30	  minutes.	  
After	  this	  step,	  cell	  lysates	  were	  applied	  to	  the	  QIAGEN-­‐tip	  100	  and	  the	  
remainder	  of	  the	  protocol	  followed	  as	  directed.	  DNA	  pellets	  were	  
resuspended	  in	  50µl	  ddH2O	  at	  4oC	  overnight,	  DNA	  concentration	  was	  
measured	  using	  a	  NanoDrop	  instrument	  (Thermo	  Scientific)	  prior	  to	  storage	  
at	  -­‐20oC.	  
TRANSIENT	  TRANSFECTION	  
Cells	  were	  transfected	  using	  either	  FuGene	  6	  (Roche)	  or	  XtremeGENE	  
9	  (Roche)	  according	  to	  the	  manufacturer’s	  guidelines.	  It	  should	  be	  noted	  that	  
Xtreme	  gene	  9	  is	  the	  replacement	  for	  FuGene	  6,	  which	  was	  discontinued	  
partway	  through	  this	  project;	  the	  formulation	  of	  these	  products	  is	  identical.	  
Briefly,	  for	  HeLa	  cells	  in	  a	  6	  well	  plate:	  one	  day	  prior	  to	  transfection,	  cells	  
were	  seeded	  to	  a	  density	  of	  2.25x105	  cells	  per	  well;	  cells	  were	  transfected	  
using	  2µg	  of	  plasmid	  DNA	  and	  6µl	  FuGENE	  6/XtremeGENE	  9	  diluted	  in	  200µl	  
Opti-­‐MEM®	  (Life	  Technologies)	  following	  the	  manufacturer’s	  instructions;	  24	  
hour	  post-­‐transfection,	  growth	  medium	  was	  changed	  and	  selection	  drugs	  
added	  if	  applicable.	  	  
SUBCLONING	  	  
A	  HeLa	  Kyoto	  cell	  line	  already	  available	  in	  the	  lab,	  or	  a	  subclone	  
thereof	  (HeLa	  Kyoto	  clone	  D,	  see	  section	  3.3),	  was	  used	  throughout	  this	  
study.	  The	  cell	  line	  was	  subcloned	  by	  seeding	  trypsinized	  cells	  to	  a	  density	  of	  
<1	  cell	  per	  well	  into	  a	  96	  well	  plate.	  That	  is,	  cells	  were	  diluted	  in	  
supplemented	  medium	  to	  a	  density	  of	  0.5	  cells	  per	  100µl,	  and	  100µl	  of	  the	  
mixture	  added	  to	  each	  well.	  The	  96	  well	  plate	  was	  incubated	  under	  usual	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tissue	  culture	  conditions	  and	  wells	  regularly	  monitored	  for	  colony	  formation.	  
After	  a	  week,	  cells	  from	  a	  number	  of	  wells	  containing	  a	  single	  colony	  were	  re-­‐
plated	  and	  expanded,	  then	  assayed	  for	  background	  abnormal	  nuclei	  indexes	  
and	  transfection	  efficiency.	  
2.2	   MOLECULAR	  BIOLOGY	  METHODS	  
SDS-­‐PAGE	  
Prior	  to	  western	  blotting,	  protein	  samples	  were	  resolved	  by	  sodium	  
dodecyl	  sulfate	  polyacrylamide	  gel	  electrophoresis	  (SDS-­‐PAGE).	  Samples	  were	  
diluted	  in	  sample	  buffer	  to	  1X	  prior	  to	  loading.	  For	  HeLa	  cells,	  cells	  were	  lysed	  
in	  30µl	  1X	  reducing	  SDS-­‐PAGE	  sample	  buffer	  per	  1x106	  cells,	  boiled	  for	  5	  
minutes	  then	  sonicated	  for	  15	  minutes	  (settings:	  30	  seconds	  on/30	  seconds	  
off;	  high	  intensity)	  using	  a	  Bioruptor	  instrument	  (Diagenode).	  Lysates	  were	  
cleared	  by	  centrifugation	  for	  3	  minutes	  at	  high	  speed	  prior	  to	  loading	  on	  a	  gel	  
or	  storage	  at	  -­‐20oC.	  Lysates	  were	  resolved	  by	  sodium	  dodecyl	  sulphate	  
polyacrylamide	  gel	  electrophoresis	  (SDS-­‐PAGE)	  in	  Laemmli	  buffer.	  For	  
western	  blotting	  applications	  (see	  below),	  proteins	  were	  transferred	  onto	  
Hybond	  ECL	  nitrocellulose	  membrane	  (GE	  Healthcare)	  by	  wet	  transfer	  at	  4oC	  
overnight	  using	  a	  constant	  voltage	  of	  30V.	  
PONCEAU	  S	  STAINING	  
Prior	  to	  western	  blotting,	  the	  extent	  and	  evenness	  of	  protein	  transfer	  
were	  verified	  by	  Ponceau	  S	  staining.	  Following	  the	  disassembly	  of	  the	  
transfer,	  membranes	  were	  first	  washed	  twice	  for	  5	  minutes	  in	  PBS-­‐tween	  
(1XPBS,	  0.2%	  (v/v)	  Tween	  20;	  hereby	  referred	  to	  as	  PBS-­‐t)	  at	  room	  
temperature	  with	  mild	  agitation.	  Membranes	  were	  then	  stained	  with	  
Ponceau	  S	  solution	  (0.5%	  w/v	  Ponceau	  S,	  1%	  acetic	  acid)	  for	  10-­‐15	  minutes.	  
Following	  staining,	  the	  Ponceau	  S	  solution	  was	  rinsed	  off	  repeatedly	  with	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water	  until	  bands	  became	  visible	  over	  the	  background.	  All	  staining	  and	  
washing	  steps	  indicated	  here	  were	  carried	  out	  at	  room	  temperature	  with	  
mild	  agitation.	  
WESTERN	  BLOTTING	  
Following	  Ponceau	  S	  staining,	  membranes	  were	  washed	  twice	  in	  PBS-­‐t	  
and	  blocked	  in	  a	  solution	  of	  5%	  (w/v)	  milk	  diluted	  PBS-­‐t	  for	  1	  hour	  at	  room	  
temperature.	  Blocked	  membranes	  were	  then	  washed	  2x5	  minutes	  in	  PBS-­‐t	  
then	  probed	  with	  the	  primary	  antibody	  diluted	  in	  5%	  milk	  PBS-­‐t	  for	  1	  hour	  at	  
room	  temperature	  (see	  2.3	  for	  antibody	  dilutions	  used).	  Unbound	  primary	  
antibody	  was	  washed	  off	  with	  2x5	  minutes	  PBS-­‐t	  washes,	  then	  the	  desired	  
secondary	  antibody	  diluted	  in	  5%	  milk	  PBS-­‐t	  was	  applied	  for	  1	  hour	  at	  room	  
temperature.	  Prior	  to	  detection,	  the	  membrane	  was	  washed	  twice	  for	  5	  
minutes	  in	  PBS-­‐t,	  then	  a	  further	  two	  times	  for	  10	  minutes	  in	  PBS-­‐t.	  When	  Li-­‐
Cor	  detection	  was	  used,	  the	  final	  wash	  was	  in	  detergent-­‐free	  PBS	  to	  avoid	  the	  
formation	  of	  bubbles	  on	  the	  membrane.	  Secondary	  antibody	  dilutions	  
employed	  were	  of	  1:5,000	  for	  ECL	  detection,	  and	  1:10,000	  for	  Li-­‐Cor	  
detection.	  	  
2.3	   MOLECULAR	  CLONING	  METHODS	  
AGAROSE	  GEL	  ELECTROPHORESIS	  
For	  DNA	  visualisation	  by	  agarose	  gel	  electrophoresis,	  the	  desired	  
weight/volume	  of	  agarose	  (SIGMA)	  was	  melted	  in	  Tris-­‐acetate-­‐EDTA	  buffer	  
(TAE).	  Gels	  were	  pre-­‐stained	  by	  the	  addition	  of	  0.5µg	  ethidium	  bromide	  
(SIGMA)	  per	  mL	  of	  gel	  prior	  to	  casting.	  DNA	  samples	  were	  mixed	  with	  the	  
appropriate	  volume	  of	  6X	  gel	  loading	  dye	  (NEB)	  prior	  to	  loading	  and	  gels	  run	  
at	  100V	  until	  the	  dye	  front	  has	  reached	  the	  edge	  of	  the	  gel.	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To	  resolve	  DNA	  fragments	  <1kb,	  1%	  (w/v)	  agarose	  gels	  were	  typically	  
employed	  and	  0.8%	  (w/v)	  gels	  were	  used	  for	  larger	  fragments.	  In	  order	  to	  
determine	  the	  size	  of	  DNA	  fragments,	  0.5µg	  of	  either	  1kb	  or	  100bp	  DNA	  
ladder	  (both	  NEB)	  were	  loaded	  alongside	  the	  samples	  to	  be	  analysed.	  	  
PCR	  AMPLIFICATION	  
Inserts	  that	  could	  not	  be	  directly	  inserted	  by	  simple	  restriction	  digest	  
were	  amplified	  by	  polymerase	  chain	  reaction	  (PCR)	  with	  primers	  containing	  
restriction	  site	  linkers	  using	  the	  Expand	  High	  Fidelity	  PCR	  system	  (Roche)	  as	  
directed	  by	  the	  manufacturer.	  Annealing	  temperatures	  and	  the	  duration	  of	  
the	  extension	  step	  were	  adjusted	  to	  suit	  the	  primer	  and	  PCR	  product	  size,	  
respectively.	  
ENDONUCLEASE	  RESTRICTION	  DIGEST	  
All	  restriction	  enzymes	  used	  in	  this	  study	  were	  from	  NEB	  and	  used	  in	  
the	  reaction	  buffers	  recommended	  and	  provided	  by	  the	  manufacturer,	  the	  
reaction	  mixture	  was	  supplemented	  with	  10mg/ml	  bovine	  serum	  albumin	  
when	  recommended.	  The	  desired	  amount	  of	  DNA	  was	  digested	  using	  10	  units	  
of	  enzyme	  per	  µg	  of	  DNA	  for	  2	  hours	  at	  37oC.	  When	  sequential	  digests	  were	  
required,	  digested	  fragments	  were	  purified	  after	  the	  first	  digestion	  using	  the	  
QIAquick	  PCR	  Purification	  Kit	  (QIAGEN)	  to	  remove	  the	  nuclease	  and	  buffer,	  
then	  eluted	  in	  30µl	  ddH2O.	  The	  eluted	  DNA	  was	  then	  supplemented	  with	  the	  
appropriate	  buffer	  and	  enzyme	  for	  the	  second	  digest.	  
BLUNT-­‐ENDING	  DNA	  FRAGMENTS	  
When	  complimentary	  sticky	  ends	  could	  not	  be	  generated,	  both	  DNA	  
fragments	  were	  first	  subjected	  to	  a	  single	  digest	  using	  a	  restriction	  
endonuclease	  cutting	  in	  the	  desired	  location,	  then	  blunt	  ended.	  For	  2-­‐4µg	  of	  
plasmid	  DNA,	  digested	  ends	  were	  blunted	  by	  the	  addition	  of	  3	  units	  T4	  DNA	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polymerase	  (NEB)	  supplemented	  with	  10mg/ml	  bovine	  serum	  albumin	  and	  
400µM	  dNTPs,	  incubated	  at	  12oC	  for	  15	  minutes	  prior	  to	  heat	  inactivation	  at	  
75oC	  for	  10	  minutes.	  Buffers	  and	  enzymes	  were	  replaced	  prior	  to	  carrying	  out	  
the	  second,	  sticky-­‐end	  generating,	  digest	  by	  using	  the	  QIAquick	  PCR	  
Purification	  Kit	  (QIAGEN)	  and	  eluting	  the	  DNA	  with	  30µl	  ddH2O.	  The	  eluted	  
DNA	  was	  supplemented	  with	  the	  necessary	  buffer	  and	  enzyme	  for	  the	  second	  
digest.	  
PRIMER	  ANNEALING	  &	  LINKER	  LIGATION	  
In	  order	  to	  generate	  a	  myc-­‐tagged	  Aurora	  B	  construct,	  a	  linker	  
containing	  an	  ATG	  initiation	  codon	  followed	  a	  3xmyc	  epitope	  tag	  plus	  
upstream	  and	  downstream	  restriction	  sites	  was	  designed	  and	  inserted	  into	  
the	  pIRES	  puro2	  vector.	  Complimentary	  oligos	  containing	  an	  AflII	  site	  distal	  to	  
the	  epitope	  tag	  were	  first	  annealed	  by	  diluting	  these	  to	  100nM	  in	  ddH2O	  and	  
10µl	  of	  each	  combined	  in	  a	  1.5ml	  eppendorf	  to	  make	  20µl	  of	  a	  50nM	  
solution.	  The	  annealing	  step	  was	  carried	  out	  in	  a	  large	  beaker	  of	  near-­‐boiling	  
water	  on	  a	  hot	  plate:	  the	  tube	  containing	  the	  oligos	  was	  added	  as	  the	  water	  
neared	  boiling	  point	  and	  the	  beaker	  kept	  on	  the	  heat	  for	  5	  minutes	  prior	  to	  
being	  removed	  from	  the	  head	  and	  allowed	  to	  slowly	  cool	  to	  ambient	  
temperature.	  A	  foam	  float	  was	  used	  to	  keep	  the	  tube	  aloft	  in	  the	  water.	  	  
Although	  initially	  designed	  with	  ClaI	  and	  NheII	  compatible	  overhangs	  
at	  the	  3’	  and	  5’	  end,	  respectively,	  the	  linker	  was	  eventually	  inserted	  into	  the	  
destination	  vector	  using	  a	  3’	  blunt	  end	  and	  a	  5’	  AlfII-­‐generated	  sticky	  end.	  
These	  ends	  were	  generated	  by	  the	  blunting,	  then	  subsequent	  digest	  of	  2µl	  
the	  annealed	  linker	  mixture	  following	  the	  protocols	  outlined	  earlier.	  The	  
modified	  linker	  was	  purified	  after	  each	  step	  using	  the	  QIAquick	  PCR	  
Purification	  Kit	  (QIAGEN)	  and	  eluted	  in	  30µl	  ddH2O.	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To	  phosphorylate	  the	  linker	  to	  allow	  ligation,	  in	  a	  PCR	  tube,	  10	  units	  of	  
polynucleotide	  kinase	  (PNK;	  NEB)	  plus	  2µl	  10X	  T4	  DNA	  ligase	  buffer	  (also	  
NEB)	  were	  added	  to	  the	  purified	  annealed	  linker	  obtained	  following	  the	  
previous	  step	  and	  made	  up	  to	  a	  final	  volume	  50µl	  with	  ddH2O.	  The	  
phosphorylation	  mixture	  was	  incubated	  on	  a	  thermocycler	  for	  30	  minutes	  at	  
37oC	  then	  inactivated	  at	  65oC	  for	  20	  minutes.	  The	  T4	  DNA	  ligase	  buffer	  was	  
used	  in	  lieu	  of	  the	  PNK	  buffer	  as	  it	  already	  contains	  the	  necessary	  
concentration	  of	  unlabeled	  ATP.	  The	  phosphorylated	  annealed	  linker	  was	  
ligated	  into	  a	  digested	  vector	  following	  the	  protocol	  described	  below	  and	  a	  
50:1	  insert	  to	  vector	  ratio.	  
PHOSPHATASE	  TREATMENT	  
	   To	  limit	  vector	  re-­‐ligation	  during	  cloning,	  digested	  vectors	  were	  
treated	  with	  Antarctic	  phosphatase	  (NEB)	  following	  manufacturer’s	  
recommendations	  immediately	  following	  digestion.	  For	  2-­‐4µg	  of	  DNA,	  5	  units	  
of	  Antarctic	  phosphatase	  were	  added	  to	  the	  digestion	  mixture	  and	  incubated	  
at	  37oC	  for	  30	  minutes.	  The	  phosphatase	  was	  then	  inactivated	  prior	  to	  further	  
handling	  by	  incubating	  the	  mixture	  for	  5	  minutes	  at	  70oC.	  Samples	  were	  then	  
gel	  extracted	  following	  the	  protocol	  indicated	  below.	  
GEL	  EXTRACTION	  
DNA	  samples	  were	  mixed	  with	  Gel	  Loading	  Dye	  (6X)	  (NEB)	  to	  a	  final	  
concentration	  of	  1X	  loading	  dye	  and	  resolved	  by	  agarose	  gel	  electrophoresis	  
on	  ethidium	  bromide	  pre-­‐stained	  gels	  as	  described	  earlier	  in	  this	  section.	  
DNA	  bands	  were	  visualized	  using	  a	  UV	  box	  and	  excised	  with	  a	  scalpel.	  Gel	  
extractions	  were	  carried	  out	  using	  the	  QIAquick	  Gel	  Extraction	  Kit	  (QIAGEN)	  
following	  the	  manufacturer’s	  instructions	  and	  eluted	  in	  30-­‐50µl	  of	  ddH2O,	  
depending	  on	  the	  intended	  use.	  In	  instances	  where	  large	  quantities	  of	  DNA	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were	  requited	  and	  the	  digestion	  protocol	  scaled	  up,	  the	  number	  of	  columns	  
used	  during	  gel	  extraction	  was	  increased.	  
LIGATION	  
All	  ligations	  were	  carried	  out	  using	  the	  Quick	  Ligation™	  Kit	  (NEB)	  as	  per	  
the	  manufacturer’s	  instructions.	  Briefly,	  a	  1:3	  ratio	  of	  vector	  and	  insert	  were	  
mixed	  together	  and	  supplemented	  with	  10µl	  2X	  buffer	  and	  ddH2O	  to	  a	  final	  
volume	  of	  19µl.	  1µl	  of	  Quick	  Ligase	  was	  then	  added	  to	  the	  mixture	  and	  
incubated	  at	  25oC	  for	  5-­‐15	  minutes.	  To	  prevent	  prematurely	  exposing	  the	  
competent	  cells	  to	  heat,	  the	  ligation	  mixture	  was	  chilled	  on	  ice	  for	  2	  minutes	  
prior	  to	  transformation	  and	  amplification	  in	  E.	  coli	  –	  10µl	  of	  the	  chilled	  
ligation	  mixture	  were	  used	  to	  transform	  100µl	  chemically	  competent	  Top10	  
cells.	  
TRANSFORMATION	  
	   For	  selection,	  storage	  and	  amplification,	  plasmids	  were	  transformed	  
into	  E.	  coli	  as	  required.	  Aseptic	  technique	  and	  sterile	  reagents	  were	  used	  
throughout.	  Unless	  otherwise	  specified,	  0.5µl	  of	  a	  plasmid	  miniprep	  or	  
equivalent	  quantities	  were	  used	  to	  transform	  50µl	  chemically	  competent	  
Top10	  cells	  using	  the	  following	  protocol.	  Aliquots	  of	  Top10	  cells	  were	  thawed	  
on	  ice	  and	  the	  required	  amount	  of	  cells	  transferred	  to	  pre-­‐chilled	  1.5ml	  
eppendorf	  tubes,	  after	  which	  the	  plasmid	  DNA	  was	  added	  to	  each	  tube	  and	  
the	  mixture	  incubated	  on	  ice	  for	  30	  minutes.	  Cell	  were	  heatshocked	  at	  42oC	  
for	  30	  seconds	  then	  cooled	  on	  ice	  for	  2	  minutes,	  after	  which	  the	  mixture	  was	  
topped	  up	  with	  Luria-­‐Bertani	  broth	  (LB	  broth)	  to	  500µl.	  To	  allow	  expression	  
of	  the	  selection	  marker	  prior	  to	  the	  application	  of	  selection,	  the	  transformed	  
mixture	  was	  incubated	  at	  37oC	  with	  agitation	  for	  1	  hour.	  Cells	  were	  plated	  
out	  onto	  LB	  plates	  containing	  the	  appropriate	  selection	  antibiotic.	  As	  a	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negative	  control,	  plasmid	  DNA	  was	  substituted	  with	  ddH2O	  –	  no	  colonies	  
should	  be	  present	  in	  this	  sample	  following	  incubation	  on	  selective	  media.	  
SITE-­‐DIRECTED	  MUTAGENESIS	  
Vectors	  were	  mutagenised	  by	  site-­‐directed	  mutagenesis	  using	  oligos	  
encoding	  the	  desired	  DNA	  base	  change(s).	  Using	  these	  oligos,	  the	  DNA	  was	  
amplified	  from	  the	  vector	  using	  the	  high	  fidelity	  polymerase	  PfuUltra	  (Agilent	  
Technologies)	  for	  16	  cycles.	  Following	  amplification,	  any	  remaining	  vector	  
DNA	  present	  was	  removed	  by	  treating	  the	  DNA	  with	  20	  units	  DpnI	  (NEB)	  for	  1	  
hour	  at	  37oC.	  The	  DpnI	  restriction	  endonuclease	  can	  cut	  methylated	  vector	  
DNA	  but	  not	  the	  unmethylated	  amplification	  product	  generated	  using	  the	  
mutagenic	  oligos.	  1µl	  DpnI-­‐digested	  DNA	  was	  used	  to	  transform	  50µl	  
chemically	  competent	  Top10	  cells	  as	  indicated	  above.	  50,	  100	  and	  200µl	  of	  
the	  500µl	  recovery	  mixture	  were	  plated	  out	  on	  LB	  plates	  containing	  selection	  
drugs,	  which	  were	  then	  incubated	  overnight	  at	  37oC.	  Selected	  clones	  were	  
picked,	  miniprepped	  and	  analysed	  for	  the	  presence	  of	  the	  desired	  mutation	  
and	  the	  integrity	  of	  the	  remainder	  of	  the	  open	  reading	  frame.	  Following	  site-­‐
directed	  mutagenesis,	  the	  mutagenized	  fragments	  were	  always	  subcloned	  
back	  into	  the	  original	  vector	  by	  to	  ensure	  the	  integrity	  of	  the	  vector	  
backbone.	  	  
SEQUENCING	  
DNA	  samples	  were	  sequenced	  as	  required	  using	  the	  Sanger	  (dideoxy)	  
sequencing	  method.	  Briefly,	  4µl	  of	  BigDye®	  Terminator	  reagent	  (Life	  
Technologies)	  was	  added	  to	  2µl	  of	  DNA	  prepared	  with	  a	  miniprep	  kit	  (or	  
equivalent	  amount)	  and	  2µl	  of	  5µM	  primer,	  and	  made	  up	  to	  a	  volume	  of	  10µl	  
with	  ddH2O.	  Samples	  were	  amplified	  for	  25	  cycles	  consisting	  of:	  96oC	  for	  30	  
seconds,	  50oC	  for	  15	  seconds,	  then	  60oC	  for	  70	  seconds.	  All	  subsequent	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sequencing	  reactions	  steps	  were	  carried	  out	  by	  the	  GenePool	  (now	  Edinburgh	  
Genomics;	  Edinburgh,	  United	  Kingdom).	  Sequence	  analysis	  was	  carried	  out	  
using	  Sequencher	  (Gene	  Codes	  Corporation).	  
2.4	   MICROSCOPY	  METHODS	  
POLY-­‐L-­‐LYSINE	  COATED	  COVERSLIP	  PREPARATION	  
For	  microscopy	  analyses,	  coverslips	  were	  sometimes	  coated	  in	  poly-­‐L-­‐
lysine	  to	  help	  retain	  mitotic	  cells.	  Glass	  coverslips	  were	  first	  acid	  washed	  in	  
70%	  ethanol,	  1%	  hydrochloric	  acid	  for	  10	  minutes	  with	  gentle	  agitation.	  
Coverslips	  were	  then	  rinsed	  in	  ddH2O	  and	  dried	  on	  Whatman	  paper.	  Dried	  
coverslips	  were	  then	  coated	  with	  poly-­‐L-­‐lysine	  by	  bathing	  in	  a	  1:10	  dilution	  of	  
0.1%	  (w/v)	  poly-­‐L-­‐lysine	  solution	  (SIGMA)	  in	  ddH2O	  for	  5	  minutes.	  Coverslips	  
were	  dried	  once	  again	  prior	  to	  sterilizing	  by	  washing	  in	  70%	  ethanol	  and	  
drying	  under	  UV	  light.	  
PHALLOIDIN	  STAINING	  
Coverslips	  were	  retrieved	  from	  experimentally	  treated	  wells	  and	  
placed	  into	  wells	  containing	  warm	  1X	  PBS.	  All	  subsequent	  washes	  and	  
incubations	  were	  carried	  out	  at	  room	  temperature.	  Taking	  care	  not	  to	  disturb	  
cells	  on	  the	  coverslips	  whilst	  aspirating	  liquids	  between	  washes,	  the	  
coverslips	  were	  washed	  twice	  for	  3	  minutes	  with	  1XPBS	  then	  fixed	  using	  4%	  
paraformaldehyde	  (PFA;	  Electron	  Microscopy	  Sciences)	  diluted	  in	  1XPBS	  for	  
10	  minutes.	  Following	  fixation,	  coverslips	  were	  washed	  twice	  for	  3	  minute	  
with	  1XPBS	  then	  samples	  were	  permeabilised	  by	  incubating	  the	  coverslips	  in	  
1XPBS,	  0.2%	  Triton	  X-­‐100	  (Bio-­‐Rad)	  for	  5	  minutes.	  At	  this	  juncture,	  the	  
coverslips	  could	  be	  stored	  at	  4oC	  for	  several	  days	  prior	  to	  phalloidin	  staining.	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Samples	  were	  stained	  with	  0.5	  units	  of	  either	  Alexa	  Fluor	  488®	  
phalloidin	  or	  rhodamine	  phalloidin	  (both	  Life	  Technologies)	  in	  1XPBS,	  1%	  
(v/v)	  BSA	  for	  20	  minutes.	  Coverslips	  were	  then	  washed	  twice	  for	  3	  minutes	  in	  
1XPBS	  washes,	  briefly	  rinsed	  in	  ddH2O,	  mounted	  using	  Vectashield	  with	  DAPI	  
(Vector	  Labs)	  and	  sealed	  with	  nailpolish.	  Slides	  were	  stored	  in	  the	  dark	  at	  4oC	  
pending	  analysis.	  	  
Representative	  images	  of	  experimental	  conditions	  were	  acquired	  
using	  a	  Deltavision	  instrument	  (Applied	  Precision,	  GE	  Healthcare)	  using	  40X	  
and	  100X	  oil	  objectives.	  
IMMUNOFLUORESCENCE	  
	   Unless	  otherwise	  indicated,	  wash	  and	  incubation	  steps	  were	  carried	  
out	  at	  room	  temperature;	  blocking	  and	  antibody	  incubation	  steps	  were	  
carried	  out	  on	  a	  parafilm	  support	  in	  a	  humid	  chamber	  using	  100-­‐50µl	  of	  
solution.	  Experimentally	  treated	  coverslips	  were	  retrieved,	  fixed	  with	  
paraformaldehyde	  and	  washed	  as	  per	  the	  phalloidin	  staining	  protocol	  above.	  
Following	  fixation	  and	  washing,	  samples	  were	  permeabilised	  using	  0.5%	  
Triton	  X,	  1XPBS	  for	  5	  minutes	  at	  room	  temperature	  then	  washed	  twice	  in	  
1XPBS	  for	  5	  minutes.	  Prior	  to	  antibody	  probing,	  coverslips	  were	  blocked	  in	  a	  
solution	  of	  3%	  BSA,	  0.05%	  Triton	  X,	  1XPBS	  for	  1	  hour	  then	  washed	  thrice	  in	  
1XPBS	  for	  5	  minutes.	  Primary	  and	  secondary	  antibodies	  were	  diluted	  in	  0.5%	  
Triton	  X,	  1XPBS	  as	  indicated	  in	  table	  2.3.	  Probing	  with	  primary	  and	  secondary	  
antibodies	  were	  carried	  out	  in	  for	  1	  hour	  at	  37oC	  and	  45	  minutes	  at	  room	  
temperature,	  respectively,	  and	  coverslips	  washed	  thrice	  in	  1XPBS	  for	  5	  
minutes	  after	  each	  step.	  Coverslips	  were	  then	  rinsed	  in	  ddH2O	  and	  mounted	  
on	  slides	  using	  VECTASHIELD®	  hardset	  mounting	  medium	  with	  DAPI	  (Vector	  
Laboratories)	  and	  sealed	  with	  nail	  polish.	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2.5	   CPC	  FUNCTION	  ASSAY	  PROTOCOL	  
The	  protocol	  below	  was	  always	  performed	  using	  HeLa	  Kyoto	  clone	  D	  
(described	  in	  Chapter	  3)	  and	  was	  employed	  to	  obtain	  the	  results	  presented	  in	  
Chapters	  3	  and	  4,	  and	  the	  second	  pass	  screen	  in	  Chapter	  5	  (section	  5.5).	  	  
Two	  days	  prior	  to	  transfection,	  cells	  were	  seeded	  to	  a	  density	  of	  5x104	  
in	  6	  well	  plates	  containing	  an	  uncoated	  16mm	  diameter	  coverslip.	  Wells	  were	  
transfected	  with	  2µg	  of	  plasmid	  using	  6µl	  FuGENE	  6	  (Roche)	  following	  the	  
manufacturer’s	  instructions.	  Transfected	  cells	  were	  selected	  by	  replacing	  the	  
growth	  medium	  with	  fresh	  medium	  supplemented	  with	  6µg/ml	  puromycin	  
and	  incubated	  for	  a	  further	  24	  hours	  prior	  to	  collection.	  Each	  series	  of	  
transfections	  contained	  two	  control	  wells	  transfected	  with	  empty	  pIRES	  
puro2	  vector	  to	  establish	  the	  background	  frequency	  of	  abnormal	  nuclei,	  and	  
wells	  transfected	  with	  the	  AURKBD218N	  expression	  construct	  as	  a	  positive	  
control.	  
Coverslips	  were	  harvested,	  washed,	  fixed	  and	  stained	  with	  phalloidin	  
as	  indicated	  earlier.	  Coverslips	  were	  imaged	  on	  an	  Axioplan2	  microscope	  
using	  a	  Plan	  NEOFLUAR	  40X/1,3	  Oil	  objective	  (both	  Zeiss).	  ≥1000	  cells	  were	  
scored	  for	  the	  frequency	  of	  normal	  and	  abnormal	  nuclei.	  Abnormal	  nuclei	  
indexes	  (ANI)	  were	  determined	  as	  the	  sum	  of	  multinucleate	  and	  
micronucleated	  cells,	  and	  cells	  with	  chromatin	  bridges,	  divided	  by	  the	  total	  
number	  of	  cells	  scored.	  The	  rate	  of	  increase	  in	  ANI	  relative	  to	  the	  control	  was	  
calculated	  by	  dividing	  the	  ANI	  by	  the	  average	  frequency	  of	  abnormal	  nuclei	  
detected	  in	  control	  coverslips	  transfected	  with	  an	  empty	  vector.	  
On	  occasion,	  the	  remaining	  cells	  in	  the	  well	  were	  harvested	  for	  
western	  blot	  analysis.	  Wells	  were	  first	  washed	  with	  1XPBS	  and	  the	  cells	  
released	  by	  the	  addition	  of	  0.5ml	  trypsin	  before	  being	  quenched	  with	  0.5ml	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of	  medium.	  Cells	  were	  then	  transferred	  to	  a	  1.5ml	  eppendorf	  tube	  and	  
pelleted	  in	  a	  benchtop	  centrifuge	  for	  5	  minutes	  at	  800rpm.	  Pellets	  were	  
washed	  by	  resuspending	  in	  1ml	  warm	  1XPBS,	  centrifuged	  once	  again	  and	  the	  
supernatant	  removed	  prior	  to	  immediately	  freezing	  at	  -­‐80oC	  pending	  analysis.	  
Pellets	  were	  lysed	  by	  the	  addition	  of	  20µl	  1XSDS	  sample	  buffer	  following	  the	  
protocol	  indicated	  earlier;	  20µl	  of	  lysate	  were	  loaded	  per	  gel	  lane	  on	  a	  1mm	  
10	  well	  10%	  SDS-­‐PAGE	  gel.	  
2.6	   SICLOPPS	  LIBRARY	  PROTOCOLS	  
LIBRARY	  CONSTRUCTION	  
The	  INCENP	  INbox	  library	  was	  created	  using	  discrete	  HPLC-­‐purified	  
long	  oligos	  encoding	  the	  97	  library	  members	  purchased	  from	  Sigma-­‐Aldrich	  
(St	  Louis,	  Missouri,	  USA)	  –	  a	  table	  containing	  the	  library	  primer	  sequences	  
can	  be	  found	  in	  Appendix	  II.	  Library	  inserts	  were	  amplified	  using	  Expand	  high	  
fidelity	  polymerase	  (Roche)	  from	  a	  NcoI	  digested	  template	  using	  the	  PCR	  
program	  described	  by	  Abel-­‐Santos	  and	  colleagues	  (Abel-­‐Santos	  et	  al.,	  2003).	  
PCR	  products	  were	  purified	  using	  the	  QIAquick	  PCR	  purification	  kit	  
(QUIAGEN)	  and	  eluted	  in	  30µl	  ddH2O	  prior	  to	  digestion	  with	  10	  units	  each	  of	  
BamHI	  HF	  and	  AflII	  (both	  NEB)	  for	  1hr	  at	  37oC.	  	  
Inserts	  were	  ligated	  into	  a	  phosphatase-­‐treated	  BamHI	  and	  AflII	  
digested	  pIRES	  puro2	  vector	  containing	  the	  test	  SICLOPPS	  construct	  and	  a	  
modified	  MCS	  lacking	  the	  AflII	  site.	  Ligations	  were	  carried	  out	  using	  as	  
described	  earlier	  using	  a	  1:5	  vector	  to	  insert	  ratio.	  10µl	  of	  the	  ligation	  mixture	  
were	  used	  to	  transform	  50µl	  Top10	  chemically	  competent	  cells	  and	  2/5th	  of	  
the	  recovery	  mixture	  plated	  out	  on	  LB	  Amp	  plates	  and	  incubated	  overnight	  at	  
37oC.	  Colonies	  were	  selected	  and	  screened	  for	  the	  presence	  of	  the	  desired	  
insert	  by	  sequencing	  using	  the	  T7	  forward	  primer.	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In	  preparation	  for	  library	  screening,	  transfection-­‐grade	  minipreps	  of	  all	  
library	  constructs	  were	  prepared	  using	  the	  transfection-­‐grade	  Plasmid	  Mini	  
Kit	  (QIAGEN)	  following	  the	  manufacturer’s	  instructions.	  DNA	  pellets	  were	  
resuspended	  in	  20µl	  ddH2O	  overnight	  at	  4oC,	  then	  quantified	  using	  the	  
Nanodrop	  instrument	  and	  diluted	  to	  a	  concentration	  of	  500ng/µl	  in	  ddH2O.	  
DNA	  samples	  were	  stored	  at	  -­‐20oC.	  Protein-­‐splicing	  deficient	  SICLOPPST69AH72A	  
mutants	  were	  generated	  by	  subcloning	  library	  inserts	  into	  the	  BamHI	  and	  
AflII	  sites	  of	  a	  pIRES	  puro2-­‐based	  SICLOPPS	  vector	  bearing	  said	  mutation	  
downstream	  of	  the	  AflII	  site.	  
Unless	  modifications	  are	  indicated	  here,	  individual	  cloning	  steps	  were	  
performed	  according	  to	  the	  protocols	  outlined	  in	  section	  2.3.	  
LIBRARY	  SCREENING	  PROTOCOL	  –	  FIRST	  PASS	  
The	  initial	  library	  screen	  was	  carried	  out	  using	  a	  different	  protocol	  
from	  the	  CPC	  assay.	  The	  chronological	  and	  practical	  reasons	  for	  employing	  
this	  simplified	  protocol	  are	  discussed	  in	  Chapter	  5.	  
One	  day	  prior	  to	  transfection,	  HeLa	  Kyoto	  cells	  were	  seeded	  to	  a	  
density	  of	  5x104	  in	  6	  well	  plates	  containing	  poly-­‐L-­‐lysine-­‐coated	  coverslips.	  
Duplicate	  wells	  were	  transfected	  with	  2µg	  of	  plasmid	  each	  using	  6µl	  FuGENE	  
6	  (Roche)	  following	  the	  manufacturer’s	  instructions.	  Transfected	  cells	  were	  
selected	  by	  replacing	  the	  growth	  medium	  with	  fresh	  medium	  supplemented	  
with	  4µg/ml	  puromycin	  24	  hour	  post-­‐transfection.	  Cells	  were	  then	  incubated	  
for	  a	  further	  24	  hours	  prior	  to	  collection.	  Each	  series	  of	  transfections	  
contained	  duplicate	  control	  wells	  transfected	  with	  empty	  pIRES	  puro2	  vector	  
to	  establish	  background	  frequencies	  of	  abnormal	  nuclei.	  
Coverslips	  were	  harvested	  and	  stained	  with	  phalloidin	  then	  imaged	  on	  
an	  Axioplan2	  microscope	  using	  a	  Plan	  NEOFLUAR	  40X/1,3	  Oil	  objective	  (both	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Zeiss).	  For	  analysis,	  5	  fields	  of	  cells	  were	  scored	  per	  coverslip.	  Abnormal	  
nuclei	  indexes	  (ANI)	  were	  determined	  as	  the	  sum	  of	  multinucleate	  and	  
micronucleated	  cells,	  and	  cells	  with	  chromatin	  bridges,	  divided	  by	  the	  total	  
number	  of	  cells	  scored.	  The	  rate	  of	  increase	  in	  ANI	  relative	  to	  the	  control	  was	  
calculated	  by	  dividing	  the	  ANI	  by	  the	  average	  frequency	  of	  abnormal	  nuclei	  
detected	  in	  control	  coverslips	  transfected	  with	  an	  empty	  vector.	  
2.7	   BIOINFORMATICS	  RESOURCES	  
Alignments	  were	  performed	  with	  ClustalW	  (Thompson	  et	  al.,	  1994)	  
using	  default	  settings,	  and	  visualised	  using	  Jalview	  (Clamp	  et	  al.,	  2004).	  
Crystal	  structure	  visualisation	  and	  figure	  output	  were	  done	  using	  Pymol	  
(Schrödinger,	  2010).	  Microscopy	  images	  were	  handled	  with	  the	  softWoRx	  
suite	  (Applied	  Precision)	  and	  ImageJ	  (Abramoff	  et	  al.,	  2004).	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2.8	   PLASMIDS	  USED	  IN	  THIS	  STUDY	  
Details	  of	  the	  SICLOPPS	  test	  construct	  donated	  by	  the	  Tyers	  lab	  can	  be	  
found	  in	  Appendix	  I.	  The	  vectors	  pcDNA3	  (Invitrogen,	  Life	  Technologies)	  and	  
pIRES	  puro2	  (Clontech)	  vectors	  were	  already	  available	  in	  the	  lab.	  Details	  of	  all	  
the	  INbox	  library	  vectors	  can	  be	  found	  in	  Appendix	  II.	  Further	  details	  of	  the	  
modified	  pIRES	  puro2	  vector	  can	  be	  found	  in	  section	  5.3.	  
Name	   Vector	   Selection	   Details	  
SICLOPPS_test	   pJ201	   K	   Original	  SICLOPPS	  vector	  	  
SICLOPPSWT	   pCDNA3	   A;	  N	   Test	  construct	  
SICLOPPSAA	   pCDNA3	   A;	  N	   Test	  construct;	  PD	  
GFP-­‐LaminA	   pCDNA3	   A;N	   	  
SICLOPPSWT	   pIRES	  puro2*	   A;	  P	   Test	  construct	  
SICLOPPSAA	   pIRES	  puro2*	   A;	  P	   Test	  construct;	  PD	  
AURKBWT	   pIRES	  puro2	   A;	  P	   N-­‐terminal	  3myc	  tag	  
AURKBD218N	   pIRES	  puro2	   A;	  P	   N-­‐terminal	  3myc	  tag	  
kinase	  dead	  
INCENPWT	   pBluescript	  KS	   A	   Source	  of	  INbox	  
SICLOPPS_INboxWT	   pIRES	  puro2*	   A;	  P	   	  
SICLOPPSAA_INboxWT	   pIRES	  puro2*	   A;	  P	   PD	  
SICLOPPS_INboxW845G	   pIRES	  puro2*	   A;	  P	   	  
SICLOPPSAA_	  INboxW845G	   pIRES	  puro2*	   A;	  P	   PD	  
SICLOPPS_INboxF881A	   pIRES	  puro2*	   A;	  P	   	  
SICLOPPSAA_	  INboxF881A	   pIRES	  puro2*	   A;	  P	   PD	  
SICLOPPS_INboxdbl	   pIRES	  puro2*	   A;	  P	   	  
SICLOPPSAA_	  INboxdbl	   pIRES	  puro2*	   A;	  P	   PD	  
SICLOPPS_INboxAAA	   pIRES	  puro2*	   A;	  P	   	  
SICLOPPSAA_	  INboxAAA	   pIRES	  puro2*	   A;	  P	   PD	  
Table	  2.1	  –	  Plasmids	  used	  in	  this	  study	  (WT:	  wild	  type;	  AA:	  T69AH72A	  
mutant;	  dbl:	  W845GF881A	  double	  mutant;	  AAA:	  TSSàAAA	  phosphosite	  
mutant*:	  modified	  pIRES	  puro2	  vector;	  A:	  ampicillin;	  P:	  puromycin;	  N:	  
neomycin;	  PD:	  processing	  deficient).	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2.9	   PRIMERS	  USED	  IN	  THIS	  STUDY	  
All	  primers	  used	  in	  this	  study	  were	  obtained	  through	  Sigma-­‐Aldrich.	  
Further	  to	  the	  primers	  listed	  in	  the	  table	  below,	  the	  sequence	  of	  all	  the	  
individual	  primers	  used	  in	  library	  construction	  can	  be	  found	  in	  Appendix	  II.	  
Name	   Application	   Feature	   Sequence	  










T7	   sequencing	   	   TAATACGACTCACTATAGGG	  
AURKB_F	   Cloning	   AflII	   CCGTCTTAAGATGGCCCAGAAGGAGAACTCC	  
AURKB_R	   Cloning	   EcoRI	   CAGACCAGCCGAAGTTAGCAATCTTAGCTC	  
INbox_F	   Cloning	   NheI	  
GCCGGCTAGCCAATGGGGCTATTGCCCATAA
TLGATCTGAATAGCGACGACTCCACCG	  
INbox_R	   Cloning	   AflII	   TCTTCAAGAAGAGCAAGCCCCGCTATCACAA
GCGCACCAGCTCTGAGTACTGCTTAAGCGGC	  
SICLOPPS_AA_F	   SDM	   T69AH72A	   GGTTCTGTGAATAGAGCTGCTAGTGACGCTC
GTTTCCTTACAACGGAC	  
SICLOPPS_AA_R	   SDM	   T69AH72A	   GTCCGTTGTAAGGAAACGAGCGTCACTAGCAGCTCTATTCACAGAACC	  
AURKB_D218N_F*	   SDM	   D218N	   GAGCTAAGATTGCTAACTTCGGCTGGTCTG	  
AURKB_D218N_R*	   SDM	   D218N	  
GGCAGAATTCGAGTCAGGCGACAGATTGAAG
GGC	  
pIRES_AflIIMCS_F	   SDM	   AflII	   CCGGTTAACAGGCCTATAGCGCTAGCTAGGC
CGC	  
pIRES_AflIIMCS_R	   SDM	   AflII	   GCGGCCTAGCTAGCGCTATAGGCCTGTTAACCGG	  
INbox_W845G_F	   SDM	   W845G	   GAAGCCCATCCCCACCGGGGCCCGAGGCAC	  
INbox_W845G_R	   SDM	   W845G	   GTGCCTCGGGCCCCGGTGGGGATGGGCTTC	  
INbox_F881A_F	   SDM	   F881A	   GGACTTGGAGGATATCGCCAAGAAGAGCAA
GC	  
INbox_F881A_R	   SDM	   F881A	   GCTTGCTCTTCTTGGCGATATCCTCCAAGTCC	  
INbox_AAA_F	   SDM	   TSSàAAA	   GCTATCACAAGCGCACCAGCTCTGAGTACTGCTTAAGTTTTGG	  
INbox_AAA_R	   SDM	   TSSàAAA	  
CCAAAACTTAAGCAGTACTCAGAGCTGGTGC
GCTTGTGATAGC	  
Table	  2.2	  –	  Primers	  used	  in	  this	  study.	  Restriction	  sites	  introduced	  by	  the	  
primer	  are	  indicated	  in	  the	  ‘Features’	  column;	  strikethrough	  denotes	  the	  
removal	  of	  a	  restriction	  site	  (F:	  forward	  primer;	  R:	  reverse	  primer;	  SDM:	  site	  
directed	  mutagenesis;	  IVT:	  in	  vitro	  translation;	  *:	  after	  (Girdler	  et	  al.,	  2006).	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2.10	   ANTIBODIES	  USED	  IN	  THIS	  STUDY	  
Antibody	   Manufacturer	   Species	   Application	   Dilution	  
α-­‐myc	  (9E10)	   Covance	   mouse	   WB	   1:1,000	  
α-­‐tubulin	  (B512)	   Invitrogen	   mouse	   WB	   1:15,000	  
ECLTM	  α-­‐mouse	  IgG	   GE	  Healthcare	   sheep	   WB	  –	  2o	   1:5,000	  
α-­‐mouse	  IRDye	  800CW	   Li-­‐Cor	   donkey	   WB	  –	  2o	   1:10,000	  
α-­‐Aurora	  B	  (ab2254)	   Abcam	   rabbit	   IF	   1:500	  
α-­‐tubulin	  (ATN02)	   Cytoskeleton,	  Inc.	   sheep	   IF	   1:200	  
ACA	   N/A	   human	   IF	   1:200	  
Table	  2.3	  –	  Antibodies	  used	  in	  this	  study.	  (N/A:	  non	  applicable,	  denotes	  
patient	  sera	  or	  non-­‐commercial	  antibodies	  available	  to	  our	  laboratory;	  WB:	  
western	  blot;	  IF:	  immunofluorescence;	  2o:	  secondary	  antibody).	  
	  
2.11	   OTHER	  REAGENTS	  
BUFFERS	  
Name	   Composition	  
3X	  SDS-­‐PAGE	  
sample	  buffer	  
50mM	  Tris-­‐HCl	  pH	  6.8;	  15%	  sucrose;	  2mM	  EDTA;	  3%	  SDS	  (for	  




25mM	  Tris	  pH	  8.8;	  192	  mM	  glycine;	  0.1%	  SDS	  
Transfer	  buffer	   25mM	  Tris	  HCl	  pH8.8;	  192mM	  glycine;	  20%	  methanol	  
PBS	   0.01	  phosphate	  buffer;	  137mM	  NaCl;	  2.7mM	  KCl;	  pH	  7.4	  
TAE	   40mM	  Tris;	  20mM	  acetic	  acid;	  1mM	  EDTA	  
LB	   1%	  tryptone;	  0.5%	  yeast	  extract;	  10mM	  NaCl;	  pH	  7.4	  
Table	  2.4	  –	  General	  buffers	  used	  in	  this	  study.	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SELECTION	  DRUGS	  
	   Selection	  drugs	  were	  freshly	  added	  to	  growth	  media	  as	  required.	  To	  
avoid	  loss	  of	  efficacy	  over	  successive	  freeze/thaw	  cycles,	  small	  aliquots	  of	  the	  
drugs	  were	  made	  prior	  to	  storage	  at	  -­‐20oC.	  All	  stock	  solutions	  were	  filtered	  
through	  a	  0.22µm	  filter	  prior	  to	  aliquoting.	  	  
Drug	   Diluent	   Stock	  concentration	   Working	  concentration	  
Puromycin	   DMSO	   1mg/ml	   1-­‐3µg/ml	  
Ampicillin	   ddH2O	   100mg/ml	   100µg/ml	  
Kanamycin	   ddH2O	   50mg/ml	   50µg/ml	  
Table	  2.5	  –	  Selection	  drugs	  used	  in	  this	  study.	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CHAPTER	  3:	  SICLOPPS	  FUNCTIONAL	  TEST	  &	  A	  CELL-­‐
BASED	  CPC	  FUNCTION	  ASSAY	  
3.1	   INTRODUCTION	  
As	  outlined	  earlier,	  one	  of	  the	  main	  aims	  of	  this	  project	  was	  to	  assess	  
the	  effects	  of	  blocking	  the	  Aurora	  B-­‐INCENP	  interaction,	  and	  test	  its	  
amenability	  to	  being	  blocked	  with	  small	  compounds.	  Another	  aim	  of	  this	  
project	  was	  to	  carry	  out	  a	  feasibility	  study	  to	  evaluate	  the	  use	  of	  SICLOPPS-­‐
generated	  cyclic	  peptide	  (CP)	  libraries	  in	  human	  cells.	  For	  this,	  we	  planned	  to	  
assay	  a	  library	  of	  small	  SICLOPPS-­‐generated	  CP	  mimics	  of	  the	  INCENP	  INbox	  in	  
HeLa	  cells.	  Prior	  instances	  of	  intein-­‐mediated	  peptide	  circularization	  in	  
human	  cells	  in	  the	  literature	  were	  limited	  to	  Kinsella	  et	  al.’s	  study	  using	  the	  
artificially	  split	  DnaB	  intein,	  We	  therefore	  first	  needed	  to	  test	  the	  
functionality	  of	  the	  naturally-­‐split	  intein	  we	  obtained	  for	  our	  study.	  The	  
differences	  between	  theses	  two	  inteins	  are	  elaborated	  upon	  in	  section	  3.3.	  
To	  assess	  the	  effect	  of	  small	  CP	  mimics	  of	  INCENP,	  it	  was	  also	  
necessary	  to	  elaborate	  a	  cell-­‐based	  assay	  capable	  of	  measuring	  a	  reliable	  
read-­‐out	  of	  CPC	  activity.	  This	  cell-­‐based	  assay	  was	  refined	  over	  several	  
iterations;	  the	  version	  of	  the	  assay	  presented	  here	  (sections	  3.3)	  is	  the	  
ultimate	  version	  used	  throughout	  this	  study	  with	  the	  exception	  of	  the	  first	  
pass	  INbox	  library	  screen	  (section	  5.4).	  The	  reasons	  for	  this	  exception	  are	  
outlined	  in	  section	  5.1.	  Discussions	  of	  the	  overall	  merits	  and	  limitations	  of	  the	  
assay	  itself	  can	  be	  found	  in	  section	  3.5	  whereas	  finer	  grained	  discussion	  of	  
the	  differences	  between	  this	  assay	  and	  the	  one	  employed	  in	  the	  first	  pass	  
screen	  are	  confined	  to	  section	  5.6.	  
	   	  
	   63	  
3.2	   RATIONALE	  FOR	  USING	  HELA	  CELLS	  
HeLa	  cells	  are	  transformed	  and	  possess	  a	  highly	  abnormal	  karyotype	  
and	  numerous	  genetic	  lesions.	  As	  is	  typical	  of	  many	  transformed	  cells,	  HeLa	  
cells	  posses	  a	  highly	  abnormal	  karyotype	  and	  are	  genetically	  unstable	  (Landry	  
et	  al.,	  2013).	  HeLa	  cells	  do,	  however,	  possess	  many	  advantages	  that,	  although	  
not	  unique,	  make	  them	  ideally	  suited	  for	  a	  cell-­‐based	  screen	  of	  CPC	  function.	  
They	  are	  adherent,	  easily	  transfected	  and	  susceptible	  to	  Aurora	  B	  inhibition	  
(Ditchfield	  et	  al.,	  2003).	  For	  these	  reasons,	  HeLa	  cells	  were	  deemed	  a	  suitable	  
model	  system	  and	  the	  expression	  and	  processing	  of	  the	  SICLOPPS	  test	  
construct	  were	  assayed	  in	  the	  cell	  line.	  	  
3.3	   FUNCTIONAL	  IN-­‐VIVO	  TEST	  OF	  SICLOPPS	  	  
Prior	  to	  proceeding	  with	  library	  construction	  and	  screening,	  it	  was	  
necessary	  to	  verify	  that	  SICLOPPS	  constructs	  can	  both	  be	  expressed	  and	  
undergo	  post-­‐translational	  splicing	  in	  human	  cells.	  At	  the	  time,	  the	  only	  
report	  of	  intein-­‐mediate	  peptide	  circularization	  in	  human	  cells	  was	  that	  made	  
by	  Kinsella	  and	  colleagues	  in	  2002,	  a	  study	  which	  employed	  an	  artificially	  split	  
DnaB	  intein	  derived	  from	  Synechocystis	  sp.	  ATCC	  in	  human	  B	  lymphocytes.	  In	  
its	  natural	  context,	  this	  intein	  exists	  as	  a	  single	  domain	  capable	  of	  excising	  
itself	  from	  a	  protein;	  it	  has	  been	  artificially	  split	  to	  permit	  trans	  splicing	  (Wu	  
et	  al.,	  1998).	  	  
To	  generate	  CPs,	  we	  opted	  to	  use	  a	  DnaE	  split	  intein-­‐derived	  construct	  
which,	  as	  described	  in	  Figure	  1.1.1,	  is	  naturally	  present	  as	  two	  separate	  
domains.	  This	  intein	  is	  frequently	  used	  for	  in	  vivo	  CP	  production	  and	  was	  
being	  piloted	  for	  use	  in	  yeast	  by	  the	  Tyers	  lab	  within	  our	  institute	  at	  the	  time.	  
This	  split	  intein	  had	  been	  demonstrated	  to	  undergo	  post-­‐translational	  splicing	  
in	  Saccharomyces	  cerevisiae	  but	  not	  yet	  in	  mammalian	  cells.	  A	  3xmyc-­‐tagged	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SICLOPPS	  test	  construct,	  which	  is	  S.	  cerevisiae	  codon	  optimized,	  was	  kindly	  
provided	  by	  R.	  Almeida	  and	  C.	  Arndt.	  An	  overview	  of	  the	  SICLOPPS	  test	  
construct	  sequence	  and	  features	  is	  provided	  in	  Appendix	  I.	  I	  subcloned	  this	  
construct	  into	  the	  BamHI	  and	  EcoRI	  sites	  of	  the	  CMV-­‐driven	  mammalian	  
expression	  vector	  pcDNA3	  (Invitrogen).	  Insertion	  of	  the	  construct	  and	  
sequence	  integrity	  were	  verified	  by	  sequencing	  (result	  not	  shown).	  
	   In	  order	  to	  ascertain	  that	  post-­‐translational	  processing	  occurred,	  a	  
negative	  control	  was	  required.	  The	  SICLOPPSH69AT72A	  double	  mutant	  lacks	  
residues	  that	  stabilize	  and	  orient	  the	  junction	  between	  the	  circularized	  
fragment	  and	  the	  N-­‐terminal	  intein,	  blocking	  cyclic	  peptide	  formation	  (Figure	  
3.3.1,	  panel	  B).	  This	  mutant	  has	  previously	  been	  used	  as	  a	  negative	  control	  
for	  intein	  post-­‐translational	  splicing	  (Kritzer	  et	  al.,	  2009)	  –	  please	  note	  that	  
the	  T69	  and	  H72	  numeration	  refers	  to	  residue	  positions	  within	  the	  original	  N-­‐
terminal	  portion	  of	  the	  DnaE	  split	  intein,	  not	  that	  in	  the	  SICLOPPS	  
orientation.	  I	  created	  this	  mutant	  by	  a	  single	  round	  of	  site-­‐directed	  
mutagenesis.	  The	  obtention	  of	  the	  desired	  double	  mutant	  was	  confirmed	  by	  
sequencing;	  the	  integrity	  of	  the	  sequence	  of	  the	  full	  open	  reading	  frame	  
(ORF)	  was	  also	  verified	  prior	  to	  subcloning	  back	  into	  the	  original	  pcDNA3	  
vector	  backbone.	  This	  was	  done	  to	  ensure	  that	  any	  mutation	  that	  might	  have	  
been	  introduced	  outside	  of	  the	  ORF	  during	  site	  directed	  mutagenesis	  is	  
removed.	  	  
	   To	  test	  SICLOPPS	  expression	  and	  processing,	  I	  first	  transiently	  
expressed	  both	  SICLOPPSWT	  and	  SICLOPPST69AH72A	  test	  constructs	  in	  HeLa	  
Kyoto	  cells	  without	  selection.	  Whole	  cell	  lysates	  collected	  48	  hours	  post-­‐
transfection	  were	  analysed	  by	  western	  blotting	  using	  an	  anti-­‐myc	  antibody	  
recognizing	  the	  epitope	  tag	  affixed	  to	  the	  SICLOPPS	  precursor.	  Both	  the	  
precursor	  and	  the	  faster	  migrating	  linear	  product	  (defined	  in	  panel	  A	  of	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Figure 3.3.1 - (A) Post-translational processing of the myc-tagged SICLOPPS 
constructs used in this study yields a myc-tagged linear product (L) and an 
untagged cyclic peptide (red), a larger unprocessed myc-tagged precursor can 
also be detected. (B) Residues T69 and H72 (orange) of the N-terminal intein  
orient the C-terminal extein-intein junction and are necessary for intein 
processing. The colour scheme in this panel is the same one employed in 
panel A, the C-terminal myc tag is not show in panel B (both after Kritzer et 
al., 2009 and PDB ID: 1ZD7).
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Figure	  3.3.1)	  could	  be	  detected	  in	  SICLOPPSWT	  sample,	  and	  the	  precursor	  only	  
in	  the	  splicing-­‐deficient	  control	  (Figure	  3.3.2,	  panel	  A,	  lanes	  4	  and	  3).	  These	  
results	  are	  consistent	  with	  SICLOPPS	  processing	  occurring	  in	  HeLa	  cells.	  
However,	  SICLOPPS	  protein	  levels	  appeared	  to	  be	  low	  as	  these	  required	  long	  
exposures	  in	  order	  to	  be	  visualized	  using	  enhanced	  chemiluminescence	  (ECL)	  
detection.	  The	  loading	  control	  was	  easily	  detected	  with	  short	  exposures,	  
indicating	  that	  overall	  protein	  levels	  were	  sufficient,	  and	  that	  the	  transfer	  
was	  efficient.	  	  
Wishing	  to	  ascertain	  whether	  the	  apparent	  low	  SICLOPPS	  protein	  
levels	  were	  due	  to	  poor	  expression	  or	  low	  transfection	  efficiency,	  I	  sought	  to	  
select	  transiently	  transfected	  cells.	  The	  pCDNA3	  vector	  contains	  a	  neomycin	  
resistance	  cassette	  conferring	  resistance	  to	  G418,	  an	  inhibitor	  of	  protein	  
synthesis.	  This	  resistance	  marker	  is	  suited	  to	  stable,	  but	  not	  transient,	  
transfection	  as	  selection	  typically	  takes	  3	  to	  7	  days	  of	  treatment	  in	  
mammalian	  cells.	  I	  therefore	  subcloned	  the	  SICLOPPS	  test	  constructs	  into	  the	  
BamHI	  and	  BstXI	  (blunted)	  sites	  of	  the	  multiple	  cloning	  site	  (MCS)	  of	  pIRES	  
puro2	  (Clontech).	  Like	  pCDN3,	  this	  vector	  contains	  a	  CMV	  promoter	  but	  also	  
a	  puromycin	  resistance	  cassette,	  which	  is	  expressed	  from	  an	  internal	  
ribosome	  entry	  site	  (IRES).	  Puromycin	  inhibits	  protein	  synthesis	  and	  allows	  
for	  the	  selection	  of	  transiently	  transfected	  cells	  within	  24	  hours	  of	  treatment.	  
As	  the	  resistance	  cassette	  is	  present	  in	  the	  same	  transcript	  as	  the	  test	  
construct,	  the	  translation	  levels	  from	  both	  ORFs	  should	  correlate,	  although	  
these	  will	  not	  be	  identical.	  
The	  transient	  transfection	  experiment	  was	  repeated	  with	  the	  pIRES	  
puro2	  versions	  of	  the	  two	  SICLOPPS	  test	  constructs	  and	  2µg/ml	  puromycin	  
selection	  was	  applied	  for	  the	  last	  24	  hours.	  Bands	  corresponding	  to	  the	  
SICLOPPS	  precursor	  and	  spliced	  products	  were	  once	  again	  present	  in	  the	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Figure 3.3.2 - SICLOPPS expression and processing tests in HeLa cells. 
Experimental schemes are outlined above their respective ECL immunoblots. 
Samples were either untransfected cells (unt), cells transfected with the 
empty vector, the SICLOPPS test construct (SIC) or the SICLOPPST69AH72A 
processing mutant (SICAA). (A) Experimental procedure and western blot 
analysis of cell lysates transiently transfected with pcDNA3-derived 
expression constructs.  (B) As in panel A but performed using the pIRES puro2 
vector along with puromycin selection prior to harvesting. (Exposure times 
are indicated on the bottom left-hand corner of each blot; loading density: 
1.5^105 cells per lane; * denotes a sample not treated with puromycin; P and 
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applicable	  samples	  48	  hours	  after	  transfection	  (Fig	  3.3.2,	  panel	  B	  lanes	  3	  and	  
4,	  and	  lane	  4,	  respectively).	  Moreover,	  these	  bands	  were	  readily	  detectable	  
by	  ECL	  under	  the	  same	  conditions	  used	  in	  the	  previous	  experiment.	  Taken	  
together,	  these	  results	  indicate	  that	  SICLOPPS	  constructs	  based	  on	  the	  Ssp	  
DnaE	  split	  intein	  are	  readily	  expressed	  in	  HeLa	  cells,	  and	  undergo	  post-­‐
translational	  processing.	  
3.4	   A	  CELL-­‐BASED	  CPC	  FUNCTION	  ASSAY	  
CONSIDERATIONS	  
In	  developing	  a	  cell-­‐based	  CPC	  function	  assay,	  the	  intention	  was	  not	  
only	  to	  assess	  the	  effects	  of	  dissociating	  the	  Aurora	  B-­‐INbox	  interaction	  
(Chapter	  4)	  but	  for	  it	  to	  form	  the	  basis	  of	  a	  genetically	  encoded	  library	  screen	  
(Chapter	  5).	  The	  library	  to	  be	  screened	  (section	  5.2)	  was	  to	  consist	  of	  ~100	  
members.	  As	  the	  generation	  of	  such	  a	  high	  number	  of	  stable	  cell	  lines	  would	  
be	  prohibitively	  time-­‐intensive,	  this	  assay	  needed	  to	  be	  compatible	  with	  
transient	  transfection.	  	  
For	  reasons	  elaborated	  in	  section	  5.1,	  the	  initial	  phase	  of	  the	  library	  
screen	  was	  carried	  out	  during	  piloting.	  In	  the	  interest	  of	  streamlining	  the	  
number	  of	  factors	  to	  be	  optimized	  at	  that	  time,	  manual	  scoring	  by	  eye	  was	  
favoured	  over	  automated	  scoring	  with	  or	  without	  automated	  image	  
acquisition.	  This	  scoring	  method	  continued	  to	  be	  employed	  for	  the	  remainder	  
of	  the	  study	  with	  additional	  handling	  steps	  to	  minimize	  scoring	  bias	  and	  
permit	  statistical	  analyses	  (discussed	  further	  below	  and	  in	  section	  5.6).	  	  
DESIGN	  &	  READ-­‐OUT	  
When	  assaying	  genetic	  constructs	  by	  transient	  transfection,	  it	  is	  
important	  to	  reliably	  identify	  transfected	  cells	  for	  scoring.	  Popular	  means	  of	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achieving	  this	  are	  the	  marking	  of	  transfected	  cells	  (e.g.	  using	  a	  fluorescent	  
marker)	  or	  the	  killing	  off	  of	  untransfected	  cells	  by	  antibiotic	  selection.	  As	  
earlier	  results	  (section	  3.3)	  indicated	  that	  puromycin	  selection	  worked	  well,	  
this	  strategy	  was	  employed.	  pIRES	  puro2	  was	  therefore	  used	  as	  a	  vector	  for	  
all	  constructs	  presented	  in	  this	  section	  and	  throughout	  the	  remainder	  of	  this	  
thesis.	  
Due	  to	  its	  multiple	  roles	  during	  cell	  division,	  loss	  of	  CPC	  function	  is	  
known	  to	  have	  pleiotropic	  consequences	  affecting	  both	  chromosome	  
segregation	  and	  cytokinesis	  (Adams	  et	  al.,	  2001).	  Furthermore,	  loss	  of	  CPC	  
function	  leads	  to	  a	  loss	  of	  the	  Aurora	  B-­‐specific	  histone	  H3	  phosphorylation	  
marks	  on	  serine	  10	  and	  28	  (Giet	  and	  Glover,	  2001;	  Sugiyama	  et	  al.,	  2002).	  Of	  
the	  consequences	  of	  CPC	  loss	  of	  function,	  cytokinesis	  is	  exquisitely	  sensitive	  –	  
expression	  of	  even	  slightly	  hypomorphic	  INCENP	  INbox	  mutants	  fails	  to	  
rescue	  cytokinesis	  defects	  in	  the	  absence	  of	  endogenous	  INCENP	  in	  chicken	  
DT40	  cells	  (Xu	  et	  al.,	  2010).	  	  
Population-­‐wide	  cytokinesis	  defects	  lead	  to	  a	  rise	  in	  binucleate	  cells,	  
which	  are	  easily	  recognizable	  by	  microscopy.	  Other	  nuclear	  morphological	  
aberrations	  typical	  of	  CPC	  loss	  of	  function	  are	  the	  presence	  of	  micronuclei	  
and	  chromatin	  bridges.	  Such	  features	  arise	  from	  lagging	  chromosomes,	  which	  
are	  due	  to	  a	  failure	  to	  achieve	  chromosome	  bi-­‐orientation	  prior	  to	  anaphase	  
onset.	  Thus,	  the	  assay	  read	  out	  would	  encompass	  all	  these	  morphological	  
nuclear	  aberrations	  (i.e.	  multinucleation,	  micronucleation,	  and	  chromatin	  
bridges)	  as	  visualized	  by	  DAPI	  staining.	  
In	  order	  to	  better	  delineate	  cells	  and	  improve	  scoring	  accuracy,	  I	  also	  
sought	  to	  highlight	  the	  cell	  perimeter.	  To	  achieve	  this,	  phalloidin	  staining	  was	  
employed	  because	  it	  is	  an	  inexpensive	  reagent	  and	  the	  staining	  protocol	  is	  
rapid.	  As	  48	  hours	  prove	  sufficient	  for	  SICLOPPS	  expression	  and	  processing,	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and	  the	  selection	  of	  transiently	  transfected	  cells,	  this	  time	  point	  was	  chosen	  
for	  the	  assay.	  The	  assay	  protocol	  is	  outlined	  in	  panel	  A	  of	  Figure	  3.4.1.	  
SCORING	  METHODOLOGY	  &	  CRITERIA	  
Stained	  samples	  were	  scored	  for	  abnormal	  nuclei	  index	  (ANI;	  defined	  
below)	  by	  eye	  using	  a	  40X	  objective.	  To	  prevent	  operator	  bias	  during	  scoring,	  
slides	  were	  first	  blinded	  and	  whole	  fields	  of	  view	  were	  scored	  until	  the	  total	  
number	  of	  cells	  counted	  exceeded	  1000.	  The	  rationale	  for	  the	  later	  step	  is	  
that,	  should	  the	  investigator	  err	  towards	  first	  counting	  normal	  or	  abnormal	  
cells/regions	  within	  a	  given	  field	  of	  view,	  the	  practice	  of	  stopping	  scoring	  as	  
soon	  as	  1000	  cells	  are	  counted	  would	  result	  in	  a	  bias	  towards	  the	  
investigator’s	  scoring	  preference.	  
The	  ANI	  score	  is	  a	  measure	  of	  the	  frequency	  of	  cells	  within	  a	  sample	  
presenting	  one	  or	  more	  of	  three	  nuclear	  morphological	  aberrations	  
consistent	  with	  CPC	  loss	  of	  function:	  multinucleation,	  micronucleation,	  and	  
chromatin	  bridges.	  Cells	  containing	  any	  of	  these	  three	  features,	  which	  are	  
defined	  below	  and	  illustrated	  in	  Figure	  3.4.1,	  as	  observed	  at	  40X	  
magnification	  were	  scored	  as	  having	  ‘abnormal	  nuclei’:	  
• Multinucleation:	  cell	  contains	  ≥2	  nuclei.	  
• Micronucleation:	  cell	  contains	  ≥1	  micronuclei.	  Micronuclei	  are	  
identifiable	  as	  round	  DAPI	  positive	  regions	  within	  the	  cell	  boundary;	  
DAPI	  positive	  regions	  whose	  size	  exceeds	  ~3/4	  that	  of	  the	  main	  nuclei	  
were	  considered	  nuclei	  rather	  than	  micronuclei,	  cells	  presenting	  these	  
were	  thus	  scored	  as	  multinucleated.	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Figure 3.4.1 - (A) Outline of the CPC function assay protocol employed 
throughout all stages of this study with the exception of the first pass INbox 
library screen (chapter 5). (B) Representative DAPI stained nuclei for each of 
the scoring classes employed in the CPC function assay. For the purpose of 
this assay, multinucleated and micronucleated cells, as well as those 
containing chromatin bridges, are considered to posess abnormal nuclei. The 
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• Chromatin	  bridges:	  cell	  contains	  a	  chromatin	  bridge.	  Chromatin	  
bridges	  are	  identifiable	  as	  a	  single	  elongated	  DAPI-­‐positive	  thread-­‐like	  
signal	  emanating	  from	  either	  the	  nucleus	  or	  a	  micronucleus	  towards	  to	  
the	  junction	  between	  the	  two	  daughter	  cells;	  this	  signal	  is	  often	  
mirrored	  in	  an	  adjacent	  cell.	  
Cells	  presenting	  abnormal	  features	  corresponding	  to	  more	  than	  one	  of	  
the	  criteria	  outlined	  above	  were	  scored	  as	  abnormal	  only	  once,	  and	  their	  
phenotype	  attributed	  to	  the	  upper-­‐most	  category	  satisfied	  according	  to	  the	  
following	  hierarchy:	  multinucleation	  >	  micronucleation	  >	  chromatin	  bridges.	  
For	  example,	  a	  binucleate	  cell	  also	  containing	  a	  micronucleus	  would	  be	  
scored	  as	  a	  multinucleate	  cell.	  Rare	  cells	  that	  could	  not	  be	  unambiguously	  
categorized	  as	  either	  normal	  or	  abnormal	  were	  skipped	  during	  scoring.	  
RE-­‐CLONING	  HELA	  KYOTO	  
The	  original	  HeLa	  Kyoto	  isolate	  used	  during	  screen	  piloting	  (see	  section	  
5.4)	  had	  a	  background	  ANI	  of	  5.27	  (SD=1.4%)	  under	  screen	  conditions	  (i.e.	  
transiently	  transfected	  at	  low	  cell	  density	  with	  an	  empty	  vector	  and	  
subjected	  to	  puromycin	  selection),	  and	  nearer	  to	  7%	  under	  typical	  culture	  
conditions.	  Prior	  to	  the	  second	  phase	  of	  the	  screen,	  we	  opted	  to	  re-­‐clone	  the	  
cell	  line	  in	  the	  hopes	  of	  obtaining	  a	  clone	  with	  a	  lower	  background	  ANI.	  	  
A	  fresh	  aliquot	  of	  low	  passage	  HeLa	  Kyoto	  cells	  was	  thawed	  and	  
allowed	  to	  recover	  prior	  to	  isolating	  clonal	  colonies.	  Isolate	  colonies	  were	  
first	  screened	  visually	  under	  a	  light	  microscope	  and	  those	  appearing	  to	  
contain	  high	  ANI	  were	  discarded,	  as	  were	  those	  with	  noticeably	  fewer	  cells,	  
which	  would	  suggest	  poor	  growth.	  Six	  clonal	  cell	  populations	  were	  then	  
picked	  and	  expanded.	  To	  preserve	  cells	  at	  low	  passages,	  aliquots	  from	  each	  
clonal	  population	  were	  made	  and	  stored	  in	  liquid	  nitrogen	  pending	  finer	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characterization	  of	  these.	  Each	  clonal	  population	  was	  assayed	  for	  puromycin	  
sensitivity,	  transfection	  efficiency,	  and	  their	  background	  ANI	  determined.	  
All	  the	  clonal	  populations	  assessed	  were	  efficiently	  killed	  by	  4µg/ml	  
puromycin	  in	  24	  hours	  (result	  not	  shown).	  In	  the	  initial	  screen	  2µg/ml	  
puromycin	  had	  been	  employed	  for	  selection	  but	  this	  was	  increased	  
thereafter	  to	  further	  promote	  the	  detachment	  of	  dead	  (i.e.	  untransfected)	  
cells	  from	  coverslips.	  Transfection	  efficiencies	  were	  determined	  by	  transient	  
transfection	  using	  a	  GFP	  lamin	  A	  construct	  and	  visually	  scoring	  the	  frequency	  
of	  cells	  with	  visible	  nuclear	  rim	  staining	  24	  hours	  post-­‐transfection	  without	  
any	  selection.	  A	  rough	  assessment	  of	  ANI	  without	  phalloidin	  staining	  was	  also	  
made	  at	  this	  time	  by	  scoring	  >500	  cells.	  Clones	  varied	  widely	  in	  their	  
transfection	  efficiency	  but	  only	  mildly	  in	  their	  background	  ANIs	  (Figure	  3.4.2,	  
panel	  A).	  	  
Clones	  A	  and	  D	  were	  selected	  for	  further	  investigation	  in	  light	  of	  their	  
high	  transfection	  efficiency	  relative	  to	  the	  original	  cell	  line,	  and	  their	  low	  ANI.	  
This	  consisted	  of	  determining	  their	  respective	  ANI	  based	  >1000	  
untransfected	  cells.	  Upon	  closer	  inspection,	  clone	  D	  had	  a	  marginally	  lower	  
ANI	  than	  either	  clone	  A	  or	  the	  original	  HeLa	  Kyoto	  cell	  line	  (Figure	  3.4.2,	  
panel	  B).	  Due	  to	  its	  appreciably	  better	  transfection	  efficiency,	  Clone	  D	  was	  
selected	  over	  the	  original	  cell	  line	  and	  employed	  in	  the	  cell-­‐based	  assay.	  With	  
respects	  to	  culturing	  this	  cell	  line,	  it	  was	  anecdotally	  observed	  during	  the	  first	  
phase	  of	  library	  screening	  that	  background	  ANI	  tended	  to	  increase	  when	  cells	  
were	  allowed	  to	  near	  confluency.	  Thus,	  this	  cell	  line	  was	  always	  passaged	  
before	  reaching	  ~75%	  confluence.	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Figure 3.4.2 - Recloning of the HeLa 
Kyoto cell line. (A) Rough abnormal 
nuclei index (ANI) and transfection 
efficiencies of the 6 isolated clones. 
Green boxes highlight clones selected 
for further analysis (see below) on 
the basis of their low ANI and high 
transfection efficiency. (B) Proportion 
of normal and abnormal nuclei 
present in HeLa Kyoto and the two 
best clones isolated quantified using 
a more stringent protocol (n>1000 
cells). The clone designated ‘Clone D’ 
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CONTROLS	  
In	  order	  to	  reflect	  the	  conditions	  of	  library	  screen,	  a	  genetically	  
encoded	  positive	  control	  disrupting	  CPC	  function	  was	  desired.	  I	  thus	  opted	  to	  
overexpress	  a	  dominant	  negative	  Aurora	  B	  kinase	  dead	  mutant.	  Two	  such	  
active	  site	  mutants	  are	  reported	  in	  the	  literatures:	  K106R	  and	  D218N.	  The	  
Aurora	  B	  D218N	  mutant	  was	  selected	  as	  it	  is	  reported	  to	  have	  the	  strongest	  
dominant	  negative	  effect	  (Girdler	  et	  al.,	  2006).	  Inserts	  encoding	  wild	  type	  and	  
kinase	  dead	  Aurora	  B	  (hereby	  referred	  to	  as	  AURKBWT	  and	  AURKBD218N)	  were	  
cloned	  into	  the	  pIRES	  puro2	  vector.	  The	  Aurora	  B	  inserts	  were	  also	  N-­‐
terminally	  tagged	  with	  a	  3xmyc	  epitope	  generated	  by	  linker	  ligation.	  
These	  constructs	  were	  assayed	  using	  the	  cell-­‐based	  assay	  and	  their	  
effect	  compared	  to	  that	  of	  an	  empty	  pIRES	  puro2	  vector	  (Figure	  3.4.3,	  panels	  
A	  and	  B).	  In	  accordance	  with	  previously	  published	  results	  (Girdler	  et	  al.,	  2006;	  
Honda	  et	  al.,	  2003),	  the	  effect	  of	  AURKBWT	  overexpression	  on	  ANI	  was	  
indistinguishable	  from	  those	  of	  the	  empty	  vector	  control	  48	  hours	  post-­‐
transfection	  (p>0.05,	  n=3,	  Mann-­‐Whitney	  U	  test).	  Overexpression	  of	  kinase-­‐
dead	  Aurora	  B	  had	  a	  very	  pronounced	  effect	  and	  elicited	  a	  highly	  significant	  
19.7	  fold	  increase	  in	  ANI	  (p<0.01,	  n=3,	  Mann-­‐Whitney	  U	  test).	  This	  result	  
indicates	  that	  loss	  of	  CPC	  function	  is	  readily	  detectable	  within	  48	  hours	  using	  
the	  cell-­‐based	  assay	  devised.	  
3.4	   SICLOPPS	  CONSTRUCTS	  DO	  NOT	  IMPAIR	  CPC	  FUNCTION	  
	   Further	  to	  testing	  the	  effect	  of	  dissociating	  the	  Aurora	  B-­‐INbox	  
interaction,	  we	  intended	  to	  use	  the	  cell-­‐based	  assay	  to	  assay	  the	  effects	  of	  
small	  CPs	  produced	  using	  the	  Ssp	  DnaE-­‐based	  SICLOPPS	  backbone.	  It	  was	  
therefore	  necessary	  to	  verify	  whether	  expression	  of	  this	  backbone	  itself	  
interferes	  with	  the	  assay.	  For	  this	  purpose,	  the	  effects	  of	  the	  SICLOPPSWT	  and	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Figure 3.4.3 - CPC function assay controls. (A) Representative micrographs 
showing transiently transfected DAPI (blue) and phalloidin (green) stained 
HeLa Kyoto cells overexpressing wild type (AURKBWT) or kinase dead 
(AURKBD218N) Aurora B 48 hours post-transfection (40X magnification). (B) 
Quantification of the abnormal nuclei index (ANI) in experimental samples 
treated as in (A). (C) Quantification of the ANI in samples overexpressing the 
SICLOPPS test construct or a splicing-deficient mutant thereof (SICLOPPSAA). 
In panels B and C: n=3, >1000 cells per replicate, error bars +/- SD, **: p<0.01, 
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SICLOPPST69AH72A	  test	  constructs	  employed	  earlier	  (section	  3.3)	  were	  assayed	  
using	  the	  protocol	  devised	  above.	  The	  extein	  region	  of	  these	  constructs,	  
designed	  by	  the	  Tyers	  laboratory,	  encodes	  the	  peptide	  CFGGSGGHPQFANA,	  
which	  has	  no	  primary	  amino	  acid	  sequence	  homology	  to	  CPC	  components.	  
	   As	  illustrated	  in	  panel	  C	  of	  Figure	  3.4.3,	  upon	  expression	  for	  48	  hours	  –	  
the	  last	  24	  hours	  of	  which	  under	  puromycin	  selection	  –	  neither	  SICLOPPSWT	  
nor	  SICLOPPST69AH72A	  construct	  elicited	  a	  significant	  change	  in	  ANI	  (both	  
p>0.05,	  Mann-­‐Whitney	  U	  test).	  SICLOPPS	  libraries	  were	  thus	  deemed	  
compatible	  with	  the	  cell-­‐based	  assay.	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3.5	   DISCUSSION	  
SICLOPPS	  FUNCTIONAL	  TEST	  
SICLOPPS	  test	  constructs	  based	  on	  the	  Ssp	  DnaE	  split	  intein	  were	  
readily	  expressed	  and	  processed	  in	  HeLa	  cells.	  To	  our	  knowledge,	  this	  is	  the	  
first	  instance	  of	  the	  Ssp	  DnaE-­‐derived	  SICLOPPS	  construct	  being	  shown	  to	  
undergo	  post-­‐translational	  splicing	  in	  human	  cells.	  Since	  these	  results	  were	  
obtained,	  a	  study	  was	  published	  demonstrating	  that	  the	  naturally-­‐split	  DnaE	  
intein	  from	  Synechococcus	  elongatus	  is	  capable	  of	  trans	  splicing	  in	  human	  
cells	  (Chen	  et	  al.,	  2010).	  
It	  should,	  however,	  be	  cautioned	  the	  CP	  product	  was	  not	  directly	  
detected.	  Instead,	  I	  infer	  the	  production	  of	  the	  CP	  on	  the	  basis	  of	  the	  
formation	  of	  the	  linear	  product	  of	  intein	  processing.	  Due	  to	  their	  small	  size	  
and	  lack	  of	  epitope	  tag,	  it	  is	  difficult	  –	  if	  at	  all	  possible	  –	  to	  detect	  CPs	  
themselves	  by	  immunoblotting.	  In	  fact,	  there	  are	  no	  published	  reports	  of	  
western	  blot	  detection	  of	  SICLOPPS	  derived	  CPs,	  only	  larger	  circularlised	  
proteins.	  The	  in	  vivo	  production	  of	  a	  12	  residue	  long	  CP	  generated	  in	  S.	  
cerevisiae	  using	  the	  same	  intein	  employed	  in	  this	  study	  has	  been	  confirmed	  
by	  mass	  spectrometry	  analysis	  of	  purified	  cell	  lysates	  by	  Kritzer	  and	  
colleagues	  (Kritzer	  et	  al.,	  2009).	  Due	  to	  time	  constraints,	  we	  have	  opted	  not	  
to	  reproduce	  this	  experiment	  in	  human	  cells.	  
RECLONING	  OF	  THE	  HELA	  CELL	  LINE	  
The	  HeLa	  cell	  line	  and	  its	  derivatives	  are	  transformed	  and	  genetically	  
unstable.	  In	  hindsight,	  the	  attempt	  to	  reclone	  HeLa	  Kyoto	  was	  therefore	  
unlikely	  to	  yield	  a	  clone	  with	  an	  appreciably	  lower	  ANI,	  or	  one	  that	  would	  
remain	  stably	  so.	  Nonetheless,	  a	  clone	  was	  obtained	  that	  had	  an	  improved	  
transfection	  efficiency	  compared	  to	  the	  starting	  HeLa	  Kyoto	  cell	  line.	  This	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clone	  was	  used	  for	  most	  of	  this	  study	  and	  it	  was	  therefore	  necessary	  to	  
explain	  its	  origins	  in	  this	  report.	  
	   CPC	  FUNCTION	  CELL-­‐BASED	  ASSAY	  
The	  phenotypic	  assay	  needed	  to	  satisfy	  two	  key	  criteria	  for	  its	  use	  as	  a	  
SICLOPPS-­‐derived	  library	  screening	  platform:	  sensitivity	  to	  loss	  of	  CPC	  
function,	  and	  insensitivity	  to	  SICLOPPS	  constructs	  themselves.	  Whilst	  the	  lack	  
of	  ANI	  increase	  indicates	  uncompromised	  CPC	  function,	  the	  inverse	  (i.e.	  that	  
an	  ANI	  increase	  must	  be	  due	  to	  compromised	  CPC	  function)	  may	  not	  
necessarily	  be	  true.	  As	  such,	  one	  must	  exercise	  caution	  in	  attributing,	  be	  it	  
directly	  or	  indirectly,	  an	  observed	  ANI	  increase	  to	  impaired	  CPC	  function	  
solely	  on	  the	  basis	  of	  the	  cell-­‐based	  assay	  described	  here.	  Doing	  so	  will	  
require	  additional	  evidence.	  
Here,	  I	  will	  evaluate	  several	  features	  of	  the	  CPC	  function	  assay	  in	  
comparison	  to	  alternatives	  that	  could	  have	  been	  employed.	  I	  will	  then	  
expand	  on	  a	  number	  of	  foreseeable	  potential	  limitations	  of	  the	  assay.	  
Cytokinesis	  failure	  results	  not	  only	  in	  nuclear	  morphological	  
aberrations	  but	  also	  in	  increased	  DNA	  content.	  An	  alternative	  screening	  
strategy	  considered	  was	  to	  employ	  flow	  cytometry	  to	  detect	  increased	  DNA	  
content.	  A	  particularly	  attractive	  possibility	  was	  that	  this	  would,	  if	  used	  in	  
conjunction	  with	  a	  fluorescent	  detection	  of	  the	  epitope	  tag,	  permit	  an	  
assessment	  of	  the	  relationship	  between	  transgene	  expression	  levels	  and	  DNA	  
content.	  However,	  this	  strategy	  was	  not	  pursued	  due	  to	  the	  difficulties	  in	  
distinguishing	  between	  mitotic	  cells	  and	  those	  having	  failed	  cytokinesis	  –	  
both	  have	  4N	  DNA	  content.	  Such	  an	  approach	  could,	  however,	  be	  useful	  in	  
validating	  hits.	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The	  use	  of	  puromycin	  selection	  to	  enrich	  for	  transfected	  cells	  is	  well	  
suited	  given	  the	  manual	  scoring	  employed	  here	  (i.e.	  scoring	  by	  eye	  without	  
image	  capture).	  Although	  suitable,	  under	  these	  scoring	  conditions,	  the	  use	  of	  
a	  fluorescent	  tag	  (e.g.	  GFP)	  to	  identify	  transfected	  cells	  might	  give	  rise	  to	  a	  
scoring	  bias	  favouring	  the	  most	  highly	  expressing	  (i.e.	  brightest)	  cells.	  As	  the	  
puromycin	  resistance	  gene	  is	  expressed	  from	  an	  internal	  ribosome	  entry	  site	  
(IRES),	  the	  expression	  of	  the	  marker	  should	  –	  although	  being	  weaker	  –	  
correlate	  with	  that	  of	  the	  transgene.	  Thus,	  a	  minimum	  transgene	  expression	  
level	  can	  be	  imposed	  through	  the	  concentration	  of	  puromycin	  applied	  during	  
selection.	  However,	  there	  may	  be	  significant	  expression	  heterogeneity	  above	  
that	  threshold.	  
An	  additional	  nuclear	  phenotype	  that	  could	  have	  been	  included	  in	  this	  
assay,	  and	  might	  have	  been	  informative,	  is	  one	  encompassing	  cells	  
presenting	  ‘grape-­‐like’	  clusters	  of	  small	  nuclei.	  This	  morphological	  feature	  is	  
indicative	  of	  mitotic	  slippage	  in	  which	  the	  cell	  exists	  mitosis	  in	  the	  presence	  
of	  scattered	  chromosomes.	  The	  reformation	  of	  the	  nuclear	  envelope	  around	  
these	  scattered	  chromosomes	  results	  in	  the	  formation	  of	  multiple	  small	  
nuclei.	  For	  the	  purpose	  of	  this	  assay,	  such	  cells	  were	  scored	  as	  being	  
multinucleated.	  Although	  not	  quantified,	  this	  phenotype	  was	  frequently	  
observed	  in	  cells	  overexpressing	  kinases-­‐dead	  Aurora	  B.	  
Given	  that	  constructs	  are	  transiently	  transfected,	  vector	  dilution	  over	  
successive	  cell	  cycles	  limits	  the	  time	  period	  over	  which	  these	  can	  be	  assayed.	  
A	  48	  hour	  assay	  time	  point	  was	  selected	  to	  allow	  sufficient	  time	  for	  
puromycin	  selection	  and	  for	  cells	  to	  undergo	  several	  cell	  cycles	  whilst	  
remaining	  in	  the	  presence	  of	  assay	  construct.	  Furthermore,	  following	  
cytokinesis	  failure	  negatively	  impacts	  on	  cell	  survival.	  Thus,	  longer	  assay	  
periods	  might	  also	  risk	  resulting	  in	  the	  gradual	  depletion	  of	  the	  most	  severely	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affected	  cells.	  The	  effects	  of	  the	  AURKBD218N	  positive	  control	  were	  readily	  
apparent	  48	  hours	  post-­‐transfection.	  This	  result	  indicates	  that	  this	  period	  of	  
exposure	  is	  sufficient	  for	  assaying	  the	  effects	  of	  genetically	  encoded	  
constructs	  on	  CPC	  function.	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CHAPTER	  4:	  EXPRESSION	  OF	  SOLUBLE	  INBOX	  IMPAIRS	  
CPC	  FUNCTION	  
4.1	   INTRODUCTION	  
In	  order	  for	  the	  CPC	  to	  perform	  its	  many	  functions,	  Aurora	  B	  must	  not	  
only	  be	  active	  but	  also	  correctly	  localized.	  Loss	  of	  either,	  or	  both,	  of	  these	  
features	  has	  serious	  deleterious	  consequences.	  Loss	  of	  Aurora	  B	  activity	  
through	  active	  site	  inhibition	  results	  in	  chromosome	  segregation	  errors,	  
cytokinesis	  failure	  and	  other	  mitotic	  defects	  (Ditchfield	  et	  al.,	  2003).	  	  
Loss	  of	  localization	  can	  be	  achieved	  through	  different	  means.	  
Treatment	  of	  cells	  with	  actinomycin	  D	  –	  an	  antibiotic	  known	  to	  inhibit	  
transcription	  and	  bind	  DNA	  duplexes	  –	  causes	  mislocalisation	  of	  the	  active	  
and	  intact	  CPC	  by	  an	  unknown	  mechanism	  (Becker	  et	  al.,	  2010).	  A	  number	  of	  
INCENP	  and	  survivin	  mutations	  disrupting	  either	  the	  survivin	  BIR	  domain	  or	  
the	  formation	  of	  the	  triple	  helix	  bundle	  supporting	  the	  localization	  module	  
have	  been	  reported	  to	  block	  CPC	  targeting	  to	  centromeres	  but	  not	  to	  the	  
spindle	  (Lens	  et	  al.,	  2006;	  Yue	  et	  al.,	  2008).	  In	  chicken	  DT40	  cells,	  
survivinD72AD73A	  can	  rescue	  loss	  of	  endogenous	  survivin	  despite	  failing	  to	  
localize	  the	  CPC	  to	  the	  centromere	  from	  prophase	  to	  metaphase.	  Such	  cells,	  
however,	  present	  a	  mild	  but	  significant	  checkpoint	  defect.	  Depletion	  of	  CPC	  
targeting	  components	  (i.e.	  INCENP,	  survivin	  and	  borealin)	  disturbs	  both	  
Aurora	  B	  activation	  and	  localization	  throughout	  mitosis,	  leading	  to	  
chromosome	  segregation	  and	  cytokinesis	  defects	  (Adams	  et	  al.,	  2001;	  
Carvalho	  et	  al.,	  2003;	  Gassmann	  et	  al.,	  2004;	  Lens	  et	  al.,	  2003).	  Chemical	  
inhibition	  of	  Aurora	  B	  causes	  similar	  defects	  (Hauf	  et	  al.,	  2003).	  It	  is	  important	  
to	  note	  that	  depletion	  of	  INCENP,	  borealin	  or	  survivin	  tends	  to	  result	  in	  a	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concomitant	  drop	  in	  the	  protein	  levels	  of	  the	  other	  CPC	  regulatory	  
components	  (Klein	  et	  al.,	  2006).	  
I	  hypothesized	  that	  simply	  abrogating	  the	  interaction	  between	  INCENP	  
and	  Aurora	  B	  would	  significantly	  impair	  CPC	  function,	  presumably	  through	  
the	  loss	  of	  Aurora	  B	  activation	  and	  localisation.	  Aurora	  B	  localisation	  would	  
be	  disturbed	  due	  to	  loss	  of	  linkage	  not	  only	  with	  the	  localization	  module	  of	  
the	  CPC	  consisting	  of	  borealin,	  survivin	  and	  the	  INCENP	  C-­‐terminus,	  but	  also	  
with	  the	  INCENP	  flexible	  coiled	  domain	  required	  for	  spindle	  association	  
(Figure	  4.2.1,	  panel	  A).	  This	  might,	  in	  turn,	  quell	  activation	  by	  preventing	  
Aurora	  B	  clustering.	  
To	  date,	  the	  experimental	  evidence	  most	  relevant	  to	  the	  targeting	  of	  
this	  interaction	  is	  limited	  to	  the	  depletion	  or	  knockout	  of	  CPC	  components.	  
Although	  highly	  informative,	  this	  experimental	  approach	  cannot	  fully	  
recapitulate	  the	  effects	  of	  dissociating	  the	  INbox	  and	  Aurora	  B	  interaction	  
alone,	  due	  to	  the	  loss	  of	  the	  endogenous	  protein.	  Thus,	  it	  was	  uncertain	  that	  
the	  consequences	  of	  simply	  abrogating	  this	  interaction	  would	  reflect	  these	  
experimental	  results.	  The	  effects	  of	  the	  loss	  of	  this	  interaction	  in	  the	  
presence	  of	  all	  intact	  endogenous	  CPC	  components	  were	  of	  particular	  
interest.	  
4.2	   EXPRESSION	  OF	  SOLUBLE	  INBOX	  IMPAIRS	  CYTOKINESIS	  
To	  test	  the	  effects	  of	  disrupting	  the	  Aurora	  B-­‐INbox	  PPI,	  I	  opted	  to	  
express	  the	  INbox	  domain	  alone.	  In	  isolation,	  this	  fragment	  of	  INCENP	  should	  
retain	  the	  ability	  to	  bind	  Aurora	  B	  whilst	  lacking	  that	  to	  associate	  with	  
microtubules,	  survivin	  and	  borealin.	  I	  sought	  to	  overexpress	  the	  full	  INbox	  
domain	  of	  human	  INCENP	  in	  HeLa	  cells	  using	  a	  Ssp	  dnaE-­‐derived	  SICLOPPS	  
scaffold	  for	  circularisation	  to	  confer	  stability	  (detailed	  in	  Chapter	  3).	  An	  insert	  	   	  
Figure 4.2.1 - (A) Domain architecture of INCENP highlighting regions of 
interaction with other proteins. The targetting domain (red) refers to the 
region participating in the triple helix bundle with borealin and survivin. (B) 
Amino-acid sequence of human INCENP residues 821 to 900, which contain 
INbox (green); the region of the INbox stably associated with the Aurora B 
N-terminal lobe in the Xenopus laevis crystal structure is contained within 
the boxed region. INbox residues known to be critical for CPC function are 
highlighted in white. (C) Sequence of the 75 residue INbox peptide 
expressed using SICLOPPS. Accessory residues include the +1 cysteine 
required for intein processing (orange) and native extein residues (blue) 
included to promote processing. Residues highlighted in white were 






















Figure 4.2.2 -  Overexpression of the INCENP INbox causes an increase in cells 
containing abnormal nuclei. HeLa cells were transiently transfected with 
splicing-competent (SIC) and deficient (SICAA) SICLOPPS constructs containing 
the human INbox sequence in the extein position. Representative DAPI and 
phalloidin stained micrographs of samples collected 48 hours after 
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spanning	  residues	  821	  to	  900	  of	  human	  INCENP	  –	  hereby	  refered	  to	  as	  
INboxWT	  –	  was	  inserted	  in	  the	  extein	  position	  of	  the	  pIRES	  puro2	  SICLOPPSWT	  
and	  SICLOPPST69AH72A	  test	  constructs	  (Figure	  4.2.1,	  panel	  B).	  In	  the	  hopes	  of	  
enhancing	  processing,	  which	  can	  be	  sensitive	  to	  extein	  residues(Scott	  et	  al.,	  
2001),	  accessory	  residues	  were	  added	  to	  either	  end	  of	  the	  INbox	  insert.	  
Native	  extein	  residues	  found	  in	  the	  Ssp	  DnaE	  protein	  were	  used	  as	  these	  are	  
known	  to	  support	  the	  processing	  of	  the	  intein.	  Further	  to	  the	  cysteine	  
residue	  in	  position	  +1,	  which	  is	  required	  for	  processing,	  the	  insert	  was	  
flanked	  with	  the	  +2	  and	  +3	  native	  C-­‐terminal,	  and	  -­‐1	  and	  -­‐2	  N-­‐terminal	  extein	  
residues	  (Figure	  4.2.1,	  panel	  C).	  Thus,	  processing	  of	  this	  construct	  is	  expected	  
to	  yield	  a	  75	  amino	  acid	  residues	  long	  CP	  spanning	  the	  whole	  INbox.	  	  
This	  construct	  was	  assayed	  using	  the	  CPC	  function	  assay	  described	  in	  
the	  previous	  chapter.	  Transient	  expression	  of	  this	  construct	  in	  HeLa	  cells	  had	  
a	  significant	  dominant	  negative	  effect	  that	  could	  be	  readily	  observed	  by	  
microscopy	  (Figure	  4.2.2).	  This	  effect	  was	  quantified	  and	  the	  extent	  of	  
SICLOPPS	  processing	  measured	  by	  quantitative	  western	  blot	  analysis.	  To	  
permit	  side-­‐by-­‐side	  comparison,	  the	  results	  of	  these	  analyses	  with	  different	  
INbox	  constructs	  are	  compiled	  in	  Figure	  4.4.2	  at	  the	  end	  of	  this	  chapter.	  48	  
hours	  after	  transfection,	  a	  5.1	  fold	  increase	  in	  abnormal	  nuclei	  index	  (ANI)	  
could	  be	  observed	  relative	  to	  the	  empty	  vector	  control	  (Figure	  4.4.2,	  panel	  A;	  
p<0.05;	  Mann-­‐Whitney	  U	  test,	  n=3).	  Western	  blot	  analysis	  of	  cell	  lysate	  
revealed	  that	  the	  extent	  of	  SICLOPPS	  processing	  was	  of	  approximately	  30%	  
(Figure	  4.4.2,	  panel	  B).	  Western	  blotting	  analysis	  indicated	  that	  the	  extent	  of	  
SICLOPPS	  processing	  was	  comparable	  across	  all	  INbox	  SICLOPPS	  constructs	  
assayed	  as	  part	  of	  this	  study	  (Figure	  4.4.1,	  panel	  B,	  and	  data	  not	  shown	  for	  
INboxAAA).	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As	  post-­‐translational	  processing	  of	  the	  Ssp	  dnaE	  intein	  was	  only	  partial,	  both	  
the	  circularized	  INbox	  and	  a	  linear	  INbox	  flanked	  by	  the	  two	  intein	  halves	  
(hereby	  referred	  to	  as	  the	  linear	  precursor)	  should	  be	  present.	  To	  
discriminate	  between	  the	  effect	  of	  the	  cyclic	  INbox	  peptide	  and	  its	  linear	  
precursor,	  a	  SICLOPPST69AH72A	  processing	  deficient	  version	  of	  the	  INbox	  
construct	  was	  generated	  in	  the	  same	  vector	  and	  assayed.	  The	  lack	  of	  intein	  
processing	  was	  confirmed	  by	  western	  blotting	  (Figure	  4.4.2,	  panel	  B).	  
Unexpectedly,	  the	  SICLOPPST69AH72A	  mutant	  with	  the	  INboxWT	  insert	  produced	  
a	  more	  pronounced	  ANI	  increase	  relative	  to	  its	  processing-­‐competent	  
counterpart.	  Transient	  expression	  of	  the	  splicing-­‐deficient	  form	  of	  the	  
INboxWT	  caused	  a	  7.9	  fold	  increase	  in	  ANI	  (Figure4.4.2,	  panel	  A;	  p<0.05;	  
Mann-­‐Whitney	  U	  test,	  n=3).	  The	  relative	  decrease	  in	  ANI	  between	  the	  
processing-­‐deficient	  and	  competent	  form	  of	  the	  INbox	  construct	  is	  of	  about	  
one	  third,	  which	  is	  roughly	  the	  same	  as	  the	  extent	  of	  intein	  processing	  in	  the	  
SICLOPPS	  construct.	  These	  results	  suggest	  that	  it	  the	  linear	  precursor	  is	  
predominantly	  responsible	  for	  the	  phenotype	  observed.	  	  
4.3	   INBOX	  RESIDUES	  W845	  AND	  F881	  ARE	  NECESSARY	  FOR	  
THE	  DOMINANT	  NEGATIVE	  EFFECT	  OF	  THE	  SOLUBLE	  INBOX	  
Previous	  work	  has	  highlighted	  several	  highly	  conserved	  features	  of	  the	  
INbox	  that	  are	  absolutely	  necessary	  for	  its	  function.	  Residues	  W845	  and	  F881	  
of	  the	  human	  INCENP	  are	  the	  most	  highly	  conserved	  INbox	  residues	  and	  
make	  close	  contacts	  with	  the	  N-­‐terminal	  lobe	  of	  Aurora	  B	  in	  both	  the	  
Xenopus	  and	  human	  crystal	  structures	  of	  the	  Aurora	  B:INCENP	  complex	  
(Elkins	  et	  al.,	  2012;	  Sessa	  et	  al.,	  2005).	  Mutants	  in	  which	  the	  residues	  
homologous	  to	  W845	  and	  F881	  are	  substituted	  for	  others	  are	  reported	  not	  to	  
bind	  nor	  activate,	  and	  not	  to	  activate	  Aurora	  B,	  respectively.	  In	  accordance	  









Figure 4.3.1 -  Overexpression of INCENP INbox mutants lacking W845 or 
F881 does not impair CPC function. Representative DAPI and phalloidin 























Figure 4.3.2 - Overexpression of a INCENP INbox TSS motif mutant, but not 
one lacking W845 and F881, impairs CPC function. Representative DAPI and 
















	   90	  
an	  alanine	  in	  the	  two	  versions	  of	  the	  SICLOPPS	  INbox	  construct.	  Respectively,	  
these	  will	  be	  referred	  to	  as	  INboxW845G	  and	  INboxF881A.	  A	  double	  mutant	  
containing	  both	  the	  W845G	  and	  F881A	  mutations,	  hereby	  referred	  to	  as	  
INboxdbl,	  was	  also	  generated	  and	  assayed	  
None	  of	  these	  constructs,	  regardless	  of	  whether	  or	  not	  they	  were	  
processing-­‐competent,	  caused	  a	  significant	  increase	  ANI	  in	  the	  cell-­‐based	  CPC	  
function	  assay	  (see	  figures	  4.3.1	  and	  4.3.2	  for	  representative	  micrographs,	  
and	  panel	  A	  of	  Figure	  4.4.1	  for	  quantifications).	  This	  would	  indicate	  that	  CPC	  
function	  is	  not	  disturbed	  under	  these	  conditions.	  Previously	  published	  
reports	  have	  already	  indicated	  that	  the	  region	  encompassing	  W845	  is	  
required	  for	  Aurora	  B	  binding	  (Honda	  et	  al.,	  2003;	  Sessa	  et	  al.,	  2005;	  Xu	  et	  al.,	  
2009).	  However,	  in	  Honda	  et	  al.’s	  study,	  a	  truncated	  INbox	  fragment	  lacking	  
the	  region	  surrounding	  F881	  could	  efficiently	  pull	  down	  Aurora	  B,	  albeit	  
inactive,	  from	  cell	  lysates	  when	  these	  were	  co-­‐expressed	  in	  Sf-­‐9	  cells.	  The	  
results	  I	  have	  obtained	  suggest	  that	  both	  W845	  and	  F881	  are	  essential,	  not	  
only	  for	  the	  activation	  of	  Aurora	  B,	  but	  also	  for	  INCENP	  binding	  to	  the	  kinase.	  
4.4	   THE	  TSS	  MOTIF	  IS	  DISPENSIBLE	  FOR	  THE	  DOMINANT	  
NEGATIVE	  EFFECT	  OF	  THE	  SOLUBLE	  INBOX	  
Another	  highly,	  if	  not	  absolutely,	  conserved	  (see	  Figure	  5.2.1)	  INbox	  
feature	  is	  the	  TSS	  motif	  present	  within	  its	  distal	  end.	  Although	  not	  involved	  in	  
Aurora	  B	  binding,	  this	  motif	  is	  phosphorylated	  by	  Aurora	  B	  and	  is	  required	  for	  
the	  full	  activation	  of	  the	  kinase.	  Phospho	  null	  and	  mimic	  INCENP	  mutants	  
cannot	  rescue	  the	  loss	  of	  endogenous	  INCENP	  despite	  only	  modest	  drops	  in	  
Aurora	  B	  activity	  as	  measured	  by	  histone	  H3	  serine	  10	  phosphorylation	  (Xu	  et	  
al.,	  2010).	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Figure 4.4.1 -  Effect of the expression of the whole INCENP INbox or mutants 
thereof in HeLa cells. Constructs were transiently expressed for 48 hours, the 
last 24 hours of which under puromycin selection. (A) Quantification of the 
abnormal nuclei index of HeLa cells transiently transfected with INbox 
SICLOPPS constructs.  The statistical significance of experimental samples 
compared to empty vector controls is indicated immediately over the error 
bars (Mann-Whitney U test, *=p>0.05, ns=not significant; n=3, >1000 cells 
scored per replicate; error bars= +/-SEM). (B) Processing of the SICLOPPS 
INbox constructs as detected by western blotting with anti-myc antibody and 
anti-tubulin used as a loading control. The precursor (P) and linear product (L) 
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A	  pair	  of	  SICLOPPS	  and	  SICLOPPST69AH72A	  constructs	  was	  made	  in	  which	  all	  
residues	  within	  the	  TSS	  motif	  are	  substituted	  with	  alanine	  (hereby	  referred	  to	  
as	  INboxAAA).	  In	  contrast	  to	  the	  W845	  and	  F881	  residue	  mutants,	  both	  
INboxAAA	  constructs	  elicited	  a	  strong	  increase	  in	  ANI	  comparable	  to	  their	  
respective	  splicing	  proficient/deficient	  INboxWT	  constructs	  (Figure	  4.3.2	  and	  
Figure	  4.4.1,	  panel	  A).	  This	  result	  suggests	  that	  the	  TSS	  motif	  is	  dispensable	  
for	  Aurora	  B	  binding	  in	  vivo	  and	  is	  consistent	  with	  Honda	  et	  al.’s	  in	  vitro	  
experiments	  (Honda	  et	  al.,	  2003).	  As	  with	  the	  INboxWT	  constructs,	  the	  
decrease	  in	  ANI	  between	  the	  SICLOPPST69AH72A	  and	  SICLOPPS	  versions	  of	  the	  
constructs	  was	  comparable	  to	  the	  extent	  of	  processing	  (panel	  A	  of	  Figure	  
4.4.1	  and	  data	  not	  shown).	  
4.5	   EXPRESSION	  OF	  SOLUBLE	  INBOX	  CAUSES	  AURORA	  B	  
MISLOCALISATION	  	  
INCENP	  is	  known	  to	  be	  required	  for	  both	  Aurora	  B	  activation	  and	  its	  
localization	  during	  mitosis.	  To	  test	  whether	  the	  soluble	  INbox	  affected	  Aurora	  
B	  localisation,	  the	  effects	  of	  transient	  expression	  of	  SICLOPPST69AH72A	  INboxWT	  
and	  INboxdbl	  in	  mitotic	  HeLa	  cells	  were	  examined	  by	  immunofluorescence	  
microscopy.	  The	  SICLOPPST69AH72A	  versions	  of	  these	  constructs	  were	  selected	  
for	  this	  assay	  because	  the	  INboxWT	  construct	  was	  most	  potent	  in	  its	  
processing	  deficient	  form.	  The	  INboxdbl	  construct	  was	  used	  because	  it	  bore	  
both	  the	  W845G	  and	  F881A	  mutations	  that	  nullified	  the	  dominant	  negative	  
effect	  of	  the	  soluble	  INbox.	  Cells	  transfected	  with	  an	  empty	  vector	  served	  as	  
a	  negative	  control.	  
Consistent	  with	  the	  hypothesis	  that	  the	  soluble	  INbox	  might	  interfere	  
with	  the	  interaction	  between	  INCENP	  and	  Aurora	  B,	  Aurora	  B	  was	  frequently	  
mislocalised	  in	  mitotic	  cells	  expressing	  SICLOPPST69AH72A	  INboxWT	  (Figure	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4.5.1).	  Compared	  to	  control	  cells	  transfected	  with	  an	  empty	  vector,	  the	  
localisation	  of	  Aurora	  B	  was	  significantly	  affected	  in	  all	  stages	  of	  mitosis	  in	  
cells	  transfected	  with	  INboxWT	  but	  not	  INboxdbl	  (p<0.001	  and	  p>0.05	  
respectively,	  n=3,	  Fisher’s	  exact	  test;	  Figure	  4.5.2,	  panel	  A).	  In	  the	  presence	  of	  
INboxWT,	  Aurora	  B	  was	  either	  completely	  or	  partially	  mislocalised	  in	  the	  vast	  
majority	  of	  cells	  fixed	  in	  prophase	  to	  anaphase	  (Figure	  4.5.2,	  panel	  A).	  The	  
localization	  of	  Aurora	  B	  in	  cells	  during	  telophase	  and	  cytokinesis	  was	  less	  
severely	  affected	  by	  INboxWT	  expression	  and	  normal	  localization	  could	  be	  
observed	  in	  roughly	  half	  the	  cells	  scored.	  	  
Given	  the	  CPC’s	  role	  in	  several	  processes	  during	  mitosis	  and	  cytokinesis,	  
mitotic	  indexes	  and	  progression	  were	  also	  monitored	  in	  these	  samples.	  All	  
samples	  had	  comparable	  mitotic	  indexes	  (empty	  vector:	  4.3%	  +/-­‐	  0.6,	  
INboxWT	  4.3%	  +/-­‐0.7,	  INboxdbl	  4.0%	  +/-­‐1.5).	  However,	  samples	  transfected	  
with	  SICLOPPST69AH72A	  INboxWT	  exhibited	  a	  significant	  increase	  in	  
prometaphase	  cells	  and	  relative	  to	  the	  empty	  vector	  control	  (p<0.001,	  n=3,	  
Chi	  square	  test;	  Figure	  4.5.2,	  panel	  B).	  The	  increase	  in	  the	  proportion	  of	  cells	  
in	  prometaphase	  suggests	  that	  the	  soluble	  INbox	  might	  cause	  a	  chromosome	  
alignment,	  but	  not	  mitotic	  checkpoint,	  defect.	  An	  appreciable	  drop	  in	  the	  
proportion	  of	  cells	  present	  in	  cytokinesis	  was	  observed	  in	  samples	  expressing	  
INboxWT	  but	  this	  was	  not	  statistically	  significant.	  	  
	   	  












Figure 4.5.1 - Localisation of Aurora B during mitosis in puromycin-selected 
transiently transfected cells after 48 hours as observed with a 100X objective. 
Cells were either transfected with an empty vector or with one expressing 
SICLOPPST69AH72A INboxWT. Cells were counterstained with anti tubulin and 
anti centromere antibody (ACA) to visulase the mitotic spindle and 
centromeres, respectively. Coloured boxes around the merged panels 
indicates how these representative cells would be classified according to the 














































































































































Figure 4.5.2 - (A) Quantifiation  of the 
localisation of Aurora B in 
puromycin-selected cells transiently 
expressing SICLOPPSAA INboxWT, 
INboxdbl or an empty vector control 
for 48 hours. The distribution of 
normal, partially and mislocalised 
cells was compared for each phase 
were compared to those found in the 
empty vector control sample using 
Fisher’s exact test. (B) Proportion of 
the mitotic cells from the same 
samples present in each stage of 
mitosis and cytokesis. The proportion 
of cells in each stage were compared 
to that of the empty vector control 
using the Chi square test. In both A 
and B: n=3; >100 cells per replicate;  
error bars: +/- SEM; *** = p<0.0001; 
unmarked samples are not 
significantly different from the 
control. 
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4.6	   DISCUSSION	  
The	  results	  presented	  in	  this	  chapter	  offer	  a	  preliminary	  insight	  into	  
the	  consequences	  of	  abrogating	  the	  Aurora	  B-­‐INCENP	  interaction.	  I	  will	  first	  
reflect	  on	  the	  significance	  and	  caveats	  of	  these	  results.	  Following	  this,	  I	  will	  
consider	  the	  performance	  of	  SICLOPPS-­‐based	  constructs	  in	  this	  context.	  
As	  cautioned	  earlier	  (section	  3.5),	  ANI	  increases	  cannot	  necessarily	  be	  
directly	  attributed	  to	  impaired	  CPC	  function.	  This	  is	  because	  other	  proteins	  
and	  complexes	  also	  play	  important	  roles	  in	  both	  chromosome	  segregation	  
and	  cytokinesis.	  It	  is,	  however,	  highly	  probable	  that	  the	  increase	  in	  ANI	  
elicited	  by	  INboxWT	  and	  INboxAAA	  constructs	  observed	  in	  HeLa	  cells	  is	  due	  to	  
CPC	  function	  impairment	  as	  these	  soluble	  constructs	  consist	  of	  the	  Aurora	  B	  
binding	  domain	  of	  INCENP.	  Both	  INboxWT	  and	  INboxAAA	  presumably	  bind	  to	  
the	  N-­‐terminal	  lobe	  of	  Aurora	  B,	  thereby	  occluding	  INCENP	  and	  the	  linked	  
targeting	  module.	  This	  is	  further	  supported	  by	  the	  mislocalisation	  of	  Aurora	  B	  
in	  mitotic	  cells	  expressing	  INboxWT.	  
Expression	  of	  INbox	  constructs	  lacking	  either	  the	  W845	  or	  F881	  
conserved	  residues,	  or	  both,	  fails	  to	  impair	  CPC	  function.	  This	  is	  reflected	  by	  
the	  unchanged	  ANI	  in	  samples	  expressing	  mutant	  constructs	  relative	  to	  
empty	  vector	  controls.	  This	  is	  interpreted	  as	  resulting	  from	  a	  lack	  of	  mutant	  
INbox	  binding	  to	  Aurora	  B.	  This	  would	  indicate	  that	  the	  W845	  and	  F881	  
residues	  are	  each	  essential	  not	  only	  for	  Aurora	  B	  activation,	  but	  for	  INCENP	  
binding	  to	  the	  kinase’s	  N-­‐terminal	  lobe.	  
Further	  to	  its	  effect	  on	  CPC	  function	  as	  observed	  with	  the	  phenotypic	  
CPC	  function	  assay,	  overexpression	  of	  INboxWT	  causes	  mislocalisation	  of	  
Aurora	  B	  and	  an	  accumulation	  of	  cells	  in	  prometaphase.	  The	  general	  
mislocalisation	  of	  Aurora	  B	  supports	  the	  hypothesis	  that	  the	  dominant	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negative	  effect	  of	  the	  soluble	  INbox	  is	  due	  to	  its	  interfering	  with	  the	  Aurora	  
B-­‐INCENP	  interaction.	  We	  observed	  that	  the	  extent	  of	  Aurora	  B	  
mislocalisation	  was	  greatest	  in	  cells	  fixed	  in	  the	  earlier	  stages	  of	  mitosis.	  The	  
appreciable	  drop	  in	  the	  severity	  of	  mislocalisation	  in	  the	  later	  phases	  could	  
be	  due	  to	  the	  use	  of	  transiently	  transfected	  constructs.	  That	  is,	  cells	  with	  
lower	  soluble	  INbox	  levels,	  which	  would	  occur	  due	  to	  expression	  
heterogeneity,	  may	  be	  less	  severely	  affected	  in	  both	  CPC	  localization	  and	  
mitotic	  progression.	  This	  may	  also	  explain	  our	  finding	  that	  the	  slight	  change	  
in	  the	  proportion	  of	  cells	  present	  in	  late	  cytokinesis	  was	  not	  significant	  
despite	  the	  fact	  that	  CPC	  function	  is	  required	  for	  this	  process.	  	  
The	  dominant	  negative	  effect	  of	  overexpressing	  the	  INbox	  domain	  was	  
less	  pronounced	  than	  that	  of	  overexpressing	  the	  kinases	  dead	  mutant	  of	  
Aurora	  B.	  This	  could	  be	  due	  to	  differences	  in	  expression	  levels,	  different	  
mechanisms	  of	  action,	  or	  a	  mixture	  of	  the	  two.	  In	  both	  instances,	  
endogenous	  Aurora	  B,	  which	  possesses	  basal	  activity,	  should	  be	  present	  in	  
the	  cells.	  However,	  kinase	  dead	  Aurora	  B	  might	  not	  only	  obstruct	  the	  binding	  
of	  endogenous	  Aurora	  B	  to	  INCENP,	  but	  also	  to	  its	  substrates.	  	  
Despite	  being	  flanked	  by	  the	  native	  extein	  residues,	  the	  processing	  of	  
the	  INbox	  SICLOPPS	  constructs	  was	  lower	  than	  that	  observed	  for	  the	  test	  
construct	  (contrast	  Figure	  3.3.2	  and	  panel	  B	  of	  Figure	  4.4.2).	  It	  is	  possible	  that	  
the	  accessory	  residues	  employed	  here	  do	  not	  promote	  intein	  processing	  as	  
efficiently	  as	  those	  present	  at	  the	  same	  positions	  in	  the	  SICLOPPS	  test	  
construct	  (see	  Appendix	  I).	  It	  is	  possible	  that	  the	  physical	  properties	  of	  the	  
extein	  (e.g.	  its	  length	  and	  flexibility/rigidity)	  may	  also	  affect	  intein	  processing.	  
The	  SICLOPPS	  test	  construct	  encoded	  a	  14	  residue	  CP	  in	  contrast	  to	  the	  75	  
residue	  long	  INbox	  CP.	  How	  best	  to	  promote	  the	  circularization	  of	  proteins	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and	  peptides	  with	  different	  sequences	  and	  properties	  remains	  to	  be	  
ascertained.	  	  
When	  comparing	  the	  respective	  ANI	  increases	  elicited	  SICLOPPS	  and	  
SICLOPPST69AH72A	  versions	  of	  the	  INboxWT	  and	  INboxAAA	  constructs,	  it	  appeared	  
that	  the	  dominant	  negative	  effect	  was	  elicited	  primarily	  by	  the	  linear	  
precursor,	  not	  the	  CP	  product.	  If	  this	  interpretation	  is	  correct,	  there	  are	  
several	  possibilities	  why	  binding	  of	  these	  INbox	  constructs	  may	  have	  been	  
impeded	  by	  intein	  processing.	  Firstly,	  and	  most	  likely,	  the	  constraint	  imposed	  
by	  circularization	  may	  have	  ‘locked’	  the	  INbox	  peptides	  in	  a	  conformation	  
that	  is	  not	  conducive	  to	  binding.	  This	  unfavourable	  conformation	  could	  have	  
been	  local	  or	  global,	  affecting	  a	  key	  stretch	  of	  residues	  or	  preventing	  the	  
whole	  peptide	  from	  crowning	  the	  Aurora	  B	  N-­‐terminal	  lobe.	  Another	  minor	  
possibility,	  which	  should	  nevertheless	  be	  considered,	  is	  that	  intein	  processing	  
somehow	  might	  promote	  the	  loss	  of	  the	  INCENP	  peptide	  rather	  than	  its	  
stabilisation.	  A	  study	  monitoring	  circularization	  of	  whole	  GFP	  by	  SICLOPPS	  
highlighted	  that,	  further	  to	  the	  circularized	  GFP,	  some	  linear	  GFP	  was	  also	  
produced	  (Zhao	  et	  al.,	  2010).	  Should	  the	  linear	  INCENP	  fragment	  in	  isolation	  
(i.e.	  without	  the	  flanking	  inteins)	  be	  produced	  to	  a	  significant	  extent	  and	  be	  
unstable	  in	  cells,	  SICLOPPS	  processing	  would	  diminish	  the	  overall	  amount	  of	  
INbox	  peptide	  in	  the	  cell.	  	  
Blocking	  the	  Aurora	  B-­‐INbox	  interaction	  resulted	  in	  cell	  division	  
defects	  that	  are	  similar,	  if	  milder,	  than	  those	  of	  overexpressing	  kinase-­‐dead	  
Aurora	  B.	  As	  demonstrated	  using	  the	  chicken	  DT40	  INCENP	  knockout,	  even	  a	  
mild	  drop	  in	  CPC	  function	  is	  incompatible	  with	  cell	  proliferation	  and	  survival	  
(Xu	  et	  al.,	  2010).	  This	  suggests	  that	  disrupting	  the	  Aurora	  B-­‐INbox	  interaction	  
will	  eventually	  lead	  to	  cell	  death.	  Whether	  this	  is	  indeed	  the	  case	  should	  be	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verified	  by	  assaying	  the	  effects	  of	  soluble	  INbox	  overexpression	  over	  longer	  
time	  periods.	  	  
Furthermore,	  the	  localization	  of	  other	  CPC	  components	  and	  the	  
activation	  status	  of	  Aurora	  B	  in	  the	  presence	  of	  the	  INboxWT	  and	  INboxAAA	  
constructs	  would	  be	  highly	  informative	  and	  remain	  to	  be	  verified.	  These	  and	  
other	  experiments	  will	  be	  discussed	  further	  in	  the	  Perspectives	  section.	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CHAPTER	  5:	  SCREENING	  A	  RATIONALLY-­‐DESIGNED	  
CYCLIC	  PEPTIDE	  INBOX	  MIMIC	  LIBRARY	  
5.1	   INTRODUCTION	  
The	  results	  presented	  in	  the	  previous	  chapter	  provide	  additional	  
evidence	  towards	  the	  validation	  of	  the	  Aurora	  B-­‐INbox	  interface	  as	  an	  anti-­‐
mitotic	  target.	  However,	  it	  is	  a	  large	  interface	  and	  our	  efforts	  to	  dissociate	  it	  
employed	  a	  construct	  with	  a	  75	  amino	  acid	  long	  stretch	  of	  homology.	  It	  was	  
unclear	  whether	  the	  Aurora	  B-­‐INbox	  interface	  is	  a	  target	  that	  can	  be	  
modulated	  by	  smaller	  compounds,	  which	  would	  indicate	  that	  it	  might	  be	  
druggable.	  I	  thus	  proceeded	  to	  express	  smaller	  pieces	  of	  the	  INbox	  in	  vivo	  to	  
attempt	  to	  identify	  fragments	  capable	  of	  recapitulating	  the	  effects	  of	  the	  
whole	  INboxWT	  and	  INboxAAA	  constructs.	  
In	  order	  to	  better	  understand	  INbox	  library	  design	  features	  and	  the	  
first-­‐pass	  screen	  presented	  within	  this	  chapter,	  the	  chronological	  order	  of	  
events	  must	  first	  be	  clarified:	  both	  these	  sections	  of	  the	  project	  were	  
completed	  early	  on	  during	  piloting.	  This	  was	  immediately	  following	  the	  
verification	  of	  SICLOPPS	  test	  construct	  processing	  in	  HeLa	  cells	  (section	  3.3).	  
Thus,	  results	  showing	  that	  the	  soluble	  INbox	  was	  more	  potent	  in	  processing	  
deficient	  than	  competent	  forms	  were	  not	  available	  at	  the	  time.	  At	  the	  stage	  
of	  library	  design,	  the	  inhibition	  of	  Aurora	  B	  activity	  by	  soluble	  INbox	  was	  
predicted,	  if	  unconfirmed.	  	  
Therefore,	  the	  ultimate	  version	  of	  the	  cell-­‐based	  CPC	  functional	  assay	  
presented	  in	  chapter	  3	  and	  employed	  in	  chapter	  4	  was	  informed	  by	  this	  early	  
work	  rather	  than	  vice	  versa.	  As	  the	  second-­‐pass	  screen	  also	  presented	  later	  in	  
this	  chapter	  employed	  the	  same	  improved	  protocol	  used	  in	  generating	  the	  
results	  presented	  in	  earlier	  chapters,	  these	  series	  of	  experiments	  remain	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comparable	  and	  the	  controls,	  first	  shown	  in	  sections	  3.3	  and	  3.4,	  relevant.	  
The	  rationales	  laid	  out	  in	  sections	  5.2	  to	  5.4	  reflect	  my	  thinking	  at	  the	  time	  
these	  experiments	  were	  devised	  and	  carried	  out.	  The	  discussion	  section	  of	  
this	  chapter	  contains	  a	  reassessment	  of	  the	  library	  design	  and	  first	  pass	  
screening	  protocol	  in	  light	  of	  subsequently	  obtained	  results.	  	  
5.2	   LIBRARY	  DESIGN	  
In	  contrast	  to	  the	  globular	  N-­‐terminal	  lobe	  of	  Aurora	  B,	  both	  the	  
Xenopus	  and	  human	  INCENP	  INbox	  adopts	  an	  extended	  conformation	  
containing	  interspersed α-­‐helical	  stretches	  (Elkins,	  2012;	  Sessa	  et	  al.,	  2005;	  
also	  recall	  Figure	  1.3.3).	  The	  intention	  was	  to	  design	  a	  library	  of	  fragments	  
matching	  the	  Aurora	  B	  –	  INbox	  interface	  based	  on	  primary	  amino	  acid	  
sequence.	  In	  contrast	  to	  the	  INbox,	  some	  adjacent	  residues	  within	  the	  Aurora	  
B	  side	  of	  the	  interface	  are	  non-­‐contiguous,	  which	  would	  have	  necessitated	  a	  
more	  complex	  mimicry	  design	  strategy.	  Thus	  I	  focused	  on	  INCENP	  rather	  than	  
Aurora	  B	  sequences.	  
Rather	  that	  base	  library	  design	  on	  the	  full	  length	  INbox,	  I	  focused	  on	  a	  
smaller	  fragment	  of	  the	  INbox	  spanning	  residues	  834	  to	  894	  (Figure	  5.2.1.A).	  
The	  rationale	  for	  this	  is	  that	  this	  region	  corresponds	  to	  the	  one	  used	  by	  Sessa	  
and	  colleagues	  in	  their	  structural	  study	  of	  the	  Xenopus	  Aurora	  B-­‐INbox	  
complex	  (Sessa	  et	  al.,	  2005).	  Thus,	  it	  is	  known	  to	  be	  associated	  with	  the	  
Aurora	  B	  N-­‐terminal	  lobe.	  In	  particular,	  residues	  842	  to	  885	  are	  visible	  in	  the	  
resulting	  crystal	  structure	  (Figure	  5.2.1.B).	  
Previous	  screens	  of	  SICLOPPS	  combinatorial	  libraries	  utilized	  cylic	  
peptides	  (CPs)	  ranging	  in	  size	  from	  penta-­‐	  to	  octapeptides	  (Cheng	  et	  al.,	  
2007;	  Kinsella	  et	  al.,	  2002).	  A	  CP	  length	  of	  8	  –	  an	  invariable	  cysteine	  plus	  7	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5.2.1.C).	  Optimal	  cyclic	  peptide	  backbone	  length	  will	  vary	  depending	  on	  the	  
epitope	  and	  cannot	  be	  predicted	  given	  currently	  available	  means.	  Therefore,	  
additional	  sub-­‐libraries	  centered	  on	  residues	  W845	  and	  F881	  –	  two	  
conserved	  residues	  critical	  for	  Aurora	  B	  binding	  and	  activation	  –	  were	  
generated	  with	  varying	  CP	  backbone	  lengths	  (Figure	  5.2.1.C).	  Totaling	  97	  
members,	  codon-­‐optimized	  reverse	  primers	  encoding	  the	  library	  were	  
manually	  designed	  using	  the	  sequence	  of	  the	  human	  INbox.	  All	  libraries	  
consist	  of	  overlapping	  peptides	  with	  a	  single	  residue	  shift	  between	  adjacent	  
library	  members.	  The	  full	  CP	  library	  and	  corresponding	  primer	  sequences	  can	  
be	  found	  in	  Appendix	  II.	  	  
In	  designing	  primers,	  a	  sequence	  of	  two	  lysine	  residues	  was	  
accidentally	  changed	  to	  a	  single	  one	  in	  the	  F881	  5	  variable	  residue	  sub-­‐
library.	  This	  mistake	  affects	  4	  library	  members	  (A11-­‐B2	  according	  to	  naming	  
system	  used	  in	  Appendix	  II)	  
5.3	   VECTOR	  OPTIMIZATION	  AND	  LIBRARY	  CONSTRUCTION	  
From	  my	  earlier	  attempts	  at	  expressing	  SICLOPPS	  constructs	  with	  and	  
without	  selection	  (section	  3.3),	  it	  was	  evident	  that	  any	  screen	  would	  require	  
the	  selection	  of	  transfected	  cells	  in	  order	  to	  minimize	  background	  noise	  from	  
untransfected	  cells.	  I	  therefore	  optimized	  the	  pIRES	  puro2	  vector	  to	  make	  it	  
compatible	  with	  library	  construction.	  	  
Two	  restriction	  sites	  lie	  sufficiently	  close	  to	  the	  variable	  CP-­‐encoding	  
region	  to	  be	  utilised	  in	  library	  construction:	  NheI	  and	  AflII.	  However,	  both	  
sites	  are	  also	  present	  in	  the	  pIRES	  puro2	  multiple	  cloning	  site	  (MCS).	  As	  NheI	  
digest	  results	  in	  a	  high	  level	  of	  vector	  re-­‐ligation	  (R.	  Almeida,	  personal	  
communications),	  AflII	  was	  favoured	  and	  its	  recognition	  site	  within	  the	  MCS	  
was	  removed	  by	  site-­‐directed	  mutagenesis.	  The	  modified	  MCS	  was	  then	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substituted	  into	  vectors	  containing	  both	  the	  SICLOPPSWT	  and	  SICLOPPST69AH72A	  
versions	  of	  the	  test	  constructs	  employed	  in	  section	  3.3.	  
Concurrently	  with	  this,	  in	  the	  hopes	  of	  saving	  time,	  I	  sought	  to	  have	  
the	  library	  built	  commercially	  and	  obtained	  quotations	  from	  DNA2.0	  and	  
GeneArt.	  Disappointingly,	  the	  quotes	  were	  in	  the	  order	  of	  US$20,000	  –	  a	  cost	  
deemed	  prohibitive.	  I	  therefore	  adapted	  the	  method	  outlined	  by	  Abel-­‐Santos	  
and	  colleagues	  (Abel-­‐Santos	  et	  al.,	  2003)	  to	  build	  the	  library	  manually,	  
simplifying	  it	  for	  use	  with	  discrete	  oligos	  rather	  than	  pooled	  oligos.	  The	  
abridged	  protocol	  omits	  the	  zipper	  PCR	  step	  as,	  in	  this	  instance,	  maximizing	  
cloning	  efficiency	  is	  a	  lesser	  concern	  than	  in	  the	  generation	  of	  combinatorial	  
libraries.	  
The	  template	  used	  for	  PCR	  amplification	  of	  library	  sequences	  was	  an	  
NcoI-­‐digested	  plasmid	  bearing	  the	  SICLOPPS	  test	  construct.	  The	  NcoI	  site	  lies	  
upstream	  from	  the	  initiation	  codon,	  but	  downstream	  of	  the	  BamHI	  site	  used	  
during	  library	  construction;	  the	  forward	  primer	  used	  to	  amplify	  library	  inserts	  
has	  an	  extension	  containing	  the	  BamHI	  site.	  This	  ensures	  that	  only	  the	  
digested	  PCR	  products	  will	  contain	  a	  BamHI	  sticky	  end,	  minimizing	  template	  
carry-­‐over	  and	  obviating	  the	  need	  to	  gel	  extract	  the	  PCR	  product.	  In	  lieu	  of	  
gel	  extraction,	  a	  kit-­‐based	  PCR	  cleanup	  was	  used.	  A	  detailed	  library	  
generation	  protocol	  can	  be	  found	  in	  the	  methods	  section.	  
	   94	  of	  the	  97	  library	  members	  designed	  were	  generated.	  Those	  still	  
missing	  are:	  C4,	  C11	  and	  E2	  (refer	  to	  Appendix	  II	  for	  further	  details).	  Library	  
member	  C4	  lies	  in	  the	  W845	  region	  of	  the	  7	  variable	  residue	  core	  library	  
whereas	  C11	  and	  E2	  lie	  in	  the	  F881	  region	  of	  the	  7	  and	  8	  variable	  residue	  
libraries,	  respectively.	  The	  sequence	  coverage	  of	  the	  completed	  library	  is	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5.4	   LIBRARY	  SCREEN	  –	  FIRST	  PASS:	  ABNORMAL	  NUCLEI	  INDEX	  	  
The	  first	  pass	  screen	  protocol	  was	  a	  precursor	  to	  the	  CPC	  function	  
assay.	  The	  rationale	  for	  readout	  selection	  and	  screen	  design	  and	  has	  already	  
been	  laid	  out	  in	  section	  3.3.	  	  
The	  first	  pass	  screen	  was	  carried	  out	  during	  piloting	  and	  97	  INbox	  
library	  members	  were	  to	  be	  assayed	  initially.	  For	  these	  reasons	  it	  was	  
desirable	  to	  streamline	  the	  assay	  protocol	  so	  that	  it	  could	  be	  completed	  
rapidly.	  Each	  library	  member	  was	  assayed	  in	  duplicate	  and	  the	  ANI	  was	  
scored	  from	  5	  random	  fields	  of	  view	  as	  visualized	  with	  a	  40X	  objective.	  Thus,	  
the	  amount	  of	  replicates	  and	  cells	  scored	  was	  lower	  than	  in	  the	  final	  version	  
of	  the	  CPC	  function	  assay.	  The	  triplicate	  scoring	  of	  >1000	  cells	  was	  resumed	  
in	  the	  final	  version	  of	  the	  CPC	  function	  assay	  during	  which	  fewer	  library	  
members	  needed	  to	  be	  assayed.	  Another	  notable	  difference	  between	  the	  
two	  protocols	  is	  the	  use	  of	  poly-­‐L-­‐lysine	  coated,	  rather	  than	  uncoated,	  
coverslips	  in	  the	  initial	  protocol.	  Initially,	  cells	  were	  simply	  DAPI	  stained.	  
Phalloidin	  staining	  was	  rapidly	  employed	  to	  highlight	  cellular	  periphery	  and	  
improve	  scoring	  reliability.	  
To	  determine	  the	  rate	  of	  increase	  in	  the	  frequency	  of	  abnormal	  nuclei,	  
abnormal	  nuclei	  indexes	  (ANI)	  measured	  for	  each	  coverslip	  were	  normalised	  
to	  the	  average	  ANI	  measured	  from	  a	  pair	  control	  coverslips	  transfected	  with	  
empty	  pIRES	  puro2	  vector	  in	  parallel	  to	  the	  experimental	  samples.	  Thus,	  we	  
compared	  ANI	  fold	  change	  rather	  than	  raw	  ANI.	  This	  was	  done	  in	  order	  to	  
attenuate	  the	  effects	  of	  any	  variability	  in	  ANI	  due	  to	  passage	  number	  or	  cell	  
confluency	  prior	  to	  seeding.	  The	  empty	  vector	  control	  was	  also	  used	  to	  
determine	  the	  spread	  in	  abnormal	  nuclei	  frequency	  and	  establish	  hit	  
thresholds.	  The	  ANI	  in	  the	  empty	  vector	  control	  population	  over	  the	  course	  
of	  screening	  was	  normally	  distributed	  (Shapiro-­‐Wilk	  test,	  p=0.89)	  and	  a	  hit	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threshold	  was	  set	  at	  an	  increase	  in	  abnormal	  nuclei	  frequency	  >2	  standard	  
deviations	  from	  the	  mean	  background	  ANI	  –	  this	  was	  calculated	  to	  be	  1.35X	  
but	  arbitrarily	  rounded	  up	  to	  1.4X	  to	  increase	  screen	  stringency.	  The	  ANI	  
increase	  typical	  of	  Aurora	  B	  overexpression	  controls	  can	  be	  found	  in	  panel	  A	  
of	  Figure	  5.5.1	  in	  the	  next	  section.	  
Of	  the	  94	  library	  members	  assessed	  in	  duplicate,	  11	  library	  constructs	  
–	  hereby	  referred	  to	  as	  strong	  initial	  hits	  –	  elicited	  an	  ANI	  increase	  greater	  
than	  the	  cutoff	  in	  both	  replicates.	  A	  further	  9	  library	  members	  were	  deemed	  
moderate	  initial	  hits	  as	  their	  average	  ANI	  increase	  –	  as	  opposed	  to	  both	  
individual	  replicate	  –	  was	  greater	  than	  2	  standard	  deviations	  from	  the	  
control.	  In	  contrast	  to	  this,	  no	  library	  members	  showed	  an	  average	  decrease	  
in	  abnormal	  nuclei	  frequency	  greater	  than	  2	  standard	  deviations	  from	  the	  
same	  control.	  The	  sequence	  of	  hit	  constructs	  is	  presented	  in	  table	  5.4.	  Figure	  
5.4.1	  shows	  the	  proportion	  of	  hit	  constructs	  relative	  to	  the	  number	  of	  library	  
members	  screened.	  Peptide	  sequences	  corresponding	  to	  80%	  of	  the	  strong	  
hits	  and	  55%	  of	  the	  moderate	  hits	  identified	  during	  this	  initial	  screen	  were	  
homologous	  to	  regions	  containing	  either	  INCENP	  W845	  or	  F881.	  Further	  to	  
this,	  another	  third	  of	  the	  moderate	  hits	  lay	  in	  regions	  immediately	  proximal	  
or	  distal	  to	  these	  two	  critical	  residues	  (Regions	  highlighted	  in	  green	  and	  red	  
in	  Table	  5.4	  and	  subsequent	  figures).	  Of	  the	  remaining	  3	  hits,	  2	  possessed	  
sequences	  that	  did	  not	  overlap	  with	  that	  of	  any	  other	  hit.	  	  
Hits	  were	  concentrated	  in	  two	  regions:	  one	  centered	  on	  INCENP	  W845	  
and	  another	  encompassing	  F881	  and	  residues	  distal	  to	  it	  (Figure	  5.4.2,	  
uppermost	  heat	  map).	  These	  two	  regions	  also	  overlap	  with	  the	  regions	  of	  
highest	  library	  coverage	  (recall	  figure	  5.3.1).	  However,	  the	  clustering	  of	  hits	  







844-851 C T WA R G T P L 1.9 9
839-845 C R K P I P T W 1.9 8
845.852 C WA R G T P L S 1.8 9
845-850 C WA R G T P 1.7 7
844-847 C T WA R 1.7 5
840-845 C K P I P T W 1.6 7
836-842 C A H P R K P I 1.6 8
838-844 C P R K P I P T 1.5 8
842-845 C I P T W 1.5 5
841-847 C P I P T WA R 1.5 8
845-849 C WA R G T 1.4 6
862-868 C P P N L L E L 1.6 8
869-875 C F G T I L P L 1.4 8
878-885 C E D I F K K S K 2.5 9
877-884 C L E D I F K K S 2 9
881-885 C F K S K P 1.7 6
881-886 C F K K S K P 1.5 7
880-886 C I F K K S K P 1.5 8
888-894 C Y H K R T S S 1.5 8
883-889 C K S K P R Y H 1.4 8
Table 5.4 - Sequence of the 20 hits derived from the intial screen of the 
INbox library. Hits are clusters according to the region of the INbox they 
map to (green: W845; blue: centre; red: F881) then ordered in descending 
order activity as indicated by abnormal nuclei index (ANI) increase, that is 
by the increase in ANI relative to an empty vector control transfected and 
scored in parallel. Bright and muted colours indicates strong and moderate 
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number	  of	  hit	  peptides	  to	  the	  number	  of	  library	  members	  (Figure	  5.4.2,	  lower	  
heat	  map).	  	  
5.5	   LIBRARY	  SCREEN	  –	  SECOND	  PASS:	  CYCLIC	  VS.	  LINEAR	  
PRECURSOR	  
	   The	  initial	  INbox	  library	  screen	  yielded	  20	  hits	  from	  97	  constructs.	  To	  
validate	  these	  hits,	  it	  was	  first	  necessary	  to	  verify	  if	  their	  effect	  was	  
reproducible.	  Secondly,	  I	  wished	  to	  verify	  if	  constructs’	  activity	  was	  due	  to	  
the	  cyclic	  peptide	  being	  produced	  rather	  than	  the	  split	  intein-­‐flanked	  
precursor.	  The	  reason	  for	  this	  was	  that	  we	  wished	  to	  ascertain	  whether	  the	  
Aurora	  B-­‐INbox	  interaction	  was	  amenable	  to	  being	  dissociated	  by	  small	  
compounds.	  To	  ascertain	  this,	  SICLOPPST69AH72A	  versions	  of	  each	  hit	  construct	  
were	  generated	  and	  assayed	  in	  parallel	  with	  their	  processing-­‐competent	  
counterparts.	  These	  mutants	  cannot	  be	  cyclized.	  
As	  previously	  indicated,	  methodological	  optimisation	  carried	  out	  
following	  the	  first	  round	  of	  screening	  led	  to	  an	  increase	  in	  the	  number	  of	  
replicates	  and	  cells	  scored.	  Because	  the	  use	  of	  poly-­‐L-­‐lysine	  coated	  coverslips	  
impeded	  the	  detachment	  of	  dead	  cells	  following	  puromycin	  selection,	  
uncoated	  coverslips	  were	  thenceforth	  utilised.	  The	  seeding	  protocol	  was	  
revised	  to	  achieve	  an	  appropriate	  cell	  density	  for	  transient	  transfection	  and	  
scoring.	  	  
The	  results	  of	  the	  rescreening	  are	  presented	  in	  figure	  5.5.1	  and	  
summarized	  in	  table	  5.5.1.	  Upon	  rescreening	  with	  the	  more	  stringent	  scoring	  
protocol,	  70%	  of	  the	  initial	  hits	  (14	  of	  20	  hits)	  were	  reproducible	  but	  only	  29%	  
of	  these	  (4	  of	  14	  reproducible	  hits)	  required	  SICLOPPS	  processing	  for	  their	  




















































































































































































































































































































































































































































































844-851 C T WA R G T P L no N/A
839-845 C R K P I P T W no N/A
845-852 C WA R G T P L S yes yes
845-850 C WA R G T P no N/A
844-847 C T WA R yes yes
840-845 C K P I P T W yes yes
836-842 C A H P R K P I yes no
838-844 C P R K P I P T yes no
842-845 C I P T W yes no
841-847 C P I P T WA R no N/A
845-849 C WA R G T yes no
862-868 C P P N L L E L yes no
869-875 C F G T I L P L yes no
878-885 C E D I F K K S K yes no
877-884 C L E D I F K K S yes no
881-885 C F K S K P yes no
881-886 C F K K S K P yes yes
880-886 C I F K K S K P yes no
888-894 C Y H K R T S S no N/A


















Table 5.5.1 - Reproducibility and processing dependency of initial hit 
peptides during the second pass screen. Hits are presented in the same 
order and with the same colour coding employed in table 5.4.  
Reproducibility indicates that the SICLOPPSWT version of the construct 
elicited a satistically significant (p<0.05) increase in ANI relative to the 
empty vector control. Processing dependency indicates that only the 
CP producing construct elicited a significant increase, i.e. that the 
SICLOPPST69AH72A version of the construct did not have a significant 
effect on ANI increase. Constructs whose effects were not reproducible 
in the first instance could not be considered to be processing 
dependent, thus are marked ‘not applicable’ (N/A).
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As	  already	  mentioned	  in	  the	  context	  of	  the	  full	  length	  INbox	  
expression	  constructs	  in	  the	  previous	  chapter,	  split-­‐intein	  mediated	  protein	  
splicing	  efficiency	  can	  be	  affected	  by	  extein	  sequence.	  It	  was	  therefore	  
expected	  that	  some	  of	  the	  library	  constructs	  would	  not	  produce	  CPs,	  or	  do	  so	  
poorly.	  I	  wished	  to	  assess	  the	  degree	  of	  SICLOPPS	  processing	  throughout	  the	  
library	  and	  verify	  whether	  there	  was	  a	  relationship	  between	  processing	  
efficiency	  and	  activity.	  A	  random	  sample	  of	  hit	  and	  non-­‐hit	  peptides	  were	  
assayed	  in	  parallel	  for	  splicing	  efficiency	  and	  ANI	  increase	  (Figure	  5.5.2.A	  and	  
B).	  No	  correlation	  could	  be	  detected	  between	  SICLOPPS	  processing	  rates	  and	  
peptide	  activity	  (Pearson’s	  r=-­‐0.11;	  p=0.54;	  n=35).	  This	  lack	  of	  correlation	  
indicates	  that	  processing	  alone	  does	  not	  determine	  a	  construct’s	  activity,	  
suggesting	  that	  activity	  is	  sequence	  dependent.	  
Further	  to	  the	  lack	  of	  correlation,	  analysis	  of	  the	  processing	  efficiency	  
throughout	  the	  library	  highlighted	  its	  heterogeneity	  (processing	  range=	  1	  to	  
99%,	  mean=36.1,	  SD=28.36).	  Unfortunately,	  this	  processing	  heterogeneity	  
confounds	  direct	  comparison	  of	  the	  effects	  of	  SICLOPPS-­‐generated	  CPs	  as	  
comparable	  levels	  of	  these	  cannot	  be	  reliably	  expressed.	  Further	  to	  
possessing	  activity	  relative	  to	  non-­‐hits,	  the	  activity	  of	  any	  genuine	  CP	  hits	  
should	  be	  concentration	  dependent.	  Genetically	  encoded	  constructs	  are	  ill-­‐
suited	  to	  assaying	  a	  wide	  concentration	  gradient.	  Thus,	  the	  SICLOPPS	  
technology	  becomes	  limiting.	  	  
As	  both	  direct	  comparisons	  of	  hit	  CP	  activities	  and	  further	  
characterization	  of	  these	  are	  logical	  continuations	  of	  this	  project,	  I	  sought	  to	  
obtain	  chemically	  synthesized	  versions	  of	  these	  peptides.	  To	  prioritize	  the	  
peptides	  to	  be	  synthesized,	  hits	  were	  ranked	  (Table	  5.5.2).	  The	  ranking	  is	  
semi-­‐arbitrary:	  constructs	  with	  the	  highest	  ANI	  increase	  (as	  a	  measure	  of	  
both	  mean	  ANI	  increase	  and	  SEM)	  were	  favoured	  and	  then	  ranked	  further	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Figure 5.5.2 - A sample of randomly selected hit and non hit library 
constructs were assayed in parallel for SICLOPPS processing by western blot 
and ANI increase using the CPC function assay. (A) Representative 
quantitative western blot analyses of hit peptides in their 
processing-competent (WT) and deficient (AA) forms (left) and non hit 
peptides (right). Recall that processing deficient mutants were only 
prepared for constructs identified as initial hits in the first pass of the 
screen. The extent of processing (i.e. the intensity of ‘L’ band divided by the 
sum of the intensity of the ‘L’ and ‘P’ band) is indicatedas a percentage 
below each processing-competent lane. The precursor (P) and linear 
product (L) bands are as defined in figure 3.3.1. (B) No correlation between 
between SICLOPPS processing rates and abnormal nuclei index (ANI) could 
be detected (Pearson’s r=-0.11; p=0.54; n=35). Mean background ANI as 
measured in control samples transfected with empty vector is indicated by a 
dashed line; the shaded region delineates +/- 2 standard deviations from 
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according	  to	  the	  effect	  of	  the	  SICLOPPST69AH72A	  mutants	  thereof.	  A	  number	  of	  
constructs	  whose	  SICLOPPST69AH72A	  mutants	  elicited	  a	  small	  yet	  statistically	  
significant	  increase	  in	  ANI	  relative	  to	  the	  empty	  vector	  control	  were	  also	  
included	  in	  the	  prioritized	  list.	  From	  this	  list,	  a	  subset	  of	  peptides	  –	  and	  
scambles	  thereof	  –	  representing	  the	  3	  hit	  regions	  identified	  during	  the	  initial	  
library	  screen	  were	  synthesized	  by	  our	  collaborators	  Daniel	  St	  Cyr,	  Samir	  
Bouayad-­‐Gervais	  and	  Mike	  Tyers	  at	  the	  Université	  de	  Montréal.	  The	  planned	  
use	  of	  these	  peptides	  will	  be	  discussed	  in	  the	  Perspectives	  section	  (Chapter	  
7).	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5.6	   DISCUSSION	  
The	  INbox	  library	  screen	  had	  two	  goals:	  firstly,	  to	  enquire	  whether	  or	  
not	  the	  Aurora	  B-­‐INbox	  interaction	  can	  be	  easily	  modulated	  and,	  secondly,	  it	  
was	  intended	  to	  serve	  as	  a	  proof-­‐of-­‐concept	  for	  the	  use	  of	  SICLOPPS-­‐derived	  
libraries	  in	  human	  cells.	  With	  regards	  to	  the	  first	  goal,	  it	  is	  not	  possible	  to	  
reach	  conclusions	  about	  the	  amenability	  of	  the	  Aurora	  B-­‐INbox	  interaction	  to	  
inhibition	  with	  small	  drug-­‐like	  compounds	  at	  this	  juncture.	  Although	  a	  
number	  of	  statistically	  significant	  and	  reproducible	  hits	  were	  obtained	  
following	  two	  rounds	  of	  screening,	  their	  effects	  were	  disappointingly	  modest.	  
The	  top	  ranked	  library	  screen	  hit	  elicited	  an	  ANI	  increase	  of	  1.7X	  fold	  relative	  
to	  the	  empty	  vector	  control	  in	  the	  second	  pass	  validation	  screen.	  In	  contrast	  
to	  this,	  the	  SICLOPPST69AH72A	  version	  of	  the	  whole	  INbox	  construct	  (i.e.	  that	  
with	  the	  greatest	  activity)	  elicited	  a	  7.9X	  increase.	  Although	  it	  is	  expected	  
that	  the	  unprocessed	  whole	  INbox	  construct	  will	  be	  present	  in	  higher	  
concentrations	  in	  cells	  than	  library-­‐derived	  CPs,	  the	  low	  relative	  activity	  of	  
library	  constructs	  remains	  disappointing.	  Furthermore,	  limitations	  of	  the	  
SICLOPPS	  approach	  have	  impeded	  the	  comparison	  of	  hit	  peptide	  activities	  
and	  the	  assaying	  of	  increasing	  CP	  concentrations.	  Given	  the	  preliminary	  
nature	  of	  these	  results,	  firm	  conclusions	  regarding	  whether	  the	  Aurora	  B-­‐
INbox	  interaction	  can	  be	  modulated	  with	  small	  drug-­‐like	  compounds	  cannot	  
be	  drawn	  from	  the	  evidence	  here.	  	  
In	  discussing	  the	  experiments	  contained	  within	  this	  chapter	  from	  the	  
perspective	  of	  a	  proof-­‐of-­‐concept	  study,	  I	  will	  begin	  with	  reflections	  on	  target	  
selection,	  library	  design	  and	  screen	  strategy.	  The	  latter	  section	  will	  focus	  a	  
reassessment	  of	  the	  initial	  screen	  protocol	  in	  light	  of	  subsequent	  
improvements.	  This	  will	  be	  followed	  by	  a	  discussion	  of	  the	  results	  of	  both	  
phases	  of	  the	  screen.	  Conclusions	  on	  the	  use	  of	  SICLOPPS	  technology,	  of	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combinatorial	  versus	  targeted	  library	  design	  approaches,	  and	  of	  screening	  in	  
human	  cells	  will	  be	  made	  in	  the	  next	  chapter.	  
TARGET	  SELECTION	  
The	  decision	  to	  target	  the	  Aurora	  B-­‐INbox	  interaction	  was	  made	  early	  
on	  with	  a	  view	  to	  evaluate	  the	  potential	  of	  screening	  genetically-­‐encoded	  
cyclic	  peptide	  libraries	  in	  human	  cells.	  Having	  been	  the	  subject	  of	  intensive	  
research,	  structural	  interactions	  between	  CPC	  were	  already	  well	  
characterized.	  Furthermore,	  widespread	  cytokinesis	  failure	  is	  a	  hallmark	  of	  
CPC	  loss	  of	  function	  that	  is	  readily	  detectable	  by	  microscopy	  or	  flow	  
cytometry;	  this	  readout	  was	  thus	  amenable	  to	  cell-­‐based	  screens.	  This	  made	  
the	  targeting	  of	  interactions	  within	  CPC	  attractive	  candidates.	  	  
Although	  a	  number	  of	  survivin	  binders	  have	  been	  developed,	  targeting	  
the	  Aurora	  B-­‐INbox	  interaction	  would	  constitute	  a	  novel	  means	  of	  quelling	  
CPC	  activity.	  Although	  it	  had	  been	  suggested	  that	  this	  interaction	  could	  be	  a	  
therapeutically	  important	  target	  (Keen	  and	  Taylor,	  2009),	  no	  agents	  targeting	  
it	  have	  been	  reported	  in	  the	  literature.	  The	  subsequent	  experiments	  in	  which	  
I	  expressed	  the	  whole	  INbox	  domain	  in	  HeLa	  cells	  (presented	  in	  Chapter	  4)	  
have	  supported	  the	  targeting	  of	  this	  interaction	  as	  a	  means	  of	  abrogating	  CPC	  
activity.	  
Lastly,	  the	  size	  range	  of	  CPs	  capable	  of	  being	  translocated	  across	  the	  
nuclear	  membrane	  and/or	  the	  nuclear	  pore	  complex	  is	  currently	  uncertain.	  
As	  nuclear	  envelope	  breakdown	  occurs	  early	  in	  mitosis,	  the	  selection	  of	  a	  
mitotic	  target	  circumvented	  this	  potential	  barrier	  and	  was	  therefore	  
attractive	  for	  a	  proof-­‐of-­‐concept	  study.	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LIBRARY	  DESIGN	  &	  CONSTRUCTION	  
DESIGN	  
As	  we	  opted	  to	  base	  the	  library	  design	  on	  primary	  amino	  acid	  
sequence	  homology	  (discussed	  further	  below),	  continuous	  epitopes	  were	  
desirable.	  Thanks	  to	  its	  extended	  conformation,	  the	  INbox	  presented	  a	  far	  
more	  attractive	  candidate	  surface	  than	  the	  complimentary	  surface	  on	  Aurora	  
B.	  In	  the	  latter	  instance,	  many	  topologically	  adjacent	  residues	  are	  not	  
contiguous.	  	  
The	  region	  of	  the	  INbox	  selected	  when	  designing	  the	  library	  was	  based	  
on	  the	  fragment	  used	  by	  Sessa	  and	  colleagues	  in	  their	  2005	  crystallography	  
study.	  This	  study	  reported	  the	  structure	  of	  Xenopus	  laevis	  Aurora	  B	  and	  INbox	  
in	  complex	  with	  the	  ATP	  analogue	  inhibitor	  hesperidin	  and	  was	  the	  only	  such	  
study	  published	  at	  that	  time.	  Subsequently	  to	  the	  design	  and	  generation	  of	  
the	  library,	  a	  crystal	  structure	  of	  the	  human	  Aurora	  B-­‐INbox	  with	  VX-­‐680	  was	  
published	  (Elkins	  et	  al.,	  2012).	  Thankfully,	  there	  is	  good	  concordance	  
between	  the	  two	  studies	  regarding	  the	  span	  of	  the	  INbox	  stably	  associated	  
with	  the	  Aurora	  B	  N-­‐terminal	  lobe.	  	  
Two	  independent	  prior	  studies	  had	  demonstrated	  the	  importance	  of	  
residues	  homologous	  to	  W845	  and	  F881	  for	  Aurora	  B	  activation	  (Sessa	  et	  al.,	  
2005;	  Xu	  et	  al.,	  2009).	  That	  INCENP	  mutants	  lacking	  these	  residues	  cannot	  
rescue	  Aurora	  B	  activation	  highlighted	  these	  regions	  as	  sites	  of	  interest.	  Sub-­‐
libraries	  were	  thus	  created	  centered	  on	  residues	  W845	  and	  F881,	  with	  an	  
enhanced	  focus	  on	  W845	  as	  the	  function	  of	  INCENPW845G	  was	  known	  to	  be	  
more	  severely	  compromised	  than	  INCENPF881A.	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The	  decision	  to	  focus	  on	  these	  residues	  and	  not,	  for	  example,	  the	  TSS	  
motif	  was	  supported	  by	  the	  whole	  INbox	  mutagenesis	  study	  I	  subsequently	  
carried	  out	  (presented	  in	  chapter	  4).	  However,	  the	  decision	  to	  create	  an	  
additional	  pentapeptide	  library	  centered	  on	  W845	  but	  not	  F881A	  was	  not	  
supported	  by	  the	  results	  of	  these	  experiments	  as	  both	  mutants	  lost	  their	  
dominant	  negative	  effect	  to	  the	  same	  extent.	  	  
Given	  the	  modest	  activities	  detected	  in	  assays	  so	  far,	  it	  appears	  that	  
directly	  templating	  the	  library	  design	  directly	  on	  primary	  amino	  acid	  
sequence	  may	  have	  been	  overly	  simplistic.	  Notably,	  screens	  of	  fully	  
randomised	  cyclic	  peptide	  or	  aptamer	  libraries	  against	  two	  hybrid-­‐based	  
reporter	  often	  yield	  hits	  with	  little	  sequence	  homology	  to	  either	  bait	  protein.	  
Beyond	  the	  sequence	  of	  the	  variable	  region	  within	  the	  library,	  it	  is	  also	  
important	  to	  consider	  other	  features	  that	  may	  have	  improved	  activity	  or	  
comparability:	  namely,	  peptide	  size	  and	  the	  possible	  addition	  of	  fixed	  
accessory	  residues	  to	  promote	  processing.	  	  
Designing	  a	  library	  of	  CP-­‐generating	  constructs	  rather	  than	  aptamer-­‐
like	  SICLOPPST69AH72A	  versions	  thereof	  (i.e.	  presenting	  the	  construct	  as	  a	  loop	  
flanked	  by	  two	  intein	  moieties)	  may	  seem	  ill	  advised	  in	  light	  of	  results	  of	  the	  
whole	  INbox	  expression.	  In	  those	  experiments,	  the	  ANI	  increase	  was	  greatest	  
in	  the	  SICLOPPST69AH72A	  versions	  of	  INboxWT	  and	  INboxTSS.	  As	  I	  have	  argued,	  in	  
that	  instance,	  the	  dominant	  negative	  effects	  observed	  were	  likely	  to	  have	  
been	  elicited	  by	  the	  linear	  precursors,	  not	  the	  CP	  products.	  There	  are,	  
however,	  numerous	  reasons	  why	  the	  INbox	  CPs	  may	  not	  have	  had	  the	  
anticipated	  effect	  (discussed	  in	  section	  4.5).	  One	  of	  the	  aims	  of	  the	  library	  
screen	  had	  been	  to	  determine	  whether	  the	  Aurora	  B-­‐INbox	  interaction	  can	  
be	  modulated	  with	  compounds	  with	  drug-­‐like	  properties.	  For	  this	  reason,	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expressing	  peptide	  epitopes	  attached	  to	  a	  large	  intein	  moiety	  was	  not	  
desirable.	  Thus,	  the	  size	  of	  the	  CPs	  screened	  was	  kept	  small.	  
When	  designing	  the	  W845	  and	  F881	  sub-­‐libraries,	  the	  intention	  was	  to	  
enhance	  chances	  of	  producing	  an	  effective	  peptide	  by	  varying	  conformational	  
constraint	  and	  promoting	  processing	  of	  peptides	  associated	  with	  key	  
epitopes.	  The	  first	  would	  be	  achieved	  by	  having	  related	  peptide	  sequences	  
present	  on	  varying	  cyclic	  peptide	  backbone	  lengths.	  By	  varying	  cyclic	  peptide	  
lengths,	  peptides	  could	  be	  generated	  containing	  similar	  sequences	  but	  with	  
different	  residues	  in	  extein	  positions	  known	  to	  modulate	  processing	  
efficiencies.	  Of	  the	  10	  library	  constructs	  eliciting	  the	  greatest	  ANI	  increase	  in	  
the	  first	  pass	  screen,	  8	  did	  not	  lie	  within	  the	  7	  variable	  residue	  core	  library.	  
This	  supports	  the	  decision	  to	  make	  sub	  libraries	  with	  varying	  cyclic	  peptide	  
length.	  	  
An	  alternative	  design	  strategy	  to	  promote	  CP	  processing	  would	  have	  
been	  to	  flank	  library	  sequences	  with	  extein	  residues	  reported	  to	  promote	  
processing	  (Scott	  et	  al.,	  2001).	  That	  is,	  further	  to	  the	  invariable	  cysteine	  
residue	  in	  position	  +1	  of	  library	  CPs,	  additional	  fixed	  non-­‐INbox	  residues	  
would	  be	  added	  to	  the	  start	  and	  end	  of	  each	  CP.	  This	  strategy	  was	  considered	  
but	  not	  pursued	  at	  the	  time	  of	  library	  design.	  The	  main	  reasons	  for	  this	  were,	  
firstly,	  that	  determining	  the	  best	  combination	  of	  residues	  would	  have	  been	  
time	  consuming	  and,	  secondly,	  that	  this	  would	  have	  added	  unwanted	  bulk	  to	  
the	  peptides.	  However,	  processing	  controls	  carried	  out	  during	  the	  second	  
phase	  of	  the	  screen	  highlighted	  unexpectedly	  high	  processing	  heterogeneity	  
within	  the	  library.	  In	  hindsight,	  this	  could	  have	  been	  a	  good	  strategy	  to	  
promote	  both	  overall	  processing	  and	  more	  homogeneous,	  thus	  more	  
comparable,	  CP	  production	  levels.	  Another	  strategy	  that	  could	  also	  be	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combined	  with	  this	  one	  is	  the	  use	  of	  other	  inteins	  reported	  to	  be	  more	  
efficient.	  This	  is	  explored	  in	  section	  6.3	  of	  the	  next	  chapter.	  
CONSTRUCTION	  
Unlike	  combinatorial	  libraries,	  the	  cost	  of	  having	  even	  a	  relatively	  
small	  library	  of	  discrete	  constructs	  generated	  commercially	  was	  
disappointingly	  prohibitive.	  However,	  the	  process	  of	  manually	  constructing	  a	  
library	  from	  long	  oligos	  proved	  straightforward	  and	  was	  completed	  in	  a	  
matter	  of	  weeks.	  Unlike	  generating	  combinatorial	  libraries	  whose	  complexity	  
and	  size	  can	  be	  dramatically	  curtailed	  by	  any	  inefficiency	  in	  the	  cloning	  
process	  (R.	  Almeida,	  personal	  communications),	  there	  were	  no	  requirements	  
for	  extensive	  optimization	  in	  this	  instance.	  	  
In	  constructing	  the	  library,	  only	  three	  individual	  clones	  could	  not	  be	  
obtained	  despite	  several	  attempts	  to	  do	  so.	  Unfortunately,	  all	  three	  overlap	  
with	  one	  or	  the	  other	  conserved	  residue	  targeted	  in	  the	  design	  of	  the	  library	  
(i.e.	  W845	  and	  F881).	  Failure	  to	  obtain	  these	  clones	  despite	  good	  yields	  of	  
PCR	  product	  could	  be	  due	  to	  a	  number	  of	  reasons	  including	  cytotoxicity	  in	  E.	  
coli.	  However,	  the	  purpose	  of	  the	  initial	  library	  screen	  was	  to	  identify	  hits,	  
not	  to	  compare	  the	  respective	  activities	  a	  continuous	  series	  of	  INbox	  
fragments.	  As	  such,	  the	  failure	  to	  obtain	  a	  small	  number	  of	  the	  desired	  clones	  
was	  not	  deemed	  problematic.	  Despite	  apparent	  questions	  as	  to	  their	  
suitability,	  the	  manual	  construction	  of	  discrete	  libraries	  on	  this	  scale	  is	  simple	  
and	  not	  a	  barrier	  in	  itself.	  
LIBRARY	  SCREENING	  APPROACH	  AND	  RESULTS	  
The	  smaller	  size	  and	  discrete	  nature	  of	  the	  rationally	  designed	  library	  
was	  attractive	  as	  it	  allowed	  for	  a	  greater	  range	  of	  screen	  readouts	  (i.e.	  these	  
were	  not	  limited	  to	  strong	  positive	  selection)	  and	  made	  screening	  in	  human	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cells	  feasible.	  The	  rationale,	  advantages	  and	  drawbacks	  of	  read	  out	  selection,	  
carrying	  out	  a	  microscopy	  –	  rather	  than	  a	  flow	  cytometry	  –	  based	  screen,	  and	  
screening	  by	  transient	  transfection	  have	  already	  been	  discussed	  in	  Chapter	  3.	  
Broader	  discussions	  regarding	  phenotypic	  screening	  of	  libraries	  for	  PPI	  
modulators	  in	  human	  cells	  will	  be	  presented	  in	  the	  Conclusions	  chapter.	  Here	  
I	  will	  focus	  first	  on	  the	  suitability	  of	  the	  various	  iterations	  of	  the	  library	  screen	  
protocol,	  followed	  by	  the	  limitations	  imposed	  by	  the	  SICLOPPS	  technology.	  
As	  mentioned,	  the	  first-­‐pass	  screen	  was	  carried	  out	  early	  in	  this	  
project	  and	  with	  a	  library	  of	  97	  members.	  Due	  to	  the	  high	  number	  of	  
constructs	  to	  be	  screened,	  the	  initial	  screening	  strategy	  was	  designed	  as	  to	  
minimize	  time	  and	  labour	  required.	  Lessons	  learnt	  from	  this	  initial	  screen	  led	  
to	  improvements	  in	  the	  experimental	  and	  scoring	  protocols.	  The	  revised	  
protocol	  was	  employed	  in	  all	  other	  ANI	  assays	  present	  within	  this	  work	  
including	  the	  finer-­‐grained	  second	  pass	  screen.	  
Two	  key	  improvements	  that	  were	  introduced	  as	  the	  assay	  was	  being	  
developed	  were	  the	  use	  of	  phalloidin	  staining	  and	  blind	  scoring.	  The	  first	  
served	  to	  improve	  scoring	  accuracy,	  the	  latter	  scoring	  reliability.	  Come	  the	  
second	  phase	  of	  the	  screen,	  experiments	  were	  carried	  out	  using	  a	  clonal	  HeLa	  
Kyoto	  isolate	  (refer	  back	  to	  section	  3.3)	  with	  a	  lower	  background	  ANI	  than	  
the	  original	  cell	  line.	  Important	  changes	  were	  also	  made	  to	  the	  scoring	  
methodology:	  constructs	  were	  assayed	  in	  triplicate	  to	  permit	  statistical	  
analyses,	  and	  >1000	  cells	  were	  scored	  instead	  of	  5	  fields	  of	  view	  (the	  
rationale	  for	  the	  former	  is	  presented	  in	  section	  3.3).	  	  
A	  shortcoming	  of	  scoring	  fixed	  numbers	  of	  fields	  of	  view	  is	  that	  this	  
leads	  to	  the	  systematic	  scoring	  of	  fewer	  cells	  in	  conditions	  that	  negatively	  
affect	  cell	  division	  rates	  and/or	  cell	  survival.	  This	  is	  a	  valid	  concern	  as	  the	  
number	  of	  cells	  scored	  in	  the	  initial	  screen	  ranged	  from	  135	  to	  580	  per	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replicate	  (average=344.4,	  SD=85.6).	  Furthermore,	  second	  pass	  screen	  
samples	  were	  assayed	  in	  triplicate,	  thereby	  permitting	  statistical	  analyses.	  	  
When	  comparing	  the	  same	  constructs,	  the	  rate	  of	  reproducibility	  
observed	  with	  the	  more	  stringent	  protocol	  was	  70%.	  With	  the	  caveat	  that	  the	  
false	  negative	  and	  positive	  rates	  in	  the	  final	  protocol	  are	  unknown,	  this	  
suggests	  a	  moderate	  false	  positive	  rate	  in	  the	  initial	  screen.	  In	  hindsight,	  the	  
initial	  protocol	  may	  have	  been	  insufficiently	  stringent,	  even	  for	  a	  rough	  initial	  
screen.	  	  
Limitations	  of	  assaying	  genetically	  encoded	  constructs	  through	  
transient	  transfections	  were	  first	  discussed	  in	  section	  4.5.	  Although	  the	  
effects	  of	  the	  INboxWT	  and	  INboxAAA	  constructs	  were	  readily	  apparent	  after	  48	  
hours	  (recall	  Chapter	  4),	  hit	  peptides	  had	  very	  modest	  effects	  over	  the	  same	  
time	  period.	  Although	  the	  effects	  of	  hit	  peptide	  ANI	  increases	  were	  
statistically	  significant	  under	  the	  screen	  conditions,	  it	  would	  have	  been	  
informative	  to	  also	  assay	  their	  effect	  over	  longer	  time	  periods.	  However,	  the	  
expression	  of	  transiently	  transfected	  SICLOPPS	  constructs	  might	  not	  persist	  
sufficiently	  long	  to	  permit	  this.	  	  
A	  possible	  explanation	  for	  the	  low	  potency	  of	  library	  constructs	  would	  
be	  that	  the	  INbox	  fragments	  assayed	  in	  the	  library	  were	  simply	  too	  short	  to	  
effectively	  recapitulate	  the	  interactions	  made	  by	  INboxWT	  and	  INboxAAA.	  
Although	  processing	  had	  a	  marked	  negative	  impact	  on	  the	  potency	  of	  the	  
INboxWT	  and	  INboxAAA	  constructs	  this	  effect	  was	  not	  clearly	  apparent	  during	  
the	  validation	  of	  library	  constructs.	  The	  ANI	  increases	  elicited	  by	  most	  of	  the	  
validated	  hits	  were	  indistinguishable	  in	  their	  processing	  competent	  and	  
deficient	  forms.	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Comparisons	  of	  hit	  activity	  proved	  extremely	  difficult	  using	  SICLOPPS	  
constructs.	  The	  greatest	  complication	  was	  the	  range	  of	  processing	  efficiency	  
within	  the	  library,	  which	  exceeded	  my	  expectations.	  However,	  the	  lack	  of	  
correlation	  between	  processing	  and	  ANI	  increase	  suggests	  that	  the	  effect	  
elicited	  by	  hits	  is	  not	  due	  to	  circularization	  efficiency	  alone.	  It	  is	  therefore	  
likely	  that	  the	  ANI	  increases	  detected	  are	  sequence	  specific.	  The	  processing	  
heterogeneity	  hampered	  the	  comparison	  of	  the	  hits	  obtained	  in	  this	  screen	  
but	  also	  dissuaded	  testing	  whether	  the	  effect	  of	  hit	  constructs	  is	  sequence	  
dependent	  using	  SICLOPPS.	  This	  is	  because	  scrambled	  or	  mutant	  (e.g.	  
creating	  the	  mutant	  equivalent	  to	  W845G	  in	  constructs	  with	  sequence	  
homology	  to	  this	  region	  of	  the	  INbox)	  versions	  of	  hit	  constructs	  might	  not	  be	  
processed	  to	  the	  same	  extent	  as	  the	  original,	  which	  would	  prevent	  direct	  
comparison.	  Alternative	  means	  of	  comparing	  hit	  peptides	  directly	  against	  
modified	  versions	  thereof	  are	  necessary	  (see	  Perspectives	  chapter).	  
The	  phenotypic	  effect	  elicited	  by	  any	  true	  hit	  should	  also	  correlate	  
with	  CP	  levels.	  Processing	  heterogeneity	  and	  technical	  constraints	  prohibiting	  
direct	  CP	  detection	  create	  significant	  hurdles	  to	  testing	  the	  correlation	  
between	  phenotype	  severity	  and	  CP	  levels	  using	  SICLOPPS	  methodology.	  
However,	  that	  between	  phenotype	  and	  SICLOPPS	  global	  expression	  (i.e.	  not	  
taking	  into	  account	  processing)	  levels	  could	  be	  verified	  thanks	  to	  the	  epitope	  
tag	  present	  on	  the	  SICLOPPS	  backbone.	  Another	  means	  of	  testing	  this	  is	  by	  
assaying	  different	  concentrations	  of	  the	  peptides.	  Although	  achievable	  
through	  inducible	  expression	  systems,	  this	  would	  still	  be	  complicated	  by	  
processing	  heterogeneity.	  For	  this	  reason,	  we	  are	  currently	  pursuing	  the	  
microinjection	  of	  synthetic	  versions	  of	  hit	  peptides	  and	  scrambled	  versions	  
thereof,	  which	  would	  serve	  a	  negative	  controls	  (see	  Perspectives	  chapter).	  
	   126	  
The	  modest	  activity	  of	  hit	  constructs	  makes	  it	  difficult	  to	  verify	  their	  
effect	  on	  the	  CPC.	  This	  is	  another	  area	  of	  interest	  that	  could	  be	  investigated	  
through	  the	  use	  of	  chemically	  synthesized	  CPs.	  Nevertheless,	  some	  of	  the	  
results	  obtained	  suggest	  that	  the	  hits	  identified	  might	  be	  specific	  to	  the	  CPC.	  
Firstly,	  CP	  activity	  appears	  to	  be	  sequence	  dependent,	  as	  evidenced	  by	  the	  
lack	  of	  correlation	  between	  processing	  efficiency	  and	  activity.	  Secondly,	  hit	  
peptides	  sequences	  clustered	  into	  two	  regions,	  each	  encompassing	  INbox	  
W845	  or	  F881	  –	  two	  INbox	  residues	  that	  are	  each	  required	  for	  INCENP	  
binding	  to	  Aurora	  B	  (Section	  4.3).	  Although	  conclusions	  regarding	  the	  
amenability	  of	  the	  Aurora	  B-­‐INbox	  interaction	  as	  a	  drug	  target	  cannot	  be	  
made	  at	  this	  stage,	  these	  are	  small	  but	  encouraging	  signs.	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CHAPTER	  6:	  CONCLUSIONS	  
6.1	   TARGETTING	  THE	  INBOX/AURORA	  B	  INTERACTION	  
CPC	  function	  is	  essential	  for	  cell	  division	  and	  survival.	  Numerous	  prior	  
studies	  had	  demonstrated	  that	  the	  presence	  and	  function	  of	  all	  CPC	  
components	  are	  essential.	  Although	  loss	  of	  the	  CPC	  at	  centromeres	  can	  be	  
tolerated	  in	  tissue	  culture,	  failure	  to	  achieve	  CPC	  localization	  to	  the	  anaphase	  
spindle	  and	  midbody	  correlates	  with	  cytokinesis	  failure	  and	  loss	  of	  viability.	  
The	  evidence	  generated	  in	  the	  present	  study	  further	  supports	  the	  hypothesis	  
that	  directly	  blocking	  the	  interaction	  between	  Aurora	  B	  and	  INCENP	  alone	  is	  
sufficient	  to	  impair	  CPC	  function	  and	  the	  completion	  of	  cell	  division.	  
Expression	  of	  the	  linear	  full-­‐length	  INbox	  resulted	  in	  a	  highly	  significant	  
increase	  in	  multinucleate	  and	  micronucleate	  cells,	  which	  is	  consistent	  with	  
CPC	  loss-­‐of-­‐function.	  	  
	  Failure	  to	  correctly	  complete	  cell	  division	  occurred	  despite	  the	  
presumed	  maintenance	  of	  both	  endogenous	  Aurora	  B	  and	  INCENP	  protein	  
levels.	  The	  respective	  localization	  of	  INCENP,	  survivin,	  and	  borealin,	  and	  the	  
activation	  state	  of	  Aurora	  B,	  under	  these	  conditions	  remain	  to	  be	  verified.	  
Such	  observations	  might	  potentially	  yield	  new	  insights	  into	  the	  biological	  role	  
and	  function	  of	  the	  CPC.	  	  
In	  partial	  agreement	  with	  previously	  published	  experimental	  results,	  
the	  failure	  of	  two	  point	  mutants	  of	  the	  INbox	  –	  W845G	  and	  F881A	  –	  to	  affect	  
CPC	  activity	  when	  overexpressed	  in	  isolation	  or	  combination	  indicates	  that	  
both	  sites	  are	  essential	  for	  INbox	  binding	  to	  Aurora	  B.	  The	  sum	  of	  these	  and	  
previous	  results	  suggests	  that	  blocking	  either	  of	  these	  contact	  points	  
between	  Aurora	  B	  and	  INCENP	  might	  be	  sufficient	  to	  impair	  CPC	  function.	  
The	  structure	  of	  the	  INbox	  is	  extended	  but	  the	  complimentary	  interaction	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surface	  on	  the	  Aurora	  B	  N-­‐terminal	  lobe	  consists	  of	  a	  shallow	  groove	  that	  
contains	  W845	  and	  F881	  interaction	  pockets.	  
Attempts	  to	  determine	  whether	  the	  Aurora	  B-­‐INbox	  interaction	  is	  one	  
that	  can	  be	  modulated	  with	  compounds	  smaller	  than	  the	  whole	  INbox	  were	  
inconclusive	  (see	  below).	  A	  small	  number	  of	  very	  modest	  but	  statistically	  
significant	  leads	  were	  obtained	  but	  their	  activity	  remains	  to	  be	  verified	  (see	  
‘Perspectives’	  section).	  Thus,	  it	  is	  not	  possible	  to	  draw	  conclusions	  on	  
whether	  this	  interaction	  is	  amenable	  to	  being	  drugged	  at	  this	  juncture.	  
Should	  the	  interaction	  prove	  amenable	  to	  inhibition	  with	  small	  drug-­‐
like	  compounds,	  this	  would	  open	  up	  the	  possibility	  of	  developing	  inhibitors	  
that	  might	  offer	  new	  research	  and	  therapeutic	  avenues.	  Although	  potentially	  
novel	  insights	  remain	  to	  be	  gained	  from	  the	  genetically	  encoded	  whole	  INbox	  
constructs,	  drugs	  allow	  for	  a	  far	  superior	  degree	  of	  temporal	  and	  
concentration	  control	  that	  might	  open	  further	  experimental	  avenues	  and	  
might	  transfer	  to	  the	  clinic.	  
6.2	   RATIONALLY-­‐DESIGNED	  CP	  LIBRARIES	  &	  SCREENING	  IN	  
HUMAN	  CELLS	  
From	  the	  perspective	  of	  carrying	  out	  a	  feasibility	  study,	  several	  
features	  of	  using	  the	  Aurora	  B-­‐INbox	  interaction	  presented	  challenges.	  
Uncertainty	  about	  the	  effects	  of	  directly	  blocking	  this	  interaction,	  and	  their	  
scale,	  in	  cell	  culture	  made	  it	  difficult	  to	  optimize	  the	  screen	  and	  assess	  its	  
results.	  When	  the	  CPC	  function	  assay	  and	  the	  screen	  were	  devised,	  no	  
reagents	  capable	  of	  directly	  inhibiting	  the	  endogenous	  Aurora	  B-­‐INbox	  
interaction	  were	  available.	  The	  dominant	  negative	  effect	  of	  the	  control	  used	  
in	  lieu	  of	  this	  –	  overexpression	  of	  a	  dominant-­‐negative	  Aurora	  B	  mutant	  –	  
was	  highly	  pronounced	  and	  expected	  to	  be	  substantially	  more	  severe	  than	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that	  of	  dissociating	  the	  Aurora	  B-­‐INbox	  interaction	  (as	  discussed	  in	  section	  
3.5	  and	  4.5).	  The	  strongest	  hits	  obtained	  after	  the	  initial	  phase	  of	  the	  INbox	  
library	  screen	  were	  very	  modest	  in	  comparison	  to	  this	  negative	  control,	  but	  
this	  was	  expected.	  However,	  the	  full-­‐length	  INbox	  overexpression	  
experiments	  (Chapter	  4)	  had	  not	  yet	  been	  performed	  at	  that	  time.	  It	  was	  
therefore	  not	  possible	  to	  gauge	  the	  relevance	  of	  hit	  activities	  compared	  to	  
this	  more	  representative	  control	  prior	  to	  proceeding	  with	  the	  second	  phase	  
of	  the	  screen.	  
Another	  challenge	  of	  using	  the	  Aurora	  B-­‐INbox	  for	  this	  pilot	  study	  was	  
the	  negative	  impact	  of	  its	  inhibition	  on	  cell	  survival.	  This	  effect	  was	  strongly	  
anticipated	  at	  the	  time	  the	  screen	  was	  devised	  and	  subsequently	  confirmed	  
by	  the	  experiments	  in	  which	  I	  overexpressed	  the	  whole	  INbox	  (Chapter	  4).	  
When	  screening	  genetically	  encoded	  libraries,	  readouts	  inconsistent	  with	  cell	  
survival	  complicate	  the	  recovery	  of	  DNA	  sequences	  associated	  with	  the	  
desired	  phenotype	  as	  cells	  expressing	  the	  strongest	  hits	  are	  missing	  from	  the	  
read-­‐out.	  Simply	  transposing	  and	  testing	  established	  SICLOPPS	  library	  design	  
in	  human	  cells	  alone	  would	  not	  have	  been	  sufficient	  –	  new	  approaches	  had	  
to	  be	  devised.	  	  
Whilst	  a	  more	  in	  depth	  assessments	  of	  hit	  peptides	  (see	  Perspectives)	  
is	  needed	  in	  order	  to	  verify	  their	  observed	  activity,	  it	  was	  clear	  that	  their	  
effect	  in	  the	  cell-­‐based	  assay	  was	  far	  less	  pronounced	  than	  that	  of	  the	  whole	  
INbox	  peptide.	  Designing	  a	  small	  library	  of	  discrete	  members	  presented	  
numerous	  practical	  advantages	  over	  a	  pooled	  library.	  Amongst	  them,	  library	  
construction	  and	  tissue	  culture	  and	  transfection	  conditions	  were	  relative	  easy	  
to	  optimize.	  Furthermore,	  the	  discrete	  nature	  of	  the	  library	  and	  its	  small	  size	  
allowed	  for	  each	  construct	  to	  be	  assayed	  in	  isolation.	  This	  circumvented	  the	  
need	  to	  recover	  hit	  peptide	  sequences	  and	  permitted	  the	  design	  of	  an	  in	  vivo	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screen	  against	  an	  essential	  interaction.	  However,	  the	  costs	  of	  trading	  off	  
chemical	  diversity	  for	  practicality	  may	  have	  been	  too	  high.	  The	  
disappointingly	  modest	  leads	  obtained	  in	  this	  study	  raise	  serious	  questions	  
about	  the	  suitability	  of	  the	  small,	  targeted,	  SICLOPPS	  library	  approach	  
employed	  in	  this	  study.	  
Acknowledging	  the	  shortcomings	  of	  basing	  a	  feasibility	  study	  on	  the	  
use	  of	  SICLOPPS	  technology	  in	  human	  cells	  on	  a	  then	  untested	  interaction,	  I	  
must	  nevertheless	  conclude	  that	  there	  remain	  significant	  hurdles	  to	  the	  
effective	  screening	  SICLOPPS	  libraries	  in	  this	  system.	  I	  must	  advise	  that	  small	  
rationally	  designed	  libraries	  based	  on	  the	  approach	  used	  in	  this	  study	  should	  
be	  discouraged.	  Iteratively	  assaying	  much	  larger	  INbox	  fragments	  in	  their	  
linear	  and	  circular	  forms	  in	  combination	  with	  flexible	  linkers	  might	  have	  
yielded	  a	  shortened	  construct	  capable	  of	  reiterating	  the	  dominant	  negative	  
effect	  of	  the	  larger	  INbox	  construct.	  If	  restricting	  the	  size	  of	  the	  cyclic	  
peptides	  is	  desired,	  a	  large	  combinatorial	  library	  (i.e.	  one	  in	  which	  all	  or	  some	  
of	  the	  peptide	  residues	  are	  randomised)	  might	  be	  better	  suited.	  Cell-­‐based	  
screening	  of	  such	  large	  libraries	  remains	  best	  suited	  to	  lower	  eukaryotes	  and	  
prokaryotes	  as	  these	  are	  more	  easily	  grown	  and	  manipulated.	  	  
With	  regards	  to	  identifying	  small	  CPs	  capable	  of	  inhibiting	  the	  Aurora	  
B-­‐INbox	  interaction	  with	  sizes	  that	  would	  indicate	  that	  this	  interaction	  could	  
be	  inhibited	  with	  drugs,	  the	  alternative	  combinatorial	  approaches	  described	  
above	  would	  have	  been	  advantageous.	  Prokaryotes	  represent	  a	  heterologous	  
system	  if	  screening	  for	  eukaryotic	  PPI	  inhibitors.	  However,	  the	  ease	  and	  
speed	  with	  which	  genetically	  encoded	  libraries	  can	  be	  screened	  in	  
prokaryotic	  systems	  outweigh	  this	  concern.	  A	  possible	  discovery	  pipeline	  
might	  first	  involve	  prokaryotic	  screens	  as	  a	  rapid	  and	  high	  throughput	  means	  
of	  the	  identifying,	  optimizing	  and	  prioritizing	  a	  panel	  of	  strong	  initial	  hits.	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These	  hits	  could	  then	  be	  subsequently	  assayed	  in	  the	  endogenous	  context	  
through	  more	  suitable	  means,	  such	  as	  by	  using	  chemically	  synthesized	  CPs.	  
This	  approach	  is	  exemplified	  by	  the	  2008	  study	  by	  Tavassoli	  and	  colleagues	  in	  
which	  cyclic	  peptide	  inhibitors	  of	  the	  interaction	  between	  HIV	  Gag	  protein	  
and	  human	  TSG101	  (tumour	  susceptibility	  gene	  101)	  were	  first	  identified	  
using	  a	  bacterial	  reverse-­‐two	  hybrid	  reporter	  (Tavassoli	  et	  al.,	  2008).	  Cell-­‐
penetrant	  versions	  of	  hit	  peptides	  were	  then	  chemically	  synthesized	  and	  
assayed	  against	  a	  reporter	  of	  HIV	  budding	  in	  293T	  cells.	  	  
The	  use	  of	  bacterial	  reverse-­‐two	  hybrid	  reporters	  might	  have	  been	  
particularly	  well	  suited	  to	  finding	  small	  peptide	  inhibitors	  of	  the	  Aurora	  B-­‐
INbox	  interaction.	  Given	  the	  absence	  of	  the	  CPC	  in	  prokaryotes,	  the	  
interaction	  can	  be	  reiterated	  within	  a	  reverse	  two-­‐hybrid	  reporter	  system	  
generating	  strong	  positive	  selection	  for	  hits.	  An	  additional	  advantage	  of	  
reverse-­‐two	  hybrid	  reporters	  is	  that,	  unlike	  a	  phenotypic	  screen,	  these	  are	  
inherently	  targeted.	  As	  discussed	  previously	  (section	  3.5),	  failure	  to	  elicit	  an	  
ANI	  increase	  in	  the	  CPC	  function	  assay	  is	  consistent	  with	  intact	  CPC	  function	  
but	  the	  converse	  is	  not	  necessarily	  true.	  This	  is	  because	  many	  other	  factors	  
than	  the	  CPC	  are	  involved	  in	  chromosome	  segregation	  and	  cytokinesis.	  	  
6.3	   REASSESSING	  SICLOPPS	  TECHNOLOGY	  
Many	  features	  of	  the	  SICLOPPS	  technology	  make	  this	  approach	  very	  
attractive	  for	  identifying	  CP	  modulators	  using	  combinatorial	  libraries.	  
However,	  several	  drawback	  and	  limitations	  of	  the	  technology	  became	  
apparent	  during	  this	  present	  study.	  The	  use	  of	  genetically	  encoded	  constructs	  
with	  varying	  rates	  of	  processing	  ultimately	  frustrated	  efforts	  to	  compare	  hit	  
peptide	  activities	  side-­‐by-­‐side,	  and	  rank	  these.	  As	  already	  mentioned,	  
SICLOPPS	  methodology	  would	  therefore	  best	  be	  deployed	  in	  the	  early	  stages	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of	  a	  discovery	  project	  with	  plans	  already	  in	  place	  to	  generate	  hit	  peptides	  
through	  other	  means	  for	  subsequent	  assays.	  	  
The	  observed	  variation	  in	  processing	  efficiency	  means	  that,	  in	  terms	  of	  
CP	  production,	  the	  library	  screened	  in	  this	  study	  may	  have	  been	  effectively	  
smaller	  than	  that	  designed.	  More	  generally,	  this	  raises	  concerns	  that	  the	  
effective	  chemical	  diversity	  contained	  within	  SICLOPPS-­‐derived	  combinatorial	  
libraries	  may	  be	  overestimated	  and	  overstated.	  	  
It	  is	  noteworthy	  that	  all	  studies	  reporting	  the	  use	  of	  split	  inteins	  to	  generate	  
CPs	  in	  vivo	  have	  thus	  far	  relied	  on	  inteins	  that	  were	  amongst	  the	  first	  
described.	  The	  Ssp	  DnaE	  intein-­‐mediated	  protein	  trans	  splicing	  reaction	  has	  
been	  reported	  to	  have	  a	  half-­‐life	  of	  175	  minutes	  at	  23oC	  (Martin	  et	  al.,	  2001).	  
As	  already	  discussed,	  the	  processing	  of	  the	  Ssp	  DnaE	  intein	  can	  also	  be	  very	  
sensitive	  to	  extein	  residues.	  Since	  then,	  inteins	  reported	  to	  possess	  much	  
faster	  processing	  speeds	  and	  greater	  tolerance	  for	  variation	  in	  extein	  
residues	  have	  been	  described.	  Of	  particular	  note	  is	  the	  dnaE	  intein	  from	  
Nostoc	  Punctiforme	  (Npu),	  which	  is	  reported	  to	  undergo	  trans	  splicing	  with	  a	  
half	  life	  of	  63	  seconds	  (Zettler	  et	  al.,	  2009).	  The	  study	  presented	  here	  was	  
done	  using	  the	  Ssp	  DnaE	  intein	  as	  it	  was	  available	  from	  our	  collaborator	  and	  
is	  still	  commonly	  used	  to	  generate	  cyclic	  peptide	  libraries.	  Newly	  
characterised	  inteins,	  however,	  have	  the	  potential	  for	  improving	  both	  
SICLOPPS	  processing	  speeds	  and	  extent,	  and	  may	  yield	  better	  CP	  libraries.	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CHAPTER	  7:	  PERSPECTIVES	  
	   The	  results	  presented	  above	  are	  but	  parts	  of	  stories	  that	  can	  be	  
further	  developed.	  As	  discussed	  in	  the	  previous	  chapter,	  two	  avenues	  that	  
could	  warrant	  further	  exploration	  are	  the	  biological	  consequences	  of	  full	  
length	  INbox	  expression	  and	  further	  validation	  of	  the	  effects	  of	  hit	  peptides	  
identified	  in	  the	  INbox	  screen.	  
Overexpression	  of	  full	  length	  INbox	  caused	  a	  significant	  increase	  in	  
cytokinesis	  failure	  and	  alignment	  defects.	  These	  effects	  are	  likely	  to	  be	  
inconsistent	  with	  cell	  survival	  over	  longer	  periods	  of	  time.	  Our	  results	  support	  
the	  targeting	  of	  the	  Aurora	  B-­‐INbox	  interaction	  as	  a	  means	  of	  abrogating	  
Aurora	  B	  activity.	  They	  also	  suggest	  that	  the	  regions	  interacting	  with	  not	  only	  
hINCENP	  W845	  but	  also	  F881	  could	  be	  suitable	  target	  sites	  for	  drug	  discovery	  
efforts.	  	  
It	  is	  interesting	  that,	  by	  using	  point	  mutants	  of	  the	  dominant	  negative	  
INbox	  construct,	  we	  implicated	  hINCENP	  F881	  in	  Aurora	  B	  binding	  in	  vivo.	  
This	  is	  in	  contrast	  to	  a	  previous	  study	  using	  heterologously	  expressed	  human	  
proteins	  that	  found	  this	  residue	  to	  be	  required	  for	  activation,	  but	  not	  binding	  
of	  Aurora	  B	  (Honda	  et	  al.,	  2003).	  The	  difference	  in	  the	  results	  obtained	  using	  
our	  approach	  –	  i.e.	  abolishing	  a	  dominant	  negative	  effect	  –	  and	  in	  vitro	  assays	  
suggests	  that	  these	  might	  differ	  in	  their	  sensitivity.	  	  
At	  the	  present	  juncture,	  the	  INbox	  SICLOPPS	  library	  screen	  has	  yielded	  
a	  series	  of	  hits	  with	  only	  moderate	  activity	  in	  the	  CPC	  function	  assay.	  To	  
further	  investigate	  these,	  three	  of	  these	  hits	  have	  been	  chemically	  
synthesized	  along	  with	  matched	  scrambled	  sequence	  peptides	  by	  our	  
collaborator	  Daniel	  St	  Cyr	  at	  the	  Université	  de	  Montréal	  (recall	  Table	  5.5.2).	  
The	  use	  of	  chemically-­‐synthesized	  peptides	  will	  permit	  the	  control	  of	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experimental	  concentrations,	  something	  that	  proved	  elusive	  using	  SICLOPPS.	  
However,	  the	  very	  modest	  effect	  of	  the	  hit	  peptides	  identified	  should	  be	  
reiterated	  –	  these	  are	  probably	  not	  be	  worth	  pursuing	  outside	  the	  scope	  of	  
this	  study.	  
Before	  commenting	  on	  the	  wider	  significance	  of	  our	  findings	  
concerning	  the	  targeting	  of	  the	  Aurora	  B-­‐INbox	  interaction,	  is	  worth	  
remembering	  that	  all	  experiments	  in	  study	  were	  carried	  out	  using	  HeLa	  Kyoto	  
or	  a	  clonal	  isolate	  thereof.	  Although	  deemed	  suitable	  for	  this	  study	  
(discussed	  in	  section	  3.2),	  HeLa	  cells	  are	  aberrant.	  Recent	  genomic	  and	  
transcriptomic	  analysis	  of	  the	  cell	  line	  has	  revealed	  massive	  genomic	  
rearrangements	  and	  differential	  expression	  of	  several	  essential	  pathways	  
(Landry	  et	  al.,	  2013).	  The	  generalisability	  of	  our	  findings	  should	  therefore	  be	  
verified	  in	  a	  range	  of	  cell	  lines,	  including	  non-­‐transformed	  cells.	  
Overall,	  our	  results	  support	  the	  targeting	  of	  the	  Aurora	  B-­‐INbox	  
interaction	  but	  are	  inconclusive	  regarding	  its	  amenability	  to	  inhibition	  with	  
small	  molecules	  or	  peptides.	  The	  potential	  novel	  mechanism	  for	  Aurora	  B	  
inhibition	  is	  highly	  interesting	  in	  itself.	  In	  light	  of	  the	  debate	  surrounding	  the	  
effectiveness	  of	  targeting	  mitosis	  in	  cancer	  therapy	  that	  has	  since	  emerged	  
(Komlodi-­‐Pasztor	  et	  al.,	  2011;	  Mitchison,	  2012),	  the	  therapeutic	  potential	  of	  
this	  approach	  appears	  to	  be	  less	  promising	  than	  when	  this	  study	  began.	  
Inhibitors	  of	  the	  Aurora	  B-­‐INbox	  interaction	  could	  nonetheless	  be	  useful	  for	  
research	  applications,	  such	  as	  in	  dissecting	  any	  possible	  CPC-­‐independent	  
role	  of	  Aurora	  B.	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APPENDIX	  I	  –	  SICLOPPS	  TEST	  CONSTRUCT	  
Sequence	  of	  the	  SICLOPPS	  test	  construct	  used	  in	  prelimary	  experiments	  and	  
library	  construction	  synthesized	  by	  DNA	  2.0	  (Menlo	  Park,	  California,	  USA).	  
Colour-­‐coding	  is	  as	  follows:	  blue	  =	  C-­‐terminal	  intein;	  cyan	  =	  N-­‐terminal	  intein;	  
green	  =	  myc	  tag;	  orange	  =	  CP	  nucleophile	  (position	  1),	  red	  =	  CP	  variable	  
region.	  Darkened	  boxes	  indicate	  residues	  critical	  for	  protein	  splicing	  which,	  
when	  mutated	  to	  alanine,	  impair	  the	  process.	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APPENDIX	  II	  –	  INCENP	  INBOX	  LIBRARY:	  SEQUENCES	  &	  
PRIMERS	  
Amino	  acid	  sequences	  of	  the	  human	  INCENP	  IN-­‐box	  CP	  library	  clones	  
and	  of	  the	  reverse	  primers	  used	  to	  generate	  these.	  The	  sequence	  indicated	  is	  
that	  of	  the	  variable	  residues	  –	  the	  invariant	  cysteine	  present	  at	  position	  1	  is	  
not	  shown.	  The	  first	  half	  of	  the	  table	  shows	  the	  sequence	  of	  all	  sublibraries,	  
in	  ascending	  length,	  centered	  on	  residues	  W845	  and	  F881.	  The	  core	  library	  
spanning	  the	  INbox	  is	  covered	  by	  clones	  E9	  through	  to	  A1.2	  –	  this	  excludes	  
the	  library	  members	  covering	  either	  W845	  or	  F881.	  The	  variable	  region	  
within	  each	  primer	  is	  highlighted.	  
	   The	  amino	  acid	  sequence	  of	  the	  human	  INCENP	  INbox	  as	  follows:	  
DEAHPRKPIPTWARGTPLSQAIIHQYYHPPNLLELFGTILPLDLEDIFKKSKPRYHKRTSS	  
Universal	  primer	   Primer	  Sequence	  (5'-­‐3')	  




Construct	   Peptide	  variable	  
region	  
Primer	  Sequence	  variable	  region	  (5'-­‐3')	  
A1	   IPTW	   CCAGGTAGGGAT	  
A2	   PTWA	   GGCCCAGGTAGG	  
A3	   TWAR	   CCTGGCCCAGGT	  
A4	   WARG	   GCCCCTGGCCC	  
A5	   PIPTW	   CCAGGTAGGGATAGG	  
A6	   IPTWA	   GGCCCAGGTAGGGAT	  
A7	   PTWAR	   CCTGGCCCAGGTAGG	  
A8	   TWARG	   GCCCCTGGCCCAGGT	  
A9	   WARGT	   GGTGCCCCTGGCCCA	  
A10	   LEDIF	   GAAGATGTCCTCCAG	  
A11	   EDIFK	   CTTGAAGATGTCCTC	  
A12	   DIFKS	   GCTCTTGAAGATGTC	  
B1	   IFKSK	   CTTGCTCTTGAAGAT	  
B2	   FKSKP	   AGGCTTGCTCTTGAA	  
B3	   KPIPTW	   CCAGGTAGGGATAGGCTT	  
B4	   PIPTWA	   GGCCCAGGTAGGGATAGG	  
B5	   IPTWAR	   CCTGGCCCAGGTAGGGAT	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B6	   PTWARG	   GCCCCTGGCCCAGGTAGG	  
B7	   TWARGT	   GGTGCCCCTGGCCCAGGT	  
B8	   WARGTP	   AGGGGTGCCCCTGGCCCA	  
B9	   DLEDIF	   GAAGATGTCCTCCAGGTC	  
B10	   LEDIFK	   CTTGAAGATGTCCTCCAG	  
B11	   EDIFKK	   CTTCTTGAAGATGTCCTC	  
B12	   DIFKKS	   GCTCTTCTTGAAGATGTC	  
C1	   IFKKSK	   CTTGCTCTTCTTGAAGAT	  
C2	   FKKSKP	   AGGCTTGCTCTTCTTGAA	  
C3	   RKPIPTW	   CCAGGTAGGGATAGGCTTCCT	  
C4	   KPIPTWA	   GGCCCAGGTAGGGATAGGCTT	  
C5	   PIPTWAR	   CCTGGCCCAGGTAGGGATAGG	  
C6	   IPTWARG	   GCCCCTGGCCCAGGTAGGGAT	  
C7	   PTWARGT	   GGTGCCCCTGGCCCAGGTAGG	  
C8	   TWARGTP	   AGGGGTGCCCCTGGCCCAGGT	  
C9	   WARGTPL	   CAGAGGGGTGCCCCTGGCCCA	  
C10	   LDLEDIF	   GAAGATGTCCTCCAGGTCCAG	  
C11	   DLEDIFK	   CTTGAAGATGTCCTCCAGGTC	  
C12	   LEDIFKK	   CTTCTTGAAGATGTCCTCCAG	  
D1	   EDIFKKS	   GCTCTTCTTGAAGATGTCCTC	  
D2	   DIFKKSK	   CTTGCTCTTCTTGAAGATGTC	  
D3	   IFKKSKP	   AGGCTTGCTCTTCTTGAAGAT	  
D4	   FKKSKPR	   CCTAGGCTTGCTCTTCTTGAA	  
D5	   PRKPIPTW	   CCAGGTAGGGATAGGCTTCCTAGGG	  
D6	   RKPIPTWA	   GGCCCAGGTAGGGATAGGCTTCCT	  
D7	   KPIPTWAR	   CCTGGCCCAGGTAGGGATAGGCTT	  
D8	   PIPTWARG	   GCCCCTGGCCCAGGTAGGGATAGG	  
D9	   IPTWARGT	   GGTGCCCCTGGCCCAGGTAGGGAT	  
D10	   PTWARGTP	   AGGGGTGCCCCTGGCCCAGGTAGG	  
D11	   TWARGTPL	   CAGAGGGGTGCCCCTGGCCCAGGT	  
D12	   WARGTPLS	   GCTCAGAGGGGTGCCCCTGGCCCA	  
E1	   PLDLEDIF	   GAAGATGTCCTCCAGGTCCAGAGG	  
E2	   LDLEDIFK	   CTTGAAGATGTCCTCCAGGTCCAG	  
E3	   DLEDIFKK	   CTTCTTGAAGATGTCCTCCAGGTC	  
E4	   LEDIFKKS	   GCTCTTCTTGAAGATGTCCTCCAG	  
E5	   EDIFKKSK	   CTTGCTCTTCTTGAAGATGTCCTC	  
E6	   DIFKKSKP	   AGGCTTGCTCTTCTTGAAGATGTC	  
E7	   IFKKSKPR	   CCTAGGCTTGCTCTTCTTGAAGAT	  
E8	   FKKSKPRY	   GTACCTAGGCTTGCTCTTCTTGAA	  
E9	   DEAHPRK	   CTTCCTAGGGTGGGCCTCGTC	  
E10	   EAHPRKP	   AGGCTTCCTAGGGTGGGCCTC	  
E11	   AHPRKPI	   GATAGGCTTCCTAGGGTGGGC	  
E12	   HPRKPIP	   AGGGATAGGCTTCCTAGGGTG	  
F1	   PRKPIPT	   GGTAGGGATAGGCTTCCTAGG	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F2	   ARGTPLS	   GCTCAGAGGGGTGCCCCTGGC	  
F3	   RGTPLSQ	   CTGGCTCAGAGGGGTGCCCCT	  
F4	   GTPLSQA	   GGCCTGGCTCAGAGGGGTGCC	  
F5	   TPLSQAI	   GATGGCCTGGCTCAGAGGGGT	  
F6	   PLSQAII	   GATGATGGCCTGGCTCAGAGG	  
F7	   LSQAIIH	   GTGGATGATGGCCTGGCTCAG	  
F8	   SQAIIHQ	   CTGGTGGATGATGGCCTGGCT	  
F9	   QAIIHQY	   GTACTGGTGGATGATGGCCTG	  
F10	   AIIHQYY	   GTAGTACTGGTGGATGATGGC	  
F11	   IIHQYYH	   GTGGTAGTACTGGTGGATGAT	  
F12	   IHQYYHP	   AGGGTGGTAGTACTGGTGGAT	  
G1	   HQYYHPP	   AGGAGGGTGGTAGTACTGGTG	  
G2	   QYYHPPN	   GTTAGGAGGGTGGTAGTACTG	  
G3	   YYHPPNL	   CAGGTTAGGAGGGTGGTAGTA	  
G4	   YHPPNLL	   CAGCAGGTTAGGAGGGTGGTA	  
G5	   HPPNLLE	   CTCCAGCAGGTTAGGAGGGTG	  
G6	   PPNLLEL	   CAGCTCCAGCAGGTTAGGAGG	  
G7	   PNLLELF	   GAACAGCTCCAGCAGGTTAGG	  
G8	   NLLELFG	   GCCGAACAGCTCCAGCAGGTT	  
G9	   LLELFGT	   GGTGCCGAACAGCTCCAGCAG	  
G10	   LELFGTI	   GATGGTGCCGAACAGCTCCAG	  
G11	   ELFGTIL	   CAGGATGGTGCCGAACAGCTC	  
G12	   LFGTILP	   AGGCAGGATGGTGCCGAACAG	  
H1	   FGTILPL	   CAGAGGCAGGATGGTGCCGAA	  
H2	   GTILPLD	   GTCCAGAGGCAGGATGGTGCC	  
H3	   TILPLDL	   CAGGTCCAGAGGCAGGATGGT	  
H4	   ILPLDLE	   CTCCAGGTCCAGAGGCAGGAT	  
H5	   LPLDLED	   GTCCTCCAGGTCCAGAGGCAG	  
H6	   PLDLEDI	   GATGTCCTCCAGGTCCAGAGG	  
H7	   KKSKPRY	   GTACCTAGGCTTGCTCTTCTT	  
H8	   KSKPRYH	   GTGGTACCTAGGCTTGCTCTT	  
H9	   SKPRYHK	   CTTGTGGTACCTAGGCTTGCT	  
H10	   KPRYHKR	   CCTCTTGTGGTACCTAGGCTT	  
H11	   PRYHKRT	   GGTCCTCTTGTGGTACCTAGG	  
H12	   RYHKRTS	   GCTGGTCCTCTTGTGGTACCT	  
A1.2	   YHKRTSS	   GCTGCTGGTCCTCTTGTGGTA	  
	  
	  
	  
	  
